Document:

EX-10.40

 

Exhibit 10.40

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

and

GTx, INC.

CONSOLIDATED, AMENDED, AND RESTATED LICENSE AGREEMENT

     THIS CONSOLIDATED, AMENDED, AND RESTATED LICENSE AGREEMENT made and entered into this
24th day of July, 2007, having an effective date of August 23, 2000 (the “Effective
Date”) by and between University of Tennessee Research Foundation (formerly known as The
University of Tennessee Research Corporation), a Tennessee corporation having an office at 1534
White Avenue, Knoxville, Tennessee 37996. (hereinafter “UTRF”), and GTx, Inc. (formerly known as
Genotherapeutics, Inc.), a Delaware corporation, located at 3 N. Dunlap St., Memphis, Tennessee
38163 (hereinafter “GTx”), hereinafter sometimes referred to individually as a “Party” and
collectively as the “Parties”.

RECITALS

     WHEREAS, UTRF owns, in whole or in part, certain Licensed Patents (as defined herein) and
Licensed Technology (as defined herein), the subject matter of which was initially developed by one
or more of the UT Contributors (as defined herein) in the course of their employment with The
University of Tennessee (“UT”);

     WHEREAS, the UT Contributors submitted to UT multiple invention disclosure forms pertaining to
SARMS (as defined herein), including (i) [ * ], designated by UTRF as file number PD [ * ]; (ii) [
* ], designated by UTRF as file number PD [ * ]; (iii) [ * ], designated by UTRF as file number PD
[ * ]; (iv) [ * ], designated by UTRF as file number PD [ * ]; and (v) [ * ] designated by UTRF as
file number PD [ * ] (individually, an “Initial SARMS Disclosure” and, collectively, the
“Initial SARMS Disclosures”);

     WHEREAS, UTRF and GTx have previously entered into two separate agreements, each being titled
“Amended and Restated Exclusive License Agreement” and made effective as of August 23, 2000,
whereby GTx was granted exclusive licenses to Licensed Patents (as defined therein) and Licensed
Technology (as defined therein) which arose out of the technology described in the Initial SARMS
Disclosures (collectively, the “Prior License Agreements”);

     WHEREAS, after submission of the Initial SARMS Disclosures to UT, Dr. James T. Dalton, a UT
Contributor, left the employ of UT, accepted employment as a faculty member at The Ohio State
University (“OSU”) and in the capacity of an OSU researcher, continued to perform research
at OSU relating to the subject matter of the Initial SARMS Disclosures with the assistance of other
staff and students of OSU working under his supervision, said research being funded by various
sponsors, including the United States government and GTx;

     WHEREAS, a number of the UT Contributors (excluding Dr. Dalton as an OSU employee),
subsequently submitted to UT an invention disclosure form titled [ * ] designated by UTRF as file
number PD [ * ] (the “Third Generation SARMS Disclosure”), a copy of which is attached
hereto as Exhibit A;

 

 

     WHEREAS, with the consent of GTx, UTRF entered into that certain agreement titled “Bridged
SARMS Inter-Institutional Agreement” with OSU effective December 22, 2004 (hereinafter “OSU
IIA#1”), attached hereto and incorporated by reference herein as Exhibit B;

     WHEREAS, pursuant to the provisions of OSU IIA#1, UTRF holds a license, with the right to
sublicense, to the interest of OSU in EXISTING INVENTIONS (defined below) pertaining to BRIDGED
SARMS the subject matter of which was conceived, created, developed, designed, invented, or reduced
to practice in whole or in part by OSU researcher Dr. Dalton and/or other OSU research staff and
students under Dr. Dalton’s direction before December 22, 2004;

     WHEREAS, pursuant to the provisions of OSU IIA#1, UTRF holds an option to a license, with the
right to sublicense, to OSU’s interest in IMPROVEMENT INVENTIONS (defined below) pertaining to
BRIDGED SARMS conceived, created, developed, designed, invented, or reduced to practice, in whole
or in part by OSU faculty researchers, research staff, or students after December 22, 2004.

     WHEREAS, UTRF also entered into that certain agreement entitled “New SARM Inventions
Inter-Institutional Agreement” with OSU effective as of December 22, 2004 (“OSU IIA#2”),
attached hereto and incorporated by reference herein as Exhibit C;

     WHEREAS, pursuant to the provisions of OSU IIA#2, UTRF holds an option to a license, with the
right to sublicense, to OSU’s interest in NEW INVENTIONS` (defined below) pertaining to certain
SARMS conceived, created, developed, designed, invented, or reduced to practice, in whole or in
part, by Dr. Dalton, or other OSU research staff, or students and not otherwise subject to OSU
IIA#1;

     WHEREAS, the Parties now desire to enter into this “Consolidated, Amended, and Restated
License Agreement” for the purpose of (i) consolidating the Prior License Agreements into one
agreement; (ii) granting GTx an exclusive license in UTRF’s interest in EXISTING INVENTIONS and
IMPROVEMENT INVENTIONS that were not previously licensed to GTx under the Prior License Agreements,
if any; (iii) granting GTx an exclusive license, subject to the provisions of OSU IIA#1, in OSU’s
interest in all LICENSED INVENTIONS (as defined in OSU IIA#1), to the extent licensed to UTRF; (iv)
granting GTx an exclusive license, subject to the provisions of OSU IIA#2, in OSU’s interest in all
LICENSED INVENTIONS (as defined in OSU IIA#2), to the extent licensed to UTRF, and in UTRF’s
interest in NEW INVENTIONS; and (v) making certain other changes regarding the rights and
obligations of the Parties, including but not limited to those changes that are necessary for UTRF
to comply with the provisions of OSU IIA#1 and OSU IIA#2; and

     WHEREAS, the Parties intend that this Agreement shall supersede the Prior License Agreements
and render them null and void.

     NOW, THEREFORE, for and in consideration of the premises and other good and valuable
consideration, including a payment in the amount of Two Hundred Ninety Thousand Dollars ($290,000;
the “Consideration Fee”),which is paid by GTx in consideration of UTRF’s execution of this Agreement, the Parties
hereto expressly agree as follows:

SECTION 1

Definitions

     1.1 “Actions” shall have the meaning set forth in Section 17.1 hereof.

     1.2 “Active Ingredient” means the material(s) in a pharmaceutical product which
provide its

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

2

 

pharmacological activity (excluding formulation components such as coatings,
stabilizers or controlled release technologies).

     1.3 “Affiliate” shall mean any corporation, partnership, or other entity that at any
time during the Term of this Agreement, directly or through one or more intermediaries, Controls or
is Controlled by or is under common Control with a Party to this Agreement or a Sublicensee, but
only for so long as the relationship exists. A corporation or other entity shall no longer be an
Affiliate when through loss, divestment, dilution or other reduction of ownership, the requisite
Control no longer exists.

     1.4
“Agreement” shall mean this Consolidated, Amended and Restated License Agreement.

     1.5
“BRIDGED SARMS” shall have the meaning set forth in OSU IIA#1.

     1.6
“Claims” shall have the meaning set forth in Section 8.1 hereof.

     1.7 “Combination Product” means either (i) any pharmaceutical product that consists of
a SARM and at least one other Active Ingredient that is not a SARM, or (ii) any combination of a
SARM and another pharmaceutical product that contains at least one other Active Ingredient that is
not a SARM where such products are not formulated together but are sold together as a single
product and invoiced as one product.

     1.8 “Confidential Information” shall have the meaning set forth in Section 18.2
hereof.

     1.9 “Control” or “Controls” or “Controlled” shall mean: (i) in the
case of a corporation, ownership or control, directly or indirectly, of at least fifty one percent
(51%) of the shares of stock entitled to vote for the election of directors; or (ii) in the case of
an entity other than a corporation, ownership or control, directly or indirectly, of at least fifty
one percent (51%) of the assets of such entity.

     1.10
“Effective Date” shall have the meaning set forth in the introductory paragraph hereof.

     1.11
“Exception Countries” shall have the meaning set forth in Section 6.6 hereof.

     1.12
“EXISTING INVENTION” shall have the meaning set forth in OSU IIA#1.

     1.13
“Federal Policy” shall have the meaning set forth in Section 2.3 hereof.

     1.14 “Generic Product” shall mean a product that is derived from, made with, uses, or
incorporates, in whole or in part, Licensed Technology, but is not covered or claimed in whole or
in part by a Valid Claim of the Licensed Patents in the country of manufacture, use, or sale or
import.

     1.15 “GTx” shall mean GTx, Inc. and its Affiliate(s) (unless such Affiliates are
clearly excluded from the referencing provision(s) at issue), provided that in no instance shall
GTx, Inc. be relieved of any duty or obligation hereunder by the inclusion of its Affiliates in the
definition of “GTx”.

     1.16 “IMPROVEMENT INVENTION” shall have the meaning set forth in OSU IIA#1.

     1.17 “Independent SARM Invention” shall have the meaning set forth in Section 2.8
hereof.

     1.18 “Initial SARMS Disclosure” and “Initial SARMS Disclosures” shall have the
meaning set forth in the Recitals.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

3

 

     1.19 “IP RIGHTS” shall have the meaning set forth in OSU IIA#1 when referring to an
EXISTING INVENTION or an IMPROVEMENT INVENTION and the meaning set forth in OSU IIA#2 when
referring to a NEW INVENTION.

     1.20 “License Maintenance Fee” shall have the meaning set forth in Section 4.1A.
hereof.

     1.21 “License Year” shall mean a 12-month period beginning on August 20 of one year
and ending on August 19 of the following year.

     1.22 “Licensed Patent” or “Licensed Patents” shall mean any or all of the (a)
the patents set forth on Appendix A, attached hereto and incorporated herein by reference, (b) the
patent applications set forth on Appendix A and any patents issuing therefrom, and (c) any other
patent applications that may in the future be filed pursuant to Section 6.1 of this Agreement by
GTx, whether in the United States of America or any other country, and any patents issuing
therefrom, including, as they pertain to patents and patent applications described in (a)-(c)
hereof, any and all substitutions for and divisional applications, continuation applications,
continuation-in-part applications, provisional applications, and non-provisional applications,
renewal applications, reissue applications, any foreign patent applications and divisional,
continuation and continuation-in-part applications therefrom or national phase applications which
claim priority from any of the pending patent applications set forth on Appendix A.

     1.23 “Licensed Product” or “Licensed Products” shall mean any Patented Product
or Generic Product, provided that in the case of a Combination Product (as defined under Section
1.7), Licensed Product shall mean only that portion of the Combination Product containing a SARM or
SARMS, and Net Sales for such Licensed Product contained within a Combination Product shall be
determined as set forth under Section 1.29.

     1.24 “Licensed Subject Matter” shall mean Licensed Patents and Licensed Technology.

     1.25 “Licensed Technology” shall mean, except to the extent published or otherwise
generally known to the public:

	 	A.	 	any know-how that is (i) related to an EXISTING INVENTION
and/or an IMPROVEMENT INVENTION licensed by UTRF from OSU under OSU IIA#1; or
(ii) related to a NEW INVENTION licensed by UTRF from OSU under OSU IIA#2; and
	 
	 	B.	 	any technology, trade secrets, methods, processes, know-how,
show-how, data, information, or results (except technology, trade secrets,
methods, processes, know-how, show-how, data, information, or results solely
related to NON-TGS NEW INVENTIONS to the extent not published or otherwise
generally known to the public) that are (i) developed by any one or more of the
UT Contributors in the course of employment by UT or developed by any other UT
employee directly from his or her research or clinical
investigation of SARMs utilizing any Proprietary SARM Know-How; and (ii)
owned solely or in part by UTRF (but, if owned in part by UTRF, only to the
extent of the part owned by UTRF); and (iii) necessary or reasonably useful
for the practice of any of the Licensed Patent(s), including (for purposes
of explaining, and without expanding, the meaning of Sections 1.25B. (i)
through (iii)) any: (1) SARMs, and compositions and compounds containing
SARMS, and analogs or isomers of SARMS, including without limitation
radiolabeled SARMS, fluorescent labeled SARMS, and SARMS with radioisotopes
incorporated therein, and SARMS comprising small molecules of
R-bicalutamide; (2) methods of making, developing, or characterizing such
SARMs, agents, compositions, and compounds of (1); and (3) any therapeutic,
diagnostic, and prognostic methods of use of (1), including but not limited
to methods of treating prostate cancer,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

4

 

	 	 	 	methods of imaging, or methods
related to fertility, contraceptive, andropause, muscle wasting, bone loss
and muscle or bone mass uses.

     1.26 “Major Countries” shall have the meaning set forth in Section 6.6 hereof.

     1.27 “Major Markets” shall mean and include the United States, Great Britain, France,
Germany, and Japan.

     1.28 “Negotiation Period” shall have the meaning set forth in Section 2.8D. hereof.

     1.29 “Net Sales” shall mean the gross amount actually received by GTx or any
Sublicensee for the use, sale or distribution (hereinafter “Sale”) of a Licensed Product
(hereinafter “Gross Receipts”), less the following:

	 	A.	 	refunds, credits, and/or discounts actually given in connection with a
particular Sale in amounts customary in the trade for quantity purchases, cash
payments, and prompt payments, but only if such refunds, credits, and/or discounts
constitute a return of amounts already included in Gross Receipts;
	 
	 	B.	 	refunds, credits and/or discounts actually given for Licensed Products that are
rejected, recalled, returned, or destroyed by customers, but only if such refunds,
credits and/or discounts constitute a return of amounts already included in Gross
Receipts;
	 
	 	C.	 	sales, tariff duties and/or use taxes directly imposed and with reference to a
particular Sale, to the extent included in Gross Receipts;
	 
	 	D.	 	outbound transportation expenses (including insurance relating thereto)
directly related to a particular Sale, to the extent included in Gross Receipts;
	 
	 	E.	 	the cost of export licenses, import duties, value added tax, and prepaid
freight directly related to a particular Sale, to the extent included in Gross
Receipts;
	 
	 	F.	 	sales commissions paid by GTx to individuals who are not employees of GTx, a
Sublicensee, or their respective Affiliates, to the extent such commissions are
directly related to a particular Sale;
	 
	 	G.	 	out-of-pocket service fees consistent with normal industry practice paid to
distributors or wholesalers of drug product in payment for distribution of Licensed
Product, provided that (a) such distributors and wholesalers are not Affiliates of GTx;
(b) if any such distributor or wholesaler is an Affiliate of a Sublicensee, such fees
are no more than that which such distributor/wholesaler actually and contemporaneously
charges unaffiliated third party
pharmaceutical companies for the same or similar service; (c) such fees may not be
deducted more than once; (d) if a Sublicense shall be in effect, the fees paid by a
Sublicensee may be deducted from Net Sales under this Agreement only if such fees
are deducted from the equivalent of Net Sales under the relevant Sublicense
agreement for purposes of calculating the royalty owed to GTx;
	 
	 	H.	 	retroactive price reductions, chargeback payments and rebates actually granted
in connection with a particular Sale to managed health care organizations or to
federal, state and local governments, their agencies, purchasers, and reimbursers, but
only if such reductions, chargeback payments, and rebates constitute a return of
amounts already included in or calculated as part of Gross Receipts; and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

5

 

	 	I.	 	[ * ] of any royalty (including a lump-sum payment) that is paid to a Third
Party by GTx pursuant to a patent license agreement between GTx and such Third Party,
provided that at the time of such payment (1) such Third Party owns or controls an
issued patent containing a Valid Claim that, in the absence of such patent license
agreement, would be infringed by the use, sale, or distribution of the composition of
matter of a SARM licensed to GTx hereunder; and (2) the purpose of such royalty is for
licensing of or acquiring such issued patent; and (3) the dollar amount of the [ * ]
deduction for any calendar quarter shall not exceed the dollar amount of Net Sales in
the same calendar quarter (computed without the application of this Section 1.29I.)
from the use, sale, or distribution of Licensed Products containing such SARM in the
country(ies) where such Third Party owns or controls such issued patent, it being
agreed, however, that GTx may carry forward to future quarter(s) the amount by which
the dollar amount of the [ * ] deduction exceeds the cumulative dollar amount of the
actual deductions taken; and (4) GTx has not entered into such patent license
agreement as of the date of execution of this Agreement.

For avoidance of doubt, no deductions shall be made for sales commissions paid to individuals who
are employees of GTx, a Sublicensee, or their respective Affiliates, or for cost of collections.
Notwithstanding the foregoing, Net Sales shall not include the amount received by GTx for the
transfer of Licensed Product to a GTx Affiliate or a Sublicensee or the amount received by a
Sublicensee for transfer or distribution of Licensed Product to GTx or a GTx Affiliate. Sales of
Licensed Product for use in conducting clinical trials of a Licensed Product candidate in a country
shall be excluded from Net Sales calculations for all purposes. Net Sales shall be determined in a
consistent manner for all products sold by or on behalf of GTx and its Sublicensees and in
accordance with applicable U.S. generally accepted accounting principles for GTx and any U.S. based
Sublicensee.

Combination Product. In the event one or more Licensed Products are sold as part of a
Combination Product in a particular country, the Net Sales of such Licensed Product(s), for the
purposes of determining payments based on Net Sales, shall be determined by multiplying the Net
Sales of the Combination Product in such country, during the applicable Net Sales reporting period,
by the fraction, A/(A+B), where:

A is the average sale price of the Licensed Product(s) by GTx or Sublicensees when sold separately
in finished form in such country and B is the average sale price by GTx or Sublicensees, or, if
they have no such right of sale, by a Third Party of the other product(s) included in the
Combination Product when sold separately in finished form in such country, in each case during the
applicable Net Sales reporting period.

In the event one or more Licensed Products are sold as part of a Combination Product and are sold
separately in finished form in such country, but the other product(s) included in the Combination
Product are not sold separately in finished form in such country, the Net Sales of the Licensed
Product, for the purposes of determining payments based on Net Sales, shall be determined by
multiplying the Net Sales of the Combination Product in such country by the fraction C/D where:

C is the average sale price, in such country, of the Licensed Product(s) contained in such
Combination Product when sold separately and D is the average sale price, in such country, for the
Combination Product, in each case during the applicable Net Sales reporting period. Under no
circumstances can C/D exceed one hundred percent (100%).

In the event that one or more of the Licensed Product(s) are not sold separately in finished form
in the country, but all of the other product(s) included in the Combination Product in such country
are sold separately, the Net Sales of the Licensed Product, for the purposes of determining
payments based on Net Sales, shall be determined by multiplying the Net Sales of the Combination
Product in such country by the fraction (D-E)/D, where:

D is the average sale price, in such country, of the Combination Product, and E is the average sale
price of the other product(s) included in the Combination Product in finished form in such country,
in each case during the applicable Net Sales reporting period.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

6

 

In the event that the Net Sales of the Licensed Product(s) when included in a Combination Product
cannot be determined using the methods above, Net Sales for the purposes of determining payments
based on Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by
the fraction of F/(F+G) where:

F is the fair market value of the Licensed Product(s) and G is the fair market value of all other
pharmaceutical product(s) included in the Combination Product, as reasonably determined in good
faith by the Parties.

     1.30 “NEW INVENTION” shall have the meaning set forth in OSU IIA#2, but limited for
purposes of this Agreement to invention(s) described in the Third Generation SARMS Disclosure.

     1.31 “NON-TGS NEW INVENTION” shall have the meaning set forth for NEW INVENTION in OSU
IIA#2, but excluding for purposes of this Agreement invention(s) described in the Third Generation
SARMS Disclosure.

     1.32 “Option” shall have the meaning set forth in Section 2.8 hereof.

     1.33 “Option Period” shall have the meaning set forth in Section 2.8A. hereof.

     1.34 “OSU” shall mean The Ohio State University, except that where it is used in
reference to OSU IIA#1 or OSU IIA#2 in which case it shall mean The Ohio State University and
OSURF, as set forth therein.

     1.35 “OSU Contributors” shall mean Dr. James T. Dalton and/or other research staff and
students at OSU.

     1.36
“OSU IIA#1” shall have the meaning set forth in the Recitals.

     1.37
“OSU IIA#2” shall have the meaning set forth in the Recitals.

     1.38 “OSURF” shall mean The Ohio State University Research Foundation.

     1.39 “Patented Product” shall mean any product whose manufacture, use, sale or import
is covered in whole or in part by a Valid Claim of the Licensed Patents in the country of
manufacture, use, sale or import.

     1.40 “Party” and “Parties” shall have the meaning set forth in the
introductory paragraph hereof.

     1.41 “Prior License Agreements” shall have the meaning set forth in the Recitals.

     1.42 “Proprietary SARM Know-How” shall mean know-how pertaining to an EXISTING
INVENTION, IMPROVEMENT INVENTION or NEW INVENTION that is obtained from GTx or a UT Contributor and
is not published or otherwise generally known to the public.

     1.43 “Regulatory Approval” shall mean any approvals granted by a governmental
authority in a particular regulatory jurisdiction (with the exception of conditional approvals)
that are necessary for the commercial manufacture, use, storage, importation, export, transport or
sale of Licensed Products in that regulatory jurisdiction.

     1.44 “Running Royalty” shall have the meaning set forth in Section 4.1B. hereof.

     1.45 “SARM” or “SARMS” shall mean selective androgen receptor modulator(s)
whose primary pharmacologic effect at any dose observed in vivo is mediated by the androgen
receptor.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

7

 

     1.46 “Sublicense” shall mean a direct grant of right, license, or option to any
Licensed Subject Matter from GTx to a GTx Affiliate or a Third Party and any further such grant at
any tier.

     1.47 “Sublicense Revenue” shall mean all payments actually received by GTx pursuant to
each Sublicense, including, without limitation, up-front license fees, milestone payments, license
maintenance fees, election fees, and all other fees and payments paid to GTx under each Sublicense
agreement, excluding running royalties received by GTx that are calculated as a percentage of
Sublicensee’s Net Sales and up-front fees paid by Ortho Biotech Products L.P. pursuant to the Joint
Collaboration and License Agreement entered into with GTx effective as of March 16, 2004. GTx may
deduct from Sublicense Revenue attributable to a particular Sublicense agreement payments received
by GTx as reimbursement for actual, otherwise unreimbursed, out-of-pocket expenses as set out in
such Sublicense agreement, provided that only reimbursements for expenses incurred in the
development of one or more Licensed Products covered by such Sublicense may be deducted from
Sublicense Revenue and then only to the extent of expenses incurred from and after the date of the
Sublicense for pre-clinical or clinical research and development, including development of the
formulation and manufacturing process, manufacturing of preclinical and clinical supplies and
analytical and stability testing as required by the Food and Drug Administration to support a New
Drug Application (NDA) filing for the Licensed Product. For the avoidance of doubt, Sublicense
Revenue will not include any payments made to Third Parties by or on behalf of a Sublicensee for
conducting clinical trials, filing new drug applications, commercially launching a product and/or
marketing and selling a product, since these are not payments received by GTx from a Sublicensee on
account of the Sublicense.

     1.48
“Sublicense Royalty” shall have the meaning set forth in Section 4.1C. hereof.

     1.49
“Sublicensee” shall mean and include any recipient of a Sublicense.

     1.50
“Sublicensee Patent Rights” shall have the meaning set forth in Section 6.2 hereof.

     1.51
“Term” shall have the meaning set forth in Section 12.1 hereof.

     1.52
“Third Generation SARMS Disclosure” shall have the meaning set forth in the Recitals.

     1.53 “Third Party” or “Third Parties” shall mean any person, party or entity
other than GTx, its Affiliates, UTRF, or UT.

     1.54 “UT” shall mean The University of Tennessee.

     1.55 “UT Contributor” and “UT Contributors” shall mean one or more of James T.
Dalton, Yali He, Dong-Jin Hwang, Leonid Kirkovsky, Craig Marhefka, Duane Miller, Michael Mohler,
Arnab Mukherjee, Igor
Rakov, Huiping Xu, Donghua Yin and any other UT employee who, while under the supervision of
Duane Miller or James T. Dalton, contributed, either before or after the Effective Date, to the
development of the Licensed Subject Matter.

     1.56 “Valid Claim” shall mean (a) a claim of an issued patent which has not expired
and which has not been held revoked, invalid or unenforceable by decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed with the time allowed for
appeal having expired, and which has not been admitted to be invalid through reissue or disclaimer
or otherwise; or (b) any claim of a pending patent application, which (i) was filed in good faith;
and (ii) has not been pending for more than eight (8) years.

     [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

8

 

SECTION 2

 Grant

     2.1 During the Term hereof, and subject to the terms and conditions of this Agreement, UTRF
hereby grants to GTx for the purpose of developing, making, having made, using, marketing, selling,
having sold, importing, distributing, and offering for sale the Licensed Product:

	 	A.	 	an exclusive, worldwide right and license, with the right to grant Sublicenses,
to practice under the Licensed Patents that are owned solely or in part by UTRF,
excluding Licensed Patents to which a license is granted in Section 2.1B.; and
	 
	 	B.	 	subject to the provisions of OSU IIA#1 and OSU IIA#2, as applicable, an
exclusive, worldwide right and license, with the right to grant Sublicenses, to
practice under the Licensed Patents and the IP RIGHTS that are owned jointly by UTRF
and OSU or owned solely by OSU and that cover an EXISTING INVENTION, an IMPROVEMENT
INVENTION or a NEW INVENTION, provided that OSU’s interest is licensed to UTRF with the
right to grant sublicenses pursuant to the provisions of OSU IIA#1 or OSU IIA#2, as the
case may be; and
	 
	 	C.	 	subject to the provisions of OSU IIA#1 and OSU IIA#2, as applicable, an
exclusive, worldwide right and license, with the right to grant Sublicenses, of the
non-exclusive rights received by UTRF from OSU under OSU IIA#1 and OSU IIA#2 to utilize
the Licensed Technology described in Section 1.25A.; and
	 
	 	D.	 	subject to the provisions of OSU IIA#1 and OSU IIA#2, as applicable, an
exclusive, worldwide, right and license, with the right to grant sublicenses, to
utilize the Licensed Technology described in Section 1.25B.

Subject to the other provisions of this Agreement, the Parties hereby agree that the term
“exclusive” means that to the extent of UTRF’s rights in the Licensed Subject Matter and subject to
Federal Policy and the provisions of OSU IIA#1 and OSU IIA#2, UTRF shall not grant any other
license under Licensed Subject Matter to any Third Party or take any action inconsistent with the
rights granted to GTx under this Agreement. The Parties further acknowledge and agree that to the
extent UTRF owns any Licensed Subject Matter “in part”, the license herein granted to GTx will not
give GTx or its Sublicensees the right to exclude UTRF’s co-owner(s) from exercising any rights
attendant to such co-ownership, whether such rights arise by law or contract, provided that UTRF
agrees that it will not negotiate or enter into a license agreement or sublicense agreement, or
otherwise grant any option or licenses or other rights with respect to such Licensed Subject Matter
(whether in whole or in part), except as required by Federal Policy. For avoidance of doubt, the
exercise by GTx of its right to grant Sublicenses will not serve to restrict GTx’s exercising of
its right, as granted above, to practice under the Licensed Patents and/or to utilize the Licensed
Technology.

     2.2 GTx agrees that UT and those persons who, as of the date of signature hereto on behalf of
UTRF, are named UT Contributors shall have the royalty-free non-exclusive right to practice under
the Licensed Patents and to utilize the Licensed Technology for non-commercial educational,
research, and academic purposes only. GTx acknowledges and agrees that OSU retains the
non-exclusive right to use EXISTING INVENTIONS and IMPROVEMENT INVENTIONS and associated IP RIGHTS
under OSU IIA#1, as well as NEW INVENTIONS and associated IP RIGHTS under OSU IIA#2, to the extent
of any of its respective rights therein, solely for non-commercial educational, research (including
non-commercial clinical research), and academic purposes, but that OSU has contractually
acknowledged that it has no rights for clinical research using a UTRF or GTx proprietary BRIDGED
SARMS compound or to refer to any GTx regulatory filing without prior written approval from UTRF or
GTx. UTRF agrees that during the Term hereof, it will not, without obtaining GTx’s prior written
consent, enter

     [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

9

 

into a modification of OSU IIA#1 or OSU IIA#2 that (i) grants any additional
ownership rights to OSU in an EXISTING INVENTION, IMPROVEMENT INVENTION, or NEW INVENTION; or (ii)
places any additional obligations on GTx.

     2.3 To the extent that any research pertaining to inventions included in Licensed Technology
and/or claimed in Licensed Patents has been or is in the future funded in whole or in part by the
United States government, the United States government retains certain rights and requires certain
obligations concerning such inventions as set forth in 35 U.S.C. §§200-212 and all regulations
promulgated thereunder, as amended, and any successor statutes and regulations and applicable
policies of such United States government sponsors, including, without limitation, to the extent
applicable, the utilization and capability requirements found in the National Institutes of Health
(NIH) Grants Policy Statement; “Developing Sponsored Research Agreements: Considerations for
Recipients of NIH Research Grants and Contracts”, Federal Register, Vol. 59, No. 215, Tuesday,
November 8, 1994, pp. 55675-55679 (collectively, “Federal Policy”). GTx acknowledges that
all rights herein granted to GTx may be subject to any such rights held by the United States
government and further subject to any restrictions or obligations that may be imposed by the United
States government pursuant to such rights. GTx shall materially comply with all aspects of Federal
Policy applicable to a licensee pertaining to Licensed Technology and/or Licensed Patents and shall
include and require its Sublicensees to include a provision in each Sublicense agreement, at any
tier, that requires the Sublicensee to materially comply with all applicable aspects of Federal
Policy. In the event UTRF or GTx shall receive notice of any action or notification by the United
States government with respect to any rights and/or obligations under Federal Policy pertaining to
any rights licensed hereunder to GTx, the Party receiving such notice shall provide prompt written
notice thereof to the other Party.

     2.4 Intentionally omitted.

     2.5 GTx shall have the right to enter into Sublicenses and to permit further sublicensing by
Sublicensees through multiple tiers with respect to the Licensed Subject Matter, subject to
notifying UTRF of the identity and address of each Sublicensee within thirty (30) days after
execution of such agreement by the parties thereto. No GTx Affiliate or Third Party shall have the
right to practice under the Licensed Patents or utilize the Licensed Technology to make, have made,
use, market, sell, have sold, import, distribute, or offer for sale any Licensed Product in the
absence of a written Sublicense agreement. Any grant of rights by GTx or a Sublicensee to practice
under the Licensed Patents or to utilize the Licensed Technology to make, have made, use, market,
sell, have sold, import, distribute, or offer for sale any Licensed Product shall constitute a
Sublicense. All Sublicenses shall be subject to this Agreement in all respects and shall include
provisions that such Sublicensee is being granted a license under the Licensed Subject Matter as
defined herein and subject to the terms hereof.

     2.6 GTx shall be responsible for its Affiliates and Sublicensees and shall not grant any
rights that are inconsistent with the rights granted to and obligations of GTx hereunder. Each
Sublicense agreement shall include a requirement that the Sublicensee use its commercially
reasonable efforts to bring the subject matter of the Sublicense into commercial use. In addition,
each Sublicense agreement shall include an acknowledgement that the
ownership of the Licensed Patents are and shall remain in the name of UTRF and/or OSU, as set
forth in OSU IIA#1 or OSU IIA#2, as the case may be, with the exception of Licensed Patents that
are properly assigned to GTx, and, except as set forth in Section 6.2 hereof, an obligation on the
part of the Sublicensee to assign, transfer and convey ownership of Licensed Patents to UTRF
and/or, as UTRF may direct, to OSU, OSURF, or GTx. Upon termination of this Agreement, each
Sublicensee’s rights under any Sublicense agreement shall also terminate, provided that if UTRF
terminates this Agreement for default by GTx, a Sublicensee’s rights under a Sublicense agreement
shall terminate only if UTRF has given such Sublicensee notice of default at least thirty (30) days
prior to the effective date of termination and the Sublicensee shall have failed to cure such
default, as provided in Section 12.3. UTRF shall have discharged its obligation to give notice of
such default to a Sublicensee by sending (through any means contemplated under Section 15) a copy
of GTx’s notice of default to the Sublicensee’s most recent street address of which UTRF has
received written notice from GTx or the Sublicensee. No Sublicense shall relieve GTx of any of its

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

10

 

obligations under this Agreement, except that a Sublicensee shall have the right to cure a default
of GTx as set out in Section 12.3. GTx shall forward to UTRF a complete copy of each Sublicense
agreement (including, without limitation, all amendments and addenda) granted hereunder within
thirty (30) days after execution of such agreement by the parties thereto, provided that each such
Sublicense agreement (and any amendments and addenda related thereto) shall be deemed GTx’s
Confidential Information and UTRF shall receive such information and documents in confidence and
shall not publicly disclose, discuss or release such information or document to Third Parties
(other than such information as may be reasonably necessary to be disclosed to UT Contributors and
those persons within UT who have a need to know such information, provided that only such
information concerning the Sublicense that is necessary to explain any payments to be made to a UT
Contributor will be shared with the UT Contributors) without the prior written approval of GTx
except for the purposes of enforcement of UTRF’s rights, defense of any claim against UTRF, UT, UT
Contributors, OSU, OSURF, or OSU Contributors, compliance with Federal Policy, compliance with OSU
IIA#1 or OSU IIA#2, or compliance with applicable law, regulation, or court order. GTx shall be
responsible for payment of royalties from Sublicensees’ Net Sales provided, however, that GTx may
arrange for such payments to be made to UTRF by a Sublicensee, with the understanding that the
amount paid to UTRF shall not be decreased thereby and that UTRF’s acceptance of such payments from
a Sublicensee does not relieve GTx of the ultimate responsibility for any other or future payment
required hereunder. Each such Sublicense agreement shall include an audit right by UTRF of the
same scope as provided in Section 5.1 herein with respect to UTRF’s audit of GTx’s books of
account.

     2.7 Any act or omission of an Affiliate or Sublicensee, which would constitute a breach of
this Agreement if performed by GTx, shall be deemed to be a breach by GTx of this Agreement,
subject however to the same cure provisions in favor of GTx, an Affiliate, or Sublicensee as are
otherwise provided herein for breach by GTx.

     2.8 During the Term hereof, UTRF shall promptly notify GTx in writing (i) upon becoming aware
of any SARM invention owned solely or in part by UTRF which is not (a) based on or developed from
Proprietary SARM Know-How or (b) developed at UT from grants or research payments made to UT by
GTx; or (ii) upon acquiring from OSU a license pursuant to OSU IIA#2, with the right to sublicense,
to a NON-TGS NEW INVENTION (each invention described in subsection (i) and subsection (ii) herein
being an “Independent SARM Invention”). Subject to the rights of Third Parties (in the
event UTRF co-owns such Independent SARM Invention with a Third Party), GTx will have an exclusive
option to acquire, to the extent possible, a worldwide, exclusive (as defined in Section 2.1),
royalty-bearing license to such Independent SARM Invention (“Option”), provided that the
grant of such Option does not violate Federal Policy and further subject to the following:

	 	A.	 	The Option shall commence upon UTRF’s written notice to GTx of the existence of
such Independent SARM Invention and shall terminate upon the earlier of (i) the
expiration of six (6) calendar months from the date of such notice; or (ii) the giving
of written notice to UTRF by GTx that it does not intend to exercise the Option; or
(iii) the termination of this Agreement (“Option Period”)
	 
	 	B.	 	GTx may exercise the Option during the Option Period by giving written notice
of same to UTRF, provided that GTx is not then in default or breach of any of its
obligations under this Agreement.
	 
	 	C.	 	Upon proper exercise of the Option by GTx, UTRF and GTx shall negotiate in good
faith in an effort to reach agreement on the economic terms of a license to GTx of the
Independent SARM Invention that is the subject of such Option, it being the intent that
upon agreement of the Parties as to such economic terms, they will be expeditiously
incorporated into a new license agreement with non-economic terms that are
substantially similar to those contained herein, to the extent applicable.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

11

 

	 	D.	 	In the event GTx does not exercise the Option for a particular Independent SARM
Invention within the Option Period or the Parties do not execute a license agreement
within six (6) months after exercise of the Option for a particular Independent SARM
Invention by GTx, which time period may be extended by written agreement of the Parties
(the “Negotiation Period”), UTRF shall have no further obligation to GTx under
this Agreement with regard to such Independent SARM Invention. In the absence of a
license agreement granting GTx rights to such Independent SARM Invention, GTx agrees
that it will not use such Independent SARM Invention for any commercial or
non-commercial purpose.
	 
	 	E.	 	During the Option Period and the Negotiation Period, if any, UTRF will confer
with GTx concerning proper protection of such Independent SARM Invention, but UTRF will
have sole authority regarding decisions concerning such protection, including patent
activities, provided that if GTx exercises the Option, UTRF shall coordinate all
decisions regarding patent protection with GTx and shall take no actions with regard to
intellectual property protection for such Independent SARM Invention that are contrary
to GTx’s advice unless UTRF reasonably believes rights may be lost unless it acts to
protect those rights. From and after the commencement of the Option Period, whether or
not GTx exercises the Option and whether or not the Parties subsequently execute a
license agreement for GTx to secure rights to the Independent SARM Invention prior to
the end of the Negotiation Period, GTx shall, within thirty (30) days after receipt of
each invoice, reimburse UTRF for all reasonable and documented out-of-pocket expenses
incurred by UTRF during the Option Period and the Negotiation Period, if any, for
filing, prosecution, and maintenance of United States and foreign patent applications,
issued patents, and other forms of intellectual property protection for such
Independent SARM Invention, which intellectual property rights shall be assigned solely
to UTRF or jointly to UTRF and its co-owner(s), if any, provided that UTRF shall have
consulted with GTx regarding such proposed patent protection and UTRF shall have
undertaken to make those filings that are reasonably necessary to protect and preserve
its rights in the Independent SARM Invention to reasonably minimize the expenses GTx
may be required to reimburse in accordance with this Section 2.8E until the Option
Period and Negotiation Period shall have expired. If GTx shall fail to enter into a
license agreement with UTRF for such Independent SARM Invention, it shall be entitled
to receive a dollar for dollar reduction against Running Royalties and/or Sublicense
Revenue (in the same manner as the reduction is to be applied in Section 4.1D) for the
total amount of costs it shall have reimbursed to UTRF for the expenses incurred by
UTRF under this Section 2.8E.

SECTION 3

Diligence

     3.1 GTx shall use its commercially reasonable efforts to develop and commercialize Licensed
Products through a commercially reasonable program for exploitation of the Licensed Patents and the
Licensed Technology.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

12

 

SECTION 4

Payments and Royalties

     4.1 For the rights, privileges and license granted hereunder, GTx shall pay to UTRF, in
addition to the Consideration Fee, the following fees and royalties in the manner hereinafter
provided until this Agreement expires or is terminated.

	 	A.	 	License Maintenance Fee. GTx shall pay UTRF a license maintenance fee
in the amount of [ * ] on [ * ] and on [ * ] thereafter during the Term of this
Agreement (“License Maintenance Fee”). The License Maintenance Fee actually
paid for a particular License Year shall reduce, dollar for dollar, the Running Royalty
(defined below) payable in the same License Year. License Maintenance Fees paid in
excess of the Running Royalty payable in the same License Year shall not be creditable
to the Running Royalty for future years. The Parties acknowledge and agree that there
are no License Maintenance Fees due and owing to UTRF by GTx under the Prior License
Agreements.
	 
	 	B.	 	Running Royalty. For the purposes of this Section 4.1(B), royalties on
Net Sales of all Patented Products and Generic Products incorporated in Combination
Products shall be subject to the calculation of Net Sales with respect to Combination
Products, as applicable, as set forth in Section 1.29.

	 	(1)	 	GTx shall pay UTRF [ * ] of Net Sales of all Patented Products; and
	 
	 	(2)	 	GTx shall pay UTRF a percentage of Net Sales attributable to
the use, sale or distribution of Generic Products, which percentage shall be
determined on a Generic Product-by-Generic Product, country-by-country, and
calendar quarter-by-calendar quarter basis. In each country the percentage
shall be calculated as the [ * ] during the applicable calendar quarter divided
by the [ * ] during the same calendar quarter [ * ] (provided that in no event
shall the resulting percentage [ * ]). Furthermore, until such time as this
Agreement shall expire in accordance with Section 12.1, should there be no
sales in the Major Markets by GTx or Sublicensees of the same Licensed Product
covered by a Valid Claim of Licensed Patents during the same calendar quarter,
the percentage shall be [ * ];

(the royalty under 4.1B.(1) and 4.1B.(2) being the “Running Royalty”).
Notwithstanding the foregoing, in the event that, for a particular Licensed Product
in a given License Year under a specific Sublicense agreement, the running royalty
(as a percentage of Net Sales) owed to GTx (including the Running Royalty owed to
UTRF, if to be paid by the Sublicensee) is less than [ * ] of Sublicensee’s Net
Sales after deduction of running royalties (calculated as a percentage of Net Sales)
owed and actually paid by or on behalf of GTx to one or more Third Parties as
consideration for the grant by such Third Party(ies) of a license to technology
incorporated in such Licensed Product, the Running Royalty owed to UTRF shall be [ *
] of the amount owed to GTx (including the Running Royalty owed to UTRF, if to be
paid by the Sublicensee) for that License Year. By way of example only, in the
event that during a particular License Year GTx is entitled to receive a running
royalty equal to [ * ] of its Sublicensee’s Net Sales of a particular Licensed
Product in the EU and is in turn required to pay, and does actually pay, [ * ] of
Sublicensee’s Net Sales of that Licensed Product in the EU to a Third Party, then
UTRF’s Running Royalty would be [ * ] of Sublicensee’s Net Sales of that Licensed
Product in the EU.

	 	C.	 	Sublicense Royalty. GTx shall pay UTRF [ * ] of Sublicense Revenue
(“Sublicense Royalty”)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

13

 

	 	D.	 	Reduction. GTX shall be entitled to reduce dollar-for-dollar the
Running Royalties and/or the Sublicense Royalties (such reduction to be applied at
GTx’s sole discretion) which are otherwise payable to UTRF by a total of [ * ] to
reimburse GTx for certain shared legal expenses previously borne by GTx in connection
with the negotiation of OSU IIA#1.

     4.2 In the event that any taxes are required by law or regulation to be levied in any foreign
country by a foreign taxing authority on any Running Royalty or Sublicense Royalty payable in
UTRF’s name under this Agreement and GTx determines in good faith that it or its Sublicensee must
withhold such taxes:

	 	A.	 	GTx or its Sublicensee shall have the right to withhold and pay such taxes
withheld on the Running Royalty and/or Sublicense Royalty to the local tax authorities
in UTRF’s name;
	 
	 	B.	 	GTx or its Sublicensee shall pay the net amount of Running Royalty and/or
Sublicense Royalty due after reduction by the amount of such taxes that are actually
withheld and paid;
	 
	 	C.	 	GTx or its Sublicensee shall provide UTRF with appropriate documentation and
receipts supporting such withholding; and
	 
	 	D.	 	GTx or its Sublicensee shall inform UTRF in writing within thirty (30) days of
being notified that taxes will be or have been required by a taxing authority to be
withheld on the Running Royalty and/or Sublicense Royalty.

     4.3 In the event that a Running Royalty is payable to UTRF on the same Net Sales revenue or a
Sublicense Royalty is payable to UTRF on the same Sublicense Revenue under this Section 4 and under
one or more other UTRF/GTx license agreements, GTx shall only be required to pay UTRF such royalty
under one such license agreement, subject to the provisions of Section 5.2 and provided that if the
amount due varies from one such license agreement to another, GTx shall pay the highest amount.

     4.4 Within [ * ] following the close of each calendar quarter in which Net Sales revenue is
received by GTx or a Sublicensee, or Sublicense Revenue is received by GTx, payment of all amounts
due to UTRF, including but not limited to Running Royalty and Sublicense Royalty, shall be made to
UTRF or its designee in United States dollars in Knoxville, Tennessee, or at such other place as
UTRF may reasonably designate consistent with the laws and regulations controlling in any foreign
country, provided that the [ * ] period may be extended for up to [ * ] after the close of each
calendar quarter if a Sublicensee under a Sublicense requires more time than [ * ] to make its
sales and royalty calculation and its royalty payment available to GTx. In the event GTx arranges
for any payment under this Section 4.4 to be made to UTRF by a Sublicensee pursuant to Section 2.6,
if such payment is not received by UTRF within the [ * ] period set forth herein (or within up to [
* ] extension period as stated above), GTx shall be deemed to be in breach of this Agreement,
subject to the same cure provisions in favor of GTx as set forth in Section 12. If any currency
conversion shall be required in connection with the payment of royalties hereunder, such conversion
shall be made by using the exchange rate procedure listed in a Sublicense, if applicable, or in the
absence of an applicable Sublicense provision addressing this issue, using the exchange rate listed
in the Wall Street Journal for major New York banks on the last business day of the calendar
quarter during which the royalty-bearing revenue was received by GTx or its Sublicensees, as the
case may be.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

14

 

SECTION 5

Reports and Records

     5.1 No more often than once each License Year, UTRF or its accounting agents shall have the
right to inspect the books of account of GTx. GTx shall keep full, true and accurate books of
account containing all
particulars that may be necessary for the purpose of showing the amounts payable to UTRF
hereunder. Said books of account shall be kept at GTx’s principal place of business or the
principal place of business of the appropriate division of GTx to which this Agreement relates.
Said books and the supporting data shall be open at all reasonable times for [ * ] following the
end of the License Year to which they pertain, to the inspection of UTRF or its accounting agents
for the purpose of verifying GTx’s royalty statements. If any examination reveals a shortage in
amounts paid to UTRF, GTx shall promptly reimburse UTRF for the shortage, together with interest
thereon as provided in Section 5.4, and if the shortage is equal to or greater than [ * ] of the
total amount due in the period under audit, GTx shall reimburse UTRF for the cost of the
examination as well. If the examination reveals an overpayment to UTRF, GTx may deduct the amount
of such overpayment from future amounts owed to UTRF hereunder.

     5.2 GTx shall deliver to UTRF true and accurate reports to confirm a royalty accounting
hereunder within [ * ] after the close of each calendar quarter (provided that the [ * ] period may
be extended for up to [ * ] after the close of each calendar quarter if a Sublicensee under a
Sublicense requires more time than [ * ] to make such information and its royalty payment available
to GTx) and a summary of GTx’s activities during such quarter to develop and commercialize Licensed
Products. These reports shall be deemed GTx’s Confidential Information and shall include at least
the following, on a Licensed Product-by-Licensed Product, country-by-country, and
Sublicensee-by-Sublicensee basis:

	 	A.	 	The number/amount of Licensed Product used, sold, or imported by and/or for GTx
and Sublicensees and other information that is reasonably necessary to allow UTRF to
properly calculate royalties due to OSU under OSU IIA#1 and, if applicable, OSU IIA#2
(e.g., the number/amount of BRIDGED SARMS or other SARMS sold);
	 
	 	B.	 	The total amounts invoiced and received by GTx and Sublicensees for Licensed
Products used or sold by GTx and/or Sublicensees including (i) an accounting of Net
Sales for Running Royalty payments due to UTRF under Section 4.1B. above, with separate
calculations for Patented Products, Generic Products, and Combination Products
reflecting the type and amount of all deductions from Gross Receipts; and (ii) an
accounting of Sublicense Revenue for Sublicense Royalty payments due to UTRF under
Section 4.1C above reflecting the type and amount of all amounts deducted or excluded
from Sublicense Revenue;
	 
	 	C.	 	The Running Royalty and Sublicense Royalty due, showing the application of any
reduction pursuant to Section 4.1D and Section 2.8E., if applicable;
	 
	 	D.	 	For all royalties due to UTRF pursuant to Section 4.1, the report shall include
(i) the manner in which such royalties were calculated and the amount allocable to each
Licensed Product; and (ii) if any such royalties are payable to UTRF under this
Agreement and under one or more other UTRF/GTx license agreements, GTx shall set out in
its report the amount of such royalties covered by multiple license agreements and
identify all such license agreements to which such royalties apply, notwithstanding
that GTx is required to pay such royalties under only one such license agreement;
	 
	 	E.	 	The names and addresses of all Sublicensees for or on whose account royalty
payments are being made in accordance with the terms hereof; and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

15

 

	 	F.	 	Upon request by UTRF, any other information that may be necessary for the
purpose of showing the amounts payable to UTRF hereunder, amounts payable to OSU
pursuant to IIA#1 and/or IIA#2 and/or compliance by GTx with the diligence provisions
of Section 3.

     5.3 With each such report submitted, GTx shall pay to UTRF the royalties due and payable under
this Agreement. If no royalties shall be due, GTx shall so report. UTRF is hereby authorized to
provide to OSU or
OSURF a copy of any written reports provided to UTRF by GTx, subject to the confidentiality
provisions of OSU IIA#1, and if applicable, OSU IIA#2.

     5.4 Any amount owed by GTx under this Agreement that is not received by UTRF on or before the
date due shall bear interest at a per annum rate [ * ] above the prime rate quoted in the Wall
Street Journal for major New York banks on the date due, or if not quoted on the date due, the rate
quoted on the first business day after the date due. GTx shall also pay all reasonable collection
costs at any time incurred by UTRF in obtaining payment of amounts past due, including reasonable
attorneys fees. If the transfer or the conversion into United States Dollar equivalents in any
such instance is not lawful or possible, the payment of such part of the royalties as is necessary
shall be made by the deposit thereof, in the currency of the country where the sales were made on
which the royalty was based, to the credit and account of UTRF or its nominee in any commercial
bank or trust company of its choice located in that country, prompt notice of which shall be given
by GTx to UTRF.

SECTION 6

Patent Prosecution

     6.1 During the Term and subject to the terms hereof and the applicable provisions of OSU IIA#1
and OSU IIA#2, GTx shall have (a) complete control of the prosecution of the Licensed Patents
listed on Appendix A and will be responsible for maintaining any patents issuing therefrom and (b)
the exclusive right and responsibility to prepare, file, prosecute and maintain all patent
applications and patents claiming (i) EXISTING INVENTIONS and IMPROVEMENT INVENTIONS that are
solely or partly owned by UTRF or licensed to UTRF under OSU IIA#1 with the right to sublicense;
(ii) NEW INVENTIONS that are licensed to UTRF under OSU IIA#2 with the right to sublicense; (iii)
inventions solely owned by UTRF that are described in the Initial SARMS Disclosures; (iv)
invention(s) disclosed in the Third Generation SARMS Disclosure that are owned in whole or in part
by UTRF and are not covered by Section 6.1(ii); and (v) Licensed Technology defined in Section
1.25B., and such patent applications and patents shall be added to Appendix A. GTx shall use
patent counsel of its own choice, at its own expense. GTx agrees to pay all costs incident to the
United States and foreign applications, patents and like protection relating to the Licensed
Subject Matter, including all costs incurred for filing, prosecution, issuance and maintenance fees
as well as any costs incurred in filing continuations, continuations-in-part, divisionals or
related applications and any re-examination, reissue, opposition, or interference proceedings.
Subject to the provisions of Section 6.4, GTx shall file and maintain patent applications claiming
Licensed Technology defined in Section 1.25B. in such countries as GTx in its sole discretion shall
select. Except for Licensed Patents listed on Appendix A that are assigned to GTx or Sublicensee
Patent Rights as described in Section 6.2, UTRF shall have the sole and exclusive right, title and
ownership in and to all Licensed Patents, including Licensed Patents claiming Licensed Technology
defined in Section 1.25B., which now exist or may exist in the future, including all United States
and foreign patent applications filed and patents issued pursuant to this Section 6, except
Licensed Patents claiming invention(s) made in whole or in part by one or more OSU Contributors or
other Third Parties as determined in accordance with applicable patent laws, ownership of which
shall be subject to the provisions of Section 6.2.

     6.2 GTx and its Sublicensees shall assign, transfer and convey to UTRF all right, title and
interest in and to all Licensed Patents, except (i) those claiming invention(s) made in whole or in
part by one or more OSU Contributors or Third Parties, which Licensed Patents are to be assigned,
in whole or in part, as the case may be, to OSU, OSURF, or in accordance with the instructions of
such Third Party(ies); and (ii) those listed on Appendix A that, as of the Effective Date, have
been assigned to GTx. GTx shall be responsible for recording an assignment, as

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

16

 

appropriate, to
UTRF and/or OSU and/or OSURF and/or to such individual(s) or entity(ies) as such Third Party(ies)
may direct, of patent applications filed pursuant to this Section 6 with the United States Patent
and Trademark Office and with each foreign Patent Office in which such applications are filed.
Notwithstanding the foregoing, GTx may permit its Sublicensees to retain ownership of patent
applications or patents claiming invention(s) made by employee(s) or agent(s) of such Sublicensee
which result from the Licensed Subject Matter (“Sublicensee Patent Rights”), provided that
the pertinent Sublicense agreement shall include provision(s) granting to UTRF, UT, OSU, and OSURF
a perpetual worldwide non-exclusive royalty-free right to practice, for non-commercial educational,
research and academic purposes only (such right to exclude the practice of Licensed Patents
for any fee-for-services arrangement or for sponsored research on behalf of any commercial entity),
under Sublicensee Patent Rights claiming inventions necessary or reasonably useful in the practice
of the Licensed Patents.

     6.3 GTx agrees to provide UTRF with reasonable (which the Parties agree generally means not
less than two weeks) advance notice prior to filing of new patent applications containing new
subject matter, including, without limitation, continuation-in-part applications, within Licensed
Patents. Copies of applications that are divisional or continuation applications of Licensed
Patents shall be furnished to UTRF and OSU or OSURF within thirty (30) days of their being
initially filed with an appropriate patent office. GTx shall keep UTRF and OSU or OSURF informed,
at GTx’s expense, of filing, prosecution, maintenance, and abandonment of applications and issued
patents within Licensed Patents pursuant to this Section 6, including submitting to UTRF and OSU or
OSURF copies of all patent applications in accordance with the previous sentence, and submitting to
UTRF and OSU or OSURF copies of material, official actions and responses thereto, and other
material written communications it or its patent counsel receives from or files with the U.S.
Patent and Trademark Office and the equivalent foreign offices within forty-five (45) days of
filing or receipt, as the case may be. Notwithstanding the foregoing, GTx shall submit information
and copies of documents to OSU or OSURF only with regard to EXISTING INVENTIONS, IMPROVEMENT
INVENTIONS, and NEW INVENTIONS. GTx shall consult with UTRF prior to the abandonment of
applications or issued patents with the Licensed Patents.

     6.4 UTRF agrees to reasonably cooperate with GTx, at GTx’s request and expense, to whatever
extent is reasonably necessary but not inconsistent with OSU IIA#1 or OSU IIA#2, when applicable,
to procure patent protection for Licensed Technology, including execution of all appropriate
documents to provide GTx the full benefit of the licenses granted herein.

     6.5 In the event that GTx decides not to continue prosecution of any United States or foreign
patent application within Licensed Patents to issuance or not to maintain any United States or
foreign patent within Licensed Patents in a particular jurisdiction, GTx shall timely notify UTRF
in writing in order that UTRF may continue said prosecution or maintenance of such patent
applications or patents at its option and at its own expense in such jurisdiction. GTx’s right
under this Agreement to practice the invention(s) under such patents and patent applications shall
immediately terminate in such jurisdiction upon UTRF’s assuming said costs provided that the
application for which GTx decides not to continue prosecution, or the patent which GTx decides not
to maintain, is before the patent office of a country that is a Major Market. Subject to the
provisions of Section 6.6 below, GTx shall not be considered in default and this Agreement shall
not terminate as to any particular jurisdiction merely due to the fact that GTx decides not to
continue prosecution of a patent application to issuance, or not to maintain any patent in any
country that is not a Major Market. If GTx fails to notify UTRF in sufficient time for UTRF to
reasonably continue prosecution, or the maintenance of, a patent or patent application in a Major
Market, GTx shall be considered in default of this Agreement.

     6.6 If (a) GTx and UTRF decide not to file a patent application claiming an EXISTING INVENTION
or an IMPROVEMENT INVENTION or a NEW INVENTION, which is licensed to GTx hereunder, or (b) if GTx
allows a pending patent application in Licensed Patents claiming an EXISTING INVENTION or an
IMPROVEMENT INVENTION or a NEW INVENTION licensed to GTx hereunder to go abandoned without filing a
continuation, division, re-issue or other application having the same priority and without issuance
of a patent

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

17

 

having the same priority and UTRF does not assume said costs pursuant to Section 6.5,
or (c) GTx decides not to maintain a previously-filed patent application or issued patent claiming
an EXISTING INVENTION or IMPROVEMENT INVENTION or a NEW INVENTION licensed to GTx hereunder and
UTRF does not assume said costs pursuant to Section 6.5, in each such case in the United States,
England, France, Germany, Italy, Spain, Canada, Australia, China, India, Russia, Switzerland, and
Japan (collectively, the “Major Countries”), OSU or OSURF may elect to file, prosecute,
and/or maintain, as the case may be, such application or patent in any Major Country in which GTx
did not file, prosecute, or maintain (collectively, the “Exception Countries”), at its sole
expense. In that event, GTx agrees that OSU or OSURF will be free to exploit and to assign or
license its interest in
such patent application and/or patent to Third Parties in the Exception Countries, provided
that any such assignment or license will be limited to domestic manufacture and sale in the
Exception Countries, with no right to export or sell products or otherwise to compete with GTx or
Sublicensees in the rest of the world. In the event GTx believes that any exploitation, assignment
or license of OSU’s or OSURF’s interests in the Exception Countries competes with or interferes
with GTx’s exclusive commercialization and exploitation of Licensed Technology licensed hereunder
in any Major Country other than the Exception Countries, GTx agrees to so notify OSU or OSURF. GTx
acknowledges that OSU or OSURF has contractually committed to take all reasonable measures to
preclude such competition or interference, including without limitation terminating any license in
the Exception Countries and taking enforcement action.

     6.7 GTx agrees to forward in a timely manner all correspondence in need of signature by OSU
Contributors to the Memphis office of UTRF (unless UTRF shall otherwise direct) in a timely manner.
UTRF agrees, in turn, to promptly forward such correspondence to OSU or OSURF for signature, but
UTRF shall have no responsibility for costs or other damages that may be incurred because of delay
at OSU or OSURF in returning signed documents.

     6.8 UTRF agrees to use reasonable business efforts to promptly notify GTx of any option to
license an IMPROVEMENT INVENTION or NEW INVENTION upon such option arising in favor of UTRF under
either OSU IIA#1 or OSU IIA#2 and to take such actions as are necessary and appropriate to exercise
any such option upon receiving notice from GTx that it wishes to file a Licensed Patent claiming
such IMPROVEMENT INVENTION or NEW INVENTION.

     6.9 GTx and all its Sublicensees shall mark all products covered by Licensed Patents with
patent numbers in accordance with the statutory requirements in the country(ies) of manufacture,
use, and sale.

     6.10 UTRF and GTx agree that one or more senior administrator representing each of the Parties
will meet at least on a semi-annual basis at a mutually agreeable time and place so that GTx may
provide UTRF with an oral update on the current development, licensing, regulatory, and
commercialization status of Licensed Products and to discuss any issues raised by either UTRF or
GTx arising out of, under, or in connection with this Agreement. UTRF agrees to notify OSURF no
less than 14 days in advance of any such meeting, and that a representative from OSURF shall have
the right to attend if they agree to confidentiality terms no less stringent than described in
Section 18.

SECTION 7

Infringement

     7.1 GTx shall inform UTRF and UTRF shall inform GTx promptly in writing of any alleged
assertion and/or claim of infringement of the Licensed Patents by a Third Party and of any
available evidence thereof.

     7.2 GTx shall have the first, sole and exclusive right, but shall not be obligated, to
prosecute or defend at its own expense all infringements or opposition, interference and ex parte
proceedings of the Licensed Patents, including prosecuting for any misappropriation of Licensed
Technology or Licensed Products. The Parties

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

18

 

acknowledge that as to Licensed Patents that UTRF
owns “in part”, such right on the part of GTx shall not preclude UTRF’s co-owner(s) from taking any
action they may have available to them in law or by contract. In furtherance of such right granted
to GTx, UTRF hereby agrees that GTx may include UTRF as a party plaintiff in any such suit, without
expense to UTRF. The total cost of any such infringement action commenced or defended by GTx shall
be borne by GTx. No settlement, consent judgment, or other voluntary final disposition of such
suits may be entered into without the consent of UTRF, provided that such consent shall not be
unreasonably withheld and that UTRF shall not condition such consent on an increase in payments to
UTRF hereunder.

     7.3 If within six (6) months after having been notified of an alleged infringement by a Third
Party, GTx has not brought or is not diligently prosecuting an infringement action, or if GTx has
notified UTRF at any time prior thereto of its intention not to bring suit against any alleged
infringement of the Patents, then, and in those events only, UTRF shall have the right, but shall
not be obligated, to prosecute at its own expense any infringement of the Licensed Patents, and
UTRF may, for such purposes, use the name of GTx as party plaintiff. No settlement, consent
judgment, or other voluntary final disposition of the suit may be entered into without the consent
of GTx, which consent shall not unreasonably be withheld. After deduction of outstanding expenses
of UTRF, including attorney fees, and any expenses of GTx, including attorney fees incurred prior
to UTRF’s pursuit of such infringement, the balance remaining from any such recovery shall be
divided equally between GTx and UTRF.

     7.4 If both UTRF and GTx elect not to enforce or continue to enforce the right of the parties
in Licensed Patents claiming an EXISTING INVENTION or IMPROVEMENT INVENTION under OSU IIA#1, or a
NEW INVENTION under OSU IIA#2, GTx agrees that OSU or OSURF shall have the right to elect to
prosecute the alleged infringers provided that (i) OSU or OSURF shall pay all costs and expenses
arising out of such prosecution, and (ii) OSU or OSURF shall not have any right to surrender OSU’s,
OSURF’s, UTRF’s or GTx’s rights or to grant any infringer any rights in the Licensed Patents
without the prior written approval of UTRF and GTx, such approval not to be unreasonably withheld.

     7.5 In the event that GTx undertakes the enforcement and/or defense of the Licensed Patents by
litigation, opposition, interference or ex parte proceedings or an inter partes proceeding
(including the defense of a declaratory judgment action pursuant to Section 7.6) in the United
States or a foreign country against a Third Party, GTx may withhold up to [ * ] of the payments
otherwise thereafter due UTRF under Section 4 that are attributable to sales of Licensed Products
in the country where such litigation or inter partes proceeding takes place and apply the same
toward reimbursement of up to [ * ] of GTx’s expenses, including reasonable attorneys’ fees, in
connection therewith. GTx may not withhold any portion of the payments due UTRF under Section 4 in
the event that GTx undertakes the enforcement and/or defense of the Licensed Patents by litigation
or an inter partes proceeding in the United States or a foreign country against an Affiliate or
Sublicensee. Any recovery of damages by GTx resulting from each such suit or inter partes
proceeding shall be applied first in satisfaction of any unreimbursed expenses and legal fees of
GTx relating to such suit, and next toward reimbursement of any unreimbursed expenses and legal
fees of UTRF relating to such suit, and next toward reimbursement of UTRF for any payments under
Section 4 withheld and applied pursuant to this Section 7.5, and the remaining balance, if any,
shall be divided equally between GTx and UTRF unless the damage award is identified by judgment of
the court or in a settlement in such suit as compensating GTx for loss of sales revenue for
Licensed Product on account of such Third Party’s unlicensed or illegal actions, in which event
(instead of dividing the remaining balance equally between the Parties), GTx shall pay to UTRF an
amount equal to the lesser of: (i) [ * ] the remaining balance; or (ii) [ * ] of the equivalent of
the lost Net Sales upon which such judgment or settlement award is based, and GTx shall retain the
rest. For sake of clarity, any recovery attributable to loss or diminution of the value of Licensed
Patents shall be divided equally between UTRF and GTX. As to a settlement of such claim or suit,
the rebuttable presumption shall be that any payment to be made to GTX under the settlement
agreement is not attributable to lost sales revenue and GTx shall have the burden of proof to
reasonably establish that the recovery of damages resulting from such settlement represents
compensation for loss of sales revenue (i.e., the equivalent of lost Net Sales hereunder).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

19

 

     7.6 In the event that a declaratory judgment action alleging invalidity or noninfringement of
any of the Licensed Patents shall be brought against UTRF, GTx at its option shall have the right,
within thirty (30) days after commencement of such action, to intervene and take over the sole
defense of the action against UTRF at its own expense, provided that GTx may not enter into a
settlement, consent judgment, or other voluntary final disposition of the matter without the prior
written approval of UTRF, which approval shall not be unreasonably withheld. This section shall
not apply to OSU’s and OSURF’s interest in the Licensed Patents.

SECTION 8

Liability and Indemnification

     8.1 GTx shall at all times during the Term of this Agreement, indemnify, defend and hold UTRF,
UT, OSU, OSURF, and their respective trustees, directors, officers, employees and Affiliates,
harmless against all claims, proceedings, demands and liabilities of any kind whatsoever, including
legal expenses and reasonable attorneys fees (collectively, “Claims”), arising out of the
death of or injury to any person or persons or out of any damage to property, to the extent
resulting from the production, manufacture, sale, use, lease, or consumption of the Licensed
Products, Licensed Technology, or associated intellectual property rights, including Licensed
Patents, or arising from any obligation or act of GTx hereunder, except, as to UTRF and UT, for
Claims arising (i) out of the use or practice of Licensed Subject Matter by UT as described in
Section 2.2 or (ii) from the willful misconduct or misrepresentation by UTRF, UT, or their
respective trustees, directors, officers, employees or Affiliates; or (iii) breach of this
Agreement by UTRF; and except, as to OSU and OSURF, for Claims arising (i) out of the use or
practice of Licensed Subject Matter by OSU as described in Section 2.2 or (ii) from the willful
misconduct or misrepresentation by OSURF, OSU, or their respective trustees, directors, officers,
employees or Affiliates. Infringement of a Third Party patent by GTx, a GTx Affiliate, or a
Sublicensee shall not be deemed for purposes of this Agreement an improper action, omission, or
negligent act on the part of UTRF, UT, OSU, OSURF, or their respective trustees, directors,
officers, employees or Affiliates.

     8.2 GTx shall obtain and carry in full force and effect from the first manufacture, use or
sale of the Licensed Products or Licensed Technology to [ * ] such manufacturing, use or sales
cease, commercial, general liability insurance which shall protect GTx, UTRF, UT, OSU, OSURF, and
their respective trustees, directors, officers, employees and Affiliates with respect to events
covered by Section 8.1 above. Such insurance shall be written by a reputable insurance company,
reasonably acceptable to UTRF, shall list UTRF as an additional named insured, shall be endorsed to
include product liability coverage and shall require thirty (30) days written notice to be given to
UTRF prior to any cancellation or material change thereof. The limits of such insurance shall not
be less than [ * ] per occurrence with an aggregate of [ * ] for personal injury or death. Upon
the request of UTRF, GTx shall provide UTRF with Certificates of Insurance evidencing the same.

     8.3 GTx, UTRF, UT, OSURF, OSU, AND THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES,
AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR
IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, IN ANY LICENSED
PRODUCT, LICENSED TECHNOLOGY OR LICENSED PATENT. SUBJECT TO THE PROVISIONS OF SECTION 8.1 AND
EXCEPT FOR A BREACH OF SECTION 18, IN NO EVENT SHALL GTx, UTRF, UT, OSURF, OSU, OR THEIR RESPECTIVE
TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES OR AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL
DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, ECONOMIC DAMAGE, INJURY TO PROPERTY OR LOST
PROFITS, REGARDLESS OF WHETHER GTx, UTRF, UT, OSURF, OR OSU, SHALL BE ADVISED, SHALL HAVE OTHER
REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF ANY OF THE FOREGOING. NOTHING IN THIS
AGREEMENT SHALL BE CONSTRUED AS:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

20

 

	 	A.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF, OSURF OR OSU THAT THE PRACTICE
BY GTX OF ANY LICENSE OR SUBLICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENTS OF
ANY THIRD PARTY;
	 
	 	B.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF, OSURF OR OSU THAT ANY PATENT
APPLICATION INCLUDED IN THE PATENTS WILL ULTIMATELY ISSUE AS A PATENT;
	 
	 	C.	 	A REPRESENTATION MADE OR WARRANTY GIVEN THAT GTX SHALL HAVE THE RIGHT TO USE
ANY PORTION OF THE LICENSED PATENTS THAT IS CLAIMED IN A PATENT OF ANY THIRD PARTY;
	 
	 	D.	 	A REQUIREMENT THAT UTRF, OSURF OR OSU SHALL BE RESPONSIBLE FOR THE EXPENSES OF
FILING OR PROSECUTING ANY PATENT APPLICATION OR MAINTAINING ANY LICENSED PATENTS IN
FORCE
	 
	 	E.	 	AN OBLIGATION ON THE PART OF UTRF, OSURF OR OSU TO BRING OR PROSECUTE ACTIONS
OR SUITS AGAINST THIRD PARTIES FOR INFRINGEMENT OF THE LICENSED PATENTS OR FOR
UNAUTHORIZED USE OF THE PATENTS OR MISAPPROPRIATION OF THE LICENSED TECHNOLOGY;
	 
	 	F.	 	AN OBLIGATION ON THE PART OF UTRF, OSURF OR OSU TO DEFEND ANY ACTION OR SUIT
BROUGHT BY ANY THIRD PARTY;
	 
	 	G.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF, OSURF OR OSU AS TO THE SAFETY,
RELIABILITY OR EFFICACY OF: 1) THE LICENSED TECHNOLOGY OR THE INVENTIONS COVERED BY THE
LICENSED PATENTS; OR 2) ANY LICENSED PRODUCT; OR
	 
	 	H.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF, OSURF OR OSU THAT ANY OF THE
UT CONTRIBUTORS OR THE OSU CONTRIBUTORS WILL AGREE TO PROVIDE TECHNICAL ASSISTANCE OR
CONSULTATION TO GTX, OR THAT SUCH TECHNICAL ASSISTANCE OR CONSULTATION, IF PROVIDED,
WOULD BE SUFFICIENT TO ENABLE GTX TO SUCCESSFULLY EXPLOIT THE LICENSED TECHNOLOGY OR
THE LICENSED PATENTS.

     8.4 UTRF represents and warrants that to the best of its actual knowledge as of the Effective
Date: (i) it has the full corporate power and authority to enter into this Agreement, to carry out
the provisions of this Agreement, and to grant the rights granted to GTx herein; (ii) it has not
previously granted and shall not grant to any Third Party any rights which are inconsistent with
the rights granted to GTx herein; (iii) it is the owner of the entire right, title, and interest in
and to the Licensed Patents and Licensed Technology except for such rights held by GTx, OSU, OSURF,
UT, the United States government, Sublicensees, and/or their respective designees and/or assignees,
if any; and (iv) it has fully complied with all requirements of 35 U.S.C. § 200 et seq. and all
implementing regulations necessary to perfect title to the rights and license granted to GTx
herein.

     8.5 UTRF acknowledges and understands that Dr. Mitchell S. Steiner is an employee of UT and
that as of the Effective Date, he is the Chief Executive Officer of GTx.

     8.6 GTx represents that: (i) it has full corporate power and authority to enter into this
Agreement and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

21

 

carry out all the provisions of this Agreement; (ii) it is authorized to execute this
Agreement on its behalf; (iii) the person executing this Agreement is duly authorized to do so; and
(iv) no consent, approval or authorization of any Third Party is required. GTx further represents
and warrants that it shall not deny, contest (through declaratory judgment action or otherwise), or
take any action inconsistent with UTRF’s and/or OSU’s and/or OSURF’s ownership in or the validity
or enforceability of any of the Licensed Patents or IP RIGHTS associated with or arising from the
Licensed Subject Matter except those Licensed Patents listed on Appendix A that are assigned to
GTx.

SECTION 9

Export Controls

     9.1 GTx acknowledges that the export of goods and/or technical data from the United States may
require some form of export control license from the United States Government. GTx agrees that
neither it nor its Sublicensees will disclose, export or re-export any materials or technical data
received under this Agreement to any countries for which the U.S. Government requires an export
license, unless GTx or its Sublicensees have obtained prior written authorization from the U.S.
Department of State, Directorate of Defense Trade Controls, Department of Commerce, U.S. Bureau of
Industry and Security or other authority responsible for such matters. GTx agrees that it or its
Sublicensees are responsible for any fees or expenses associated with obtaining an export license,
if required, and acknowledges that failure to obtain such export control license may result in
criminal liability. UTRF neither represents that a license shall not be required nor that, if
required, it shall be issued.

SECTION 10

Non-Use of Names

     10.1 GTx shall not use the names or trademarks of UTRF, UT, OSURF, or OSU, or any adaptation
thereof, in any advertising, promotional or sales literature without prior written consent obtained
from UTRF, UT, OSURF, or OSU, as the case may be, except that GTx may state that it has licensed
the Licensed Patents and Licensed Technology from UTRF.

     10.2 Neither UTRF nor UT shall use the names or trademarks of GTx, or any adaptation thereof,
in any advertising, promotional or sales literature without prior written consent obtained from
GTx, except that UTRF may state that it has licensed the Licensed Patents and Licensed Technology
to GTx.

SECTION 11

Dispute Resolution

     11.1 Except for the right of either party to apply to a court of competent jurisdiction for a
temporary restraining order, a preliminary injunction, or other equitable relief to preserve the
status quo or to prevent irreparable harm, any and all claims, disputes or controversies arising
under, out of, or in connection with this Agreement, shall be resolved upon thirty (30) days
written notice of either party to the other by final and binding arbitration in Knoxville,
Tennessee under the Commercial Arbitration Rules of the American Arbitration Association, or the
Patent Arbitration Rules if applicable, then in effect. The arbitrator(s) shall have no power to
add to, subtract from or modify any of the terms or conditions of this Agreement, nor to award
punitive damages. The prevailing party in any such arbitration shall, in addition to recovering
reasonable out-of-pocket costs of the arbitration, be entitled to an award of reasonable attorneys
fees incurred in connection with the arbitration, with any action necessary to perfect the
arbitration award as a judgment, and for any collection action required to secure
payment of any arbitration award. Any award rendered in such arbitration may be entered and
enforced by either party in either the courts of the State of Tennessee or in the United States
District Court for the Eastern District of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

22

 

Tennessee, to whose jurisdiction for such purposes UTRF and GTx each hereby irrevocably
consents and submits, or in any other United States court having jurisdiction.

     11.2 Notwithstanding the foregoing, nothing in this Section shall be construed to waive any
rights or timely performance of any obligations existing under this Agreement.

SECTION 12

Term of Agreement and Termination

     12.1 This Consolidated, Amended, and Restated License Agreement shall take effect for all
purposes upon the date of execution by the Parties, and unless earlier terminated in accordance
with the provisions of this Section 12, shall continue in full force and effect on a
country-by-country basis for the longer of (i) a period of twenty (20) years from the Effective
Date, or (ii) in each country in which a Valid Claim for any Licensed Patent shall continue to
exist, until the last Valid Claim for any Licensed Patent shall expire in the country, at which
time this Agreement shall expire as to such country (“Term”).

     12.2 After expiration of the Term in a country, GTx shall have a perpetual, fully paid,
royalty-free license to the Licensed Patents and Licensed Technology in such country, such license
being of no greater scope than that granted hereunder. GTx shall continue to be obligated to pay
(i) Running Royalties on account of Licensed Product used, marketed, sold, manufactured or
distributed in or imported from any country for which the Term shall not have expired; and (ii)
Sublicense Royalties on Sublicense Revenue generated under any Sublicense that includes a grant of
rights in any Major Country for which the Term shall not have expired; and (iii) the License
Maintenance Fee as long as there is at least one Major Country for which the Term shall not have
expired. GTx shall continue to enjoy the rights and license to the Licensed Subject Matter granted
hereunder in each country for which the Term shall not have expired.

     12.3 In the event of default or failure by GTx to perform any of the terms, covenants or
provisions of this Agreement (hereinafter, “default”), GTx shall have thirty (30) days to cure such
default after the giving of written notice of such default by UTRF. In accordance with Section
2.6, no Sublicensee’s rights under a Sublicense shall terminate on account of a default by GTx
unless UTRF shall have given written notice of such default to the Sublicensee and the Sublicensee
shall have failed to cure or have cured such default within thirty (30) days of such notice. If
such default is not cured by GTx, its Affiliates, and/or its Sublicensees within the said thirty
(30) day period, UTRF shall have the right, at its option, to terminate this Agreement. The failure
of UTRF to exercise such right of termination for non-payment of royalties or otherwise shall not
be deemed to be a waiver of any right UTRF might have, nor shall such failure preclude UTRF from
exercising or enforcing said right upon any subsequent failure by GTx.

     12.4 UTRF shall have the right, at its option, to terminate this Agreement in the event that
GTx is finally declared bankrupt, or is placed in receivership pursuant to proceedings affecting
the operation of its business. In the event of termination of this Agreement pursuant to Sections
12.3 or 12.4 hereof, all rights to the Licensed Patents and Licensed Technology granted to GTx
herein shall revert to UTRF, except as otherwise provided in Section 2.6.

     12.5 Upon termination of this Agreement for any reason, nothing herein shall be construed to
release either party from any obligation that matured prior to the effective date of such
termination; and Sections 1, 4.4, 5, 8, 9-12, 14, 18, 20, and 21 shall survive any such
termination.

     12.6 No termination of this Agreement shall constitute a termination or a waiver of any rights
of either Party against the other Party accruing at or prior to the time of such termination.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

23

 

     12.7 GTx shall have the right to terminate this Agreement at any time on three (3) months
notice to UTRF and upon payment of all amounts due UTRF through the effective date of the
termination.

SECTION 13

Assignability

     13.1 This Agreement shall be binding upon and shall inure to the benefit of UTRF and its
assigns and successors, and shall be binding upon and shall inure to the benefit of GTx and its
assigns provided that prior written approval by UTRF is first obtained, which approval shall not be
unreasonably withheld. Notwithstanding the foregoing, no prior written approval from UTRF shall be
required for any assignment by GTx to (i) an Affiliate of GTx (or any entity into which GTx shall
have been merged or consolidated, provided that at least 51% of such merged or consolidated entity
is owed by shareholders holding at least 51% of GTx immediately prior to such merger or
consolidation) or (ii) a Third Party which acquires all or substantially all of GTx’s assets or a
Controlling interest in the business to which this Agreement relates if, but only if, the Third
Party can reasonably demonstrate a financial net worth or market cap equal to or better than the
financial net worth of GTx existing prior to the acquisition, but not less than a net worth of One
Hundred Million Dollars ($100,000,000) or a market cap of Five Hundred Million Dollars
($500,000,000). No assignment shall be deemed effective unless such assignee has agreed in
writing to be bound by the terms and provisions of this Agreement. Any attempt to assign or
assignment made in violation of this Section 13.1 shall be void ab initio. GTx shall give notice
to UTRF of any assignment of this Agreement within thirty (30) days thereafter, such notice to
include a copy of assignee’s written agreement to be bound by the terms and provisions of this
Agreement.

SECTION 14

Governmental Compliance

     14.1 GTx shall at all times during the Term of this Agreement and for so long as it shall
develop, make, have made, use, market, sell, have sold, import, distribute, or offer to sell
Licensed Products or Licensed Technology comply and cause its Sublicensees to comply with all laws
that may control the import, export, manufacture, use, sale, marketing, distribution and other
commercial exploitation of Licensed Products, Licensed Technology, or Licensed Patents or any other
activity undertaken pursuant to this Agreement.

SECTION 15

Notices

     15.1 Any notice or other communication required or permitted hereunder (hereinafter “notice”)
shall be in writing and shall be hand-delivered, sent by overnight courier, mailed by certified
United States mail, return receipt requested, or sent by email, to the addresses given below or to
such other addresses as the parties may hereafter specify in writing. Notice shall be deemed given
and received five (5) days after being deposited with the U.S. Postal Service with sufficient
postage, or if notice is hand-delivered or sent by overnight courier, upon the date of actual
delivery, or if sent by email, upon the date the receiving party acknowledges receipt. An email
notice shall be given concurrently to all the email address(es) provided by the recipient party and
the first acknowledgment of receipt from the recipient party shall establish the date on which such
notice is given.

	 	 	 
	UTRF:
	 	 
	 

	 	If notice is given by means other than email, to:
	 
	 	 
	 

	 	University of Tennessee Research Foundation

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

24

 

1534 White Avenue, Suite 403

Knoxville, Tennessee, U.S.A. 37996-1527

Attn: President

With a copy to:

University of Tennessee Research Foundation

920 Madison, Suite 515

Memphis, TN 38163

If notice is given by email, to:

rmagid1@utmem.edu

jlsnider@utk.edu

vhunley@tennessee.edu

GTx:

If notice is given by means other than email, to:

GTx, Inc.

3 N. Dunlap Street, 3rd Floor

Memphis, Tennessee 38163

Attn: Dr. Mitchell Steiner, CEO

With a copy to:

GTx, Inc.

3 N. Dunlap Street, 3rd Floor

Memphis, TN 38163

Attn: Henry P. Doggrell, Vice President, General Counsel

If notice is given by email, to:

msteiner@gtxinc.com

hdoggrell@gtxinc.com

OSU or OSURF:

If notice is given by means other than email, to:

1960 Kenny Road, 2nd Floor

Columbus, OH 43210

Attn: Jane New

If notice is given by email, to:

new.16@osu.edu

Notice or other material provided to the above address will satisfy any obligation under this
Agreement for notice or copying either OSU and OSURF.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

25

 

SECTION 16

Severability of Provisions

     16.1 If any provision of this Agreement shall be declared by a court of competent jurisdiction
to be invalid, illegal or incapable of being enforced in whole or in part, the remaining conditions
and provisions or portions thereof shall nevertheless remain in full force and effect and
enforceable to the extent they are valid, legal and enforceable, and no provision shall be deemed
dependent upon any other covenant or provision unless so expressed herein.

SECTION 17

Governing Law

     17.1 This Agreement shall be deemed to be subject to, and have been made under, and shall be
construed and interpreted in accordance with the laws of the State of Tennessee. This Agreement is
expressly acknowledged to be subject to all applicable federal laws. No conflict-of-laws rule or
law that might refer such construction and interpretation to the laws of another state, republic,
or country shall be considered. The Parties irrevocably and unconditionally agree that the
exclusive place of jurisdiction for any action, suit or proceeding for a temporary restraining
order, a preliminary injunction, or other equitable relief to preserve the status quo or to prevent
irreparable harm, arising under, out of, or in connection with this Agreement (“Actions”),
shall be in the courts of the United States of America sitting in the city, state and country of
State of Tennessee, or, if such courts shall not have jurisdiction over the subject matter thereof,
in the courts of the State of Tennessee sitting therein, and each such party hereby irrevocably and
unconditionally agrees to submit to the jurisdiction of such courts for the purposes of any such
Actions. If any such State court also does not have jurisdiction over the subject matter thereof,
then such an Action may be brought in the federal or state courts located in the states of the
principal place of business of any Party hereto.

SECTION 18

Confidentiality

     18.1 Nothing herein shall preclude a Party from disclosing the existence of this Agreement and
the general scope of the license granted hereunder. However, neither Party shall disclose the
economic terms of this Agreement except that UTRF may disclose such economic terms to the UT
Contributors, UT, OSURF, and OSU or as required by Federal Policy.

     18.2 Subject to the exceptions set forth herein, all information or material disclosed
pursuant to this Agreement and/or related to the Licensed Patents, Licensed Products, Licensed
Technology, and Independent SARM Inventions shall be confidential (“Confidential
Information”). Recipient (the “Receiving Party”) of another Party’s Confidential Information
(the “Providing Party”) agrees to hold in confidence, and not to distribute or disseminate to any
person or entity, for any reason for a period of seven (7) years after receipt, any Confidential
Information received, under or relating to this Agreement, except for Confidential Information of
the Providing Party which:

	 	A.	 	was known or used by the Receiving Party prior to the date of disclosure to the
Receiving Party as evidenced by written records; or
	 
	 	B.	 	either before or after the date of disclosure is lawfully disclosed to the
Receiving Party by sources other than the Providing Party which are rightfully in
possession of the Confidential Information and not subject to any obligation of
confidentiality, as evidenced by written records; or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

26

 

	 	C.	 	either before or after the date of disclosure to the Receiving Party becomes
published, through no fault or omission on the part of the Receiving Party; or
	 
	 	D.	 	is independently developed by or for the Receiving Party without reference to,
knowledge of, or reliance upon the Confidential Information as evidenced by written
records; or
	 
	 	E.	 	is required to be disclosed by the Receiving Party to comply with applicable
laws or court order, to defend or prosecute litigation or arbitration or to comply with
governmental regulations or Federal Policy, provided that the Receiving Party provides
prior written notice of such disclosure to the Providing Party and takes reasonable and
lawful actions to avoid and/or minimize the degree of such disclosure, and further
provided that specific information shall not be deemed to be within any of these
exclusions merely because it is embraced by more general information falling with these
exclusions; or
	 
	 	F.	 	is disclosed by either Party to OSU or OSURF pursuant to the requirements of
OSU IIA#1 or OSU IIA#2; or
	 
	 	G.	 	is disclosed by UTRF to UT, the UT Contributors, or the State of Tennessee,
such disclosure being subject to the provisions of Section 2.6, if and as applicable.

All information concerning (i) Licensed Patents and/or Licensed Technology owned solely or partly
by UTRF and (ii) Independent SARM Inventions shall be deemed Confidential Information of UTRF.
Disclosures of Confidential Information to GTx concerning (i) and (ii), including, without
limitation, disclosures that are made to GTx by UT Contributors or OSU Contributors, shall be
deemed, for purposes of this Section, to be disclosures made by UTRF. Nothing herein shall be
construed in such a manner as to permit UTRF, UT, any UT Contributor, OSU, OSURF, or any OSU
Contributor to take any action with regard to Licensed Patents, Licensed Technology, or Independent
SARM Inventions that is contrary to the rights herein granted to GTx or to permit UTRF, UT, any UT
Contributor, OSU, OSURF, or any OSU Contributor to include any Confidential Information of GTx in
any patent application or regulatory filing or application without obtaining GTx’s prior written
approval except to the extent such activity falls within the exceptions to confidentiality set
forth in Sections 18.2A through G.

          18.3 GTx recognizes that under UTRF and UT policy, research results must be publishable and
agrees that researchers engaged in such research shall have the right, with regard to the Licensed
Subject Matter, to present at symposia, professional meetings and to publish in journals, theses or
dissertations, or otherwise of their own choosing (“Publications”) provided that UTRF shall
provide to GTx a copy of a draft of such Publication, if received by UTRF in draft form, or a copy
of the final Publication, if first received by UTRF in that form, in either case promptly upon
receipt and in the manner and form in which received in order that GTx may review the Publication
to identify and protect any Confidential Information of GTx that may be contained therein and to
allow for the preparation and filing of a patent application by GTx or Sublicensees. UTRF shall
not be deemed in breach or default of this Agreement merely due to a Publication that UTRF does not
receive prior to publication.

          18.4 The Parties recognize that GTx has previously entered into certain research agreement(s)
with OSURF, UT has entered into certain agreement(s) with OSU and/or OSURF either as a contractor
and/or a subcontractor, GTx has entered into certain consulting agreement(s) with one or more of
the UT Contributors and/or the OSU Contributors, and that UTRF has entered into OSU IIA#1 and OSU
IIA#2 with OSU, which agreements may contain confidentiality obligations and/or restrictions on
publication regarding information or material related to this Agreement, the Licensed Patents
and/or the Licensed Technology. While UTRF acknowledges the need for such confidentiality
obligations and restrictions on publication in order for GTx to preserve United States and foreign
patent rights, UTRF MAKES NO REPRESENTATIONS OR WARRANTIES, AND HAS NO OBLIGATION HEREUNDER,
REGARDING THE CONFIDENTIALITY OR PUBLICATION OBLIGATIONS OF UT, THE UT CONTRIBUTORS, OSU, OSURF, OR
THE OSU CONTRIBUTORS.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

27

 

          18.5 The Parties agree that counsel of the Parties, who have a duty of confidentiality to the
respective Parties, may receive Confidential Information.

SECTION 19

Reformation

          19.1 All Parties hereby agree that neither Party intends to violate any public policy,
statutory or common law, rule, regulation, treaty or decision of any government agency or executive
body thereof of any country or community or association of countries; that if any word, sentence,
paragraph or clause or combination thereof of this Agreement is found, by a court or executive body
with judicial powers having jurisdiction over this Agreement or any of its Parties hereto, in a
final unappealed order to be in violation of any such provision in any country or community or
association of countries, such words, sentences, paragraphs or clauses or combination shall be
inoperative in such country or community or association of countries, and the remainder of this
Agreement shall remain binding upon the Parties hereto.

SECTION 20

Non-Waiver 

          20.1 The Parties covenant and agree that if a Party fails or neglects for any reason to take
advantage of any of the terms provided for the termination of this Agreement or if a Party, having
the right to declare this Agreement terminated, shall fail to do so, any such failure or neglect by
such Party shall not be a waiver or be deemed or be construed to be a waiver of any cause for the
termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants
or conditions of this Agreement or of the performance thereof. None of the terms, covenants and
conditions of this Agreement may be waived by a Party except by its written consent.

SECTION 21

Entire Agreement 

          21.1 This Agreement, as amended and restated herein, contains the entire agreement and
understanding of the parties as of the Effective Date with respect to the subject matter hereof,
supersedes any prior agreements and understandings with respect thereto, including, without
limitation, the Prior License Agreements, and cannot be modified, amended or waived, in whole or in
part, except in writing signed by the Party to be charged. Any such purported non-written
modification, amendment, or waiver shall be null and void. A discharge of the terms of this
Agreement shall not be deemed valid unless by full performance of the Parties hereto or by writing
signed by the Parties hereto. A waiver by UTRF of any breach by GTx of any provision or condition
of this Agreement to be performed by GTx shall not be deemed a waiver of similar or dissimilar
provisions or conditions at the same or any prior or subsequent time.

SECTION 22

Effect of Agreement

          22.1 This Consolidated, Amended, and Restated License Agreement shall supersede and render
null and void the Prior License Agreements.

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple
originals by their duly authorized officers and representatives on the respective dates shown
below. The undersigned representative of UTRF is authorized to execute this Agreement on its behalf
and bind UTRF to the terms and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

28

 

conditions set forth herein, and the undersigned representative of GTx is authorized to execute
this Agreement on its behalf and bind GTx to the terms and conditions set forth herein.

	 	 	 	 	 	 	 	 	 	 	 
	UNIVERSITY OF TENNESSEE 

RESEARCH FOUNDATION

(UTRF)	 	 	 	GTx, INC. (GTx)	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Fred D. Tompkins
 

Fred D. Tompkins
	 	 
	 	By:

Name:
	 	/s/ Henry P. Doggrell
 

Henry P. Doggrell
	 	 
	Title:

	 	President
	 	 	 	Title:
	 	Vice President, General Counsel & Secretary	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	7/25/07
	 	 	 	Date:
	 	July 24, 2007	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

29

 

Exhibit A

Third Generation SARMS Disclosure

[ * ]

[ * ]

[ * ]

[ * ]

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Exhibit B

OSU IIA #1

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

BRIDGED SARMS

INTER-INSTITUTIONAL AGREEMENT

BETWEEN

THE OHIO STATE UNIVERSITY

AND

THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

THIS BRIDGED SARMS INTER-INSTITUTIONAL AGREEMENT (the “AGREEMENT”) is effective the 22nd day of
December, 2004 (hereafter, the “EFFECTIVE DATE”) by and between The Ohio State University on behalf
of itself and The Ohio State University Research Foundation and its Office for Technology Licensing
(collectively, hereinafter “OSU”) having an address at 1960 Kenny Road, Columbus, Ohio 43210, and
the University of Tennessee Research Foundation (hereinafter “UTRF”) having an address at 1534
White Avenue, Knoxville, Tennessee 37996.

BACKGROUND

OSU and UTRF wish to establish an understanding between the parties with respect to the
patenting, enforcement, and commercialization of EXISTING INVENTIONS and IMPROVEMENT
INVENTIONS (as defined below) and how any commercialization revenues derived therefrom will
be divided between the parties.

In furtherance thereof, OSU wishes to exclusively license its interest in the EXISTING
INVENTIONS to UTRF and UTRF wishes to obtain an exclusive License to OSU’s interest in the
EXISTING INVENTIONS pursuant to the provisions of this AGREEMENT.

OSU also wishes to grant UTRF an exclusive option to obtain an exclusive license to OSU’s
interest in IMPROVEMENT INVENTIONS and UTRF wishes to obtain an exclusive option to obtain
an exclusive license to OSU’s interest in IMPROVEMENT INVENTIONS pursuant to the provisions
of this AGREEMENT.

Therefore, in consideration of the mutual obligations set forth below, OSU and UTRF agree
as follows:

	1.	 	DEFINITIONS. The following capitalized terms used in this AGREEMENT have the following
meanings:
	 
	1.1	 	“BRIDGED SARMS” means SARM compounds [ * ], including those described in the patents and
patent applications listed in Attachment A.
	 
	1.2	 	“EXISTING INVENTIONS” means any TECHNOLOGY that pertains to BRIDGED SARMS (as defined above)
conceived, created, developed, designed, invented, or reduced to practice, in whole or in part
by OSU researcher Dr. James Dalton and/or other OSU research staff and students under his
direction before the EFFECTIVE DATE, including inventions that are the subject of one or more
VALID CLAIMS of the issued patents or patent applications set forth in Attachment A and
foreign counterparts thereof.
	 
	1.3	 	“IMPROVEMENT INVENTION” means any TECHNOLOGY that pertains to BRIDGED SARMS conceived, created,
developed, designed, invented, or reduced to practice, in whole or in part by OSU faculty
researchers, research staff, or students
following the EFFECTIVE DATE, and which is the subject of a VALID CLAIM of a continuation in part
application or a new application claiming priority from an issued

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	patent or patent application listed in Attachment A or whose manufacture, use, or sale would
infringe or fall within the scope of a VALID CLAIM covering an Existing Invention or an
Improvement Invention.
	 
	1.4	 	“IP COSTS” means the documented, unreimbursed, out-of-pocket, reasonable expenses incurred by
UTRF in the preparation, filing, prosecution, defense, enforcement and maintenance of IP
RIGHTS associated with the EXISTING INVENTIONS and IMPROVEMENT INVENTIONS.
	 
	1.5	 	“IP RIGHTS” means any and all right, title and interest (whether now existing or arising in
the future) in, to and under EXISTING or IMPROVEMENT INVENTIONS, including, without
limitation, patents, patent applications, provisional patent applications and any divisions,
reissues, renewals, reexaminations, substitutions, continuations, continuations-in-part, and
any corresponding foreign counterparts thereof; and other proprietary rights arising or
enforceable under any United States federal or state law, rule or regulation, non-United
States law, rule or regulation or international treaty.
	 
	1.6	 	“LICENSE AGREEMENT” means any agreement that is entered into by UTRF that grants to a third
party any right or license to the LICENSED INVENTIONS, including, without limitation, the two
existing Amended and Restated Exclusive License Agreements dated August 23, 2000 by and
between UTRF and GTx, Inc., as the same may be amended from time to time (the two referenced
pre-existing agreements between UTRF and GTx, Inc., being hereinafter referred to as the
“Exclusive License Agreements”), and any agreement entered into by UTRF granting an option for
such a right or license.
	 
	1.7	 	“LICENSEE” means any 3rd party licensee to a LICENSE AGREEMENT.
	 
	1.8	 	“LICENSED INVENTIONS” means EXISTING INVENTIONS, IMPROVEMENT INVENTIONS, and associated IP
RIGHTS licensed to UTRF in Sections 2.1 and/or 2.7 herein.
	 
	1.9	 	“NET REVENUES” means all gross proceeds received by UTRF from the licensing of the LICENSED
INVENTIONS and/or associated IP RIGHTS less IP COSTS.
	 
	1.10	 	“[ * ]BRIDGE SARMS” means SARM compounds [ * ].
	 
	1.11	 	“SARM” means selective androgen receptor modulator.
	 
	1.12	 	“[ * ]BRIDGE SARMS” means SARM compounds [ * ].
	 
	1.13	 	“SUBLICENSE AGREEMENT” means any agreement that is entered into by LICENSEE that grants to
SUBLICENSEE thereunder any right or license to the LICENSED INVENTIONS, or any agreement granting
an option for such a right or license.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	1.14	 	SUBLICENSEE” means any sublicensee to a SUBLICENSE AGREEMENT.
	 
	1.15	 	“TECHNOLOGY” means any and all compounds; compositions; conclusions; designs; inventions;
methods; procedures; processes; products; services; substances; techniques; and/or business,
engineering, manufacturing, scientific, medical, clinical, pharmacology, toxicology, or other
data or material, in any form, method or manner of expression or communication now known or
that hereinafter becomes known (whether or not tangible or intangible, or able to be protected
by patent or trademark), and any documentation or work product comprising the same.
	 
	1.16	 	“TERM” shall have the meaning set forth in Section 10.1 hereof.
	 
	1.16	 	“VALID CLAIM(s)” means any claim(s) in an unexpired patent or pending in a patent application
or provisional application which has not been held unenforceable, unpatentable, or invalid by
a decision of a court or other governmental agency of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal, and which has not been abandoned or admitted to
be invalid or unenforceable through reissue or disclaimer. The parties acknowledge the
requirement under United States law that patent claims must satisfy the written description
requirement of 35 U.S.C. §112.
	 
	2.	 	GRANT OF LICENSE
	 
	2.1	 	Subject to Section 2.8 herein, OSU hereby grants to UTRF an exclusive, worldwide,
sublicensable (through multiple tiers) license to OSU’s interest in the EXISTING INVENTIONS
and associated IP RIGHTS for the duration of each such IP RIGHT.
	 
	2.2	 	Subject to Section 2.8, OSU hereby grants to UTRF a non-exclusive, sublicensable (through
multiple tiers) license to OSU’s interest in know-how related to the EXISTING INVENTIONS.
	 
	2.3	 	Subject to the terms of this AGREEMENT, UTRF shall be the sole party which (i) negotiates the
terms of any LICENSE AGREEMENT, including any amendments thereto, (ii) collects all proceeds
paid pursuant to any such LICENSE AGREEMENT, and (iii) accounts to OSU for OSU’s portion of
all NET REVENUE and pays such portion thereof to OSU as required by this AGREEMENT.
	 
	2.4	 	OSU hereby grants to UTRF an exclusive option to an exclusive, worldwide, sublicensable
(through multiple tiers) license to OSU’s interest in each IMPROVEMENT INVENTION and associated IP RIGHTS for the duration of each IP RIGHT and an
option to a non-exclusive, sublicensable (through multiple tiers) license to OSU’s interest
in know-how related to an IMPROVEMENT INVENTION under the terms of this AGREEMENT
(collectively, the “OPTION”).
	 
	2.5	 	The OPTION shall commence for each IMPROVEMENT INVENTION when it becomes known to the OSU
Office for Technology Licensing or UTRF and shall expire [ * ].

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	2.6	 	UTRF may exercise the OPTION as to each IMPROVEMENT INVENTION by notifying OSU in writing
during the OPTION PERIOD for that IMPROVEMENT INVENTION.
	 
	2.7	 	Subject to Section 2.8 herein, upon UTRF’s exercise of its OPTION as to a particular
IMPROVEMENT INVENTION, OSU grants and agrees to grant to UTRF an exclusive, worldwide,
sublicensable (through multiple tiers) license to OSU’s right, title, and interest in such
IMPROVEMENT INVENTION and associated IP RIGHTS for the duration of each such IP RIGHT and a
non-exclusive sublicensable (through multiple tiers) license to OSU’s interest in know-how
related to the same IMPROVEMENT INVENTION under the terms of this AGREEMENT. OSU and UTRF
agree to amend the AGREEMENT to include each licensed IMPROVEMENT INVENTION on Attachment A,
which shall be incorporated by reference herein.
	 
	2.8	 	To the extent that any research pertaining to a LICENSED INVENTION has been or is in the
future funded in whole or in part by the United States government, the United States
government retains certain rights and requires certain obligations concerning such inventions
as set forth in 35 U.S.C. §§200-212 and all regulations promulgated thereunder, as amended,
and any successor statutes and regulations and applicable policies of such United States
government sponsors, including, without limitation, to the extent applicable, the utilization
and capability requirements found in the National Institutes of Health (NIH) Grants Policy
Statement: “Developing Sponsored Research Agreements: Considerations for Recipients of NIH
Research Grants and Contracts”, Federal Register, Vol. 59, No. 215, Tuesday, November 8, 1994,
pp. 55674-55679 (collectively, “Federal Policy”). UTRF and OSU acknowledge and shall
materially comply with all aspects of Federal Policy applicable to EXISTING INVENTIONS and
IMPROVEMENT INVENTIONS and shall require that each LICENSE AGREEMENT include a provision
requiring the LICENSEE to materially comply with all applicable aspects of Federal Policy. In
the event that either party receives notice of any action or notification by the United States
government with respect to such rights and/or obligations, the party agrees to provide the
other prompt written notice of such action or notification.
	 
	2.9	 	If UTRF fails to exercise its OPTION to an IMPROVEMENT INVENTION and associated IP RIGHTS
within the OPTION PERIOD, then UTRF’s OPTION to that IMPROVEMENT INVENTION shall automatically
terminate upon the expiration of the OPTION PERIOD.
	 
	2.10	 	OSU shall retain the right to use the LICENSED INVENTIONS and associated IP RIGHTS (to the
extent of any of its respective rights therein) solely for non-commercial educational,
research (including non-commercial clinical research), and academic purposes. OSU, however,
shall have no rights for clinical research using a UTRF or LICENSEE proprietary BRIDGED SARMS
compound or to refer to any LICENSEE regulatory filing without prior written approval from
UTRF or its LICENSEE, in their discretion.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	2.11	 	OSU agrees that during the TERM, it will not negotiate or enter into any LICENSE AGREEMENT or
SUBLICENSE AGREEMENT, or otherwise grant any options or licenses or other rights with respect
to the LICENSED INVENTIONS and associated IP RIGHTS, except as required by Federal Policy as
set forth in Section 2.8 of this AGREEMENT. Further, during the TERM and notwithstanding the
duty of candor and good faith under 37 CFR §1.56, neither OSU nor any party on its behalf,
will -oppose, request reexamination, or take any action that would otherwise diminish the IP
RIGHTS in the EXISTING OR IMPROVEMENT INVENTIONS. OSU agrees to forward as soon as possible to
UTRF any and all information which it has knowledge of or believes is material under § 1.56 in
order for submission of such material to the Patent Office by patent counsel. OSU and UTRF
reserve the right to correct inventorship and contest ownership of the IP RIGHTS associated
with the LICENSED INVENTIONS, provided that all such LICENSED INVENTIONS and associated IP
RIGHTS are still and shall continue to be licensed to UTRF under this AGREEMENT.
	 
	3.	 	PATENT PROSECUTION AND PROTECTION
	 
	3.1	 	As determined by UTRF and/or its LICENSEE, UTRF and/or its LICENSEE shall control prosecution
and be responsible to prepare, file and/or maintain appropriate United States patent
applications covering the LICENSED INVENTIONS, provided, however, that OSU may advise and
consult with UTRF in such filing, prosecution, and/or maintenance. UTRF shall provide or
require its LICENSEE to provide OSU with reasonable notice prior to filing a patent
application containing any new matter claiming priority to an application for an EXISTING
INVENTION or an IMPROVEMENT INVENTION. UTRF shall also provide or require its LICENSEE to
provide OSU with copies of all office actions and other written communications it or its
patent counsel receives from or files with the U.S. Patent and Trademark Office and the
equivalent foreign offices after the EFFECTIVE DATE with respect to the LICENSED INVENTIONS.
	 
	3.2	 	UTRF and/or its LICENSEE shall make an election whether, when, and in what countries, it
wishes to file foreign patent applications covering the LICENSED INVENTIONS, provided,
however, that OSU may advise and consult with UTRF in such election. UTRF shall notify or
require its LICENSEE to notify OSU in writing of any decision after the EFFECTIVE DATE
regarding foreign filing for LICENSED INVENTIONS.
	 
	3.3	 	OSU shall have no responsibility for any costs incurred by UTRF and/or its LICENSEE for
patent filing, prosecution, maintenance and enforcement of the LICENSED INVENTIONS.
	 
	3.4	 	As required, UTRF and/or its LICENSEE will record and/or maintain assignments of IP RIGHTS in
the LICENSED INVENTIONS in the United States Patent and Trademark Office and UTRF will provide
or require its LICENSEE to provide OSU with a photocopy of each recorded assignment.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	3.5	 	If, after the EFFECTIVE DATE, UTRF and/or its LICENSEE determine (a) not to file a patent
application under IP RIGHTS in the LICENSED INVENTIONS or (b) to allow a pending patent
application under IP RIGHTS in the LICENSED INVENTIONS to go abandoned without filing a
continuation, division, re-issue or other application having the same priority and without
issuance of a patent having the same priority, or (c) not to maintain a previously-filed
patent application or issued patent under IP RIGHTS in the LICENSED INVENTIONS in the United
States, England, France, Germany, Italy, Spain, Canada, Australia, China, India, Russia,
Switzerland, and Japan (collectively, the “Major Countries”), it shall provide reasonable
prior written notice to OSU of such determination as required under Section 3.1 of this
AGREEMENT. Following such determination by UTRF and/or its LICENSEE, OSU may, by written
notice to UTRF, elect to file, prosecute, and/or maintain such application or patent in any
Major Country in which UTRF and/or its LICENSEE did not file (the “Exception Countries”), at
OSU’s sole expense. In that event, OSU will be free to exploit and to assign or license OSU’s
interest in such patent application and/or patent to third parties in the Exception Countries,
provided that any such assignment or license will be limited to domestic manufacture and sale
in the Exception Countries, with no right to export or sell products or otherwise to compete
with UTRF and/or its LICENSEE (including SUBLICENSEES) in the rest of the world. In the event
UTRF and/or its LICENSEE believes that any exploitation, assignment, or license of OSU’s
interests in the Exception Countries competes with or interferes with UTRF’s or its LICENSEE’s
exclusive commercialization and exploitation of the LICENSED INVENTIONS in the Major Countries
other than the Exception Countries, OSU shall, upon notice, take all reasonable measures to
preclude such competition or interference, including terminating any license in the Exception
Countries and taking enforcement action. [ * ]
	 
	3.6	 	OSU agrees to cooperate with UTRF and/or its LICENSEE in the preparation, filing,
prosecution, and maintenance of patent applications and patents under IP RIGHTS in the
LICENSED INVENTIONS by disclosing such information as may be necessary or appropriate and
promptly executing such documents as UTRF and/or its LICENSEE may reasonably request. Each
party will bear its own costs in connection with its cooperation with the other party under
this Section. UTRF and/or its LICENSEE agree to forward all correspondence in need of
signature by OSU inventors to OSU’s Office for Technology Licensing in a timely manner. OSU’s
Office for Technology shall obtain signatures from OSU inventors in a timely manner and
promptly return such documents upon reasonable notice and request by UTRF or its LICENSEE. If
costs for extensions of time become due because of unreasonable delay at OSU in returning
signed documents, OSU shall provide reimbursement for such reasonable costs.
	 
	4.	 	LICENSING
	 
	4.1	 	UTRF shall use reasonable efforts to maintain and/or seek a LICENSEE for the commercial development
of the LICENSED INVENTIONS. The parties acknowledge that, as of the EFFECTIVE DATE, UTRF has
complied with this section by virtue of the current EXCLUSIVE LICENSE AGREEMENTS. UTRF shall
promptly provide OSU

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	with copies of all LICENSE AGREEMENTS and amendments thereto that relate to the LICENSED
INVENTIONS. UTRF shall use reasonable efforts to require LICENSEE’S compliance with the terms
of any LICENSE AGREEMENT provided that this provision shall not be interpreted to require UTRF
to bring suit against LICENSEE.
	 
	4.2	 	Any LICENSE AGREEMENT must include, but is not limited to, the following terms: an earned
royalty, payment of patent costs associated with the IP RIGHTS licensed thereunder by the
LICENSEE, commercially reasonable diligence terms, a disclaimer of warranties on the part of
OSU and UTRF, and a prohibition of the use of the name of OSU. OSU shall be provided with
reasonable time to review and comment on LICENSE AGREEMENTS and amendments to LICENSE
AGREEMENTS. If any LICENSE AGREEMENT would cause OSU to violate any law, rule, regulation or
Federal Policy to which it is subject, the parties agree to negotiate in good faith a revision
to such LICENSE AGREEMENT to be proposed to the LICENSEE to enable OSU to be in compliance
with any such law, rule or regulation.
	 
	4.3	 	UTRF shall include a provision in each LICENSE AGREEMENT that the LICENSEE shall indemnify,
defend, and hold OSU harmless against all claims resulting from the production, manufacture,
sale, use, lease, or consumption of the LICENSED INVENTIONS and associated IP RIGHTS,
excluding any claim resulting from the willful misconduct or misrepresentation by OSU, its
trustees, directors, officers, employees, and affiliates, as the case may be.
	 
	5.	 	WARRANTIES, INDEMNIFICATION, AND DISCLAIMERS
	 
	5.1	 	OSU represents and warrants that:

	 	5.1.1	 	OSU has the right to enter into this AGREEMENT, to grant the licenses herein
and to bind The Ohio State University Research Foundation to the terms of this
Agreement in the same manner that The Ohio State University is bound, and hereby binds
OSURF thereto;
	 
	 	5.1.2	 	To the best of its knowledge, by entering into and performing under this
AGREEMENT, it shall not be in violation of any applicable law, rule, regulation, or
contractual obligation owed to any third party, and that it shall have obtained all
permits, licenses, or permissions required to comply with such laws, rules,
regulations, or obligations;
	 
	 	5.1.3	 	Prior to and at any time during the TERM, it knowingly has not nor will it
make any agreements and/or transfer of rights or powers in the LICENSED INVENTIONS or
otherwise encumber the LICENSED INVENTIONS or the associated IP RIGHTS (including
IMPROVEMENT INVENTIONS during the OPTION PERIOD) in a manner that is inconsistent with
or in derogation of the exclusive license or the OPTION granted to UTRF herein, except
as permitted under Sections 2 and 3 herein;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	5.1.4	 	As of the EFFECTIVE DATE, OSU, to the best of its knowledge, is not aware of
any pending or threatened litigation involving the EXISTING INVENTIONS, IMPROVEMENT
INVENTIONS, or associated IP RIGHTS and agrees to notify UTRF in the event it becomes
aware of pending or threatened litigation involving any of the EXISTING INVENTIONS,
IMPROVEMENT INVENTIONS or associated IP RIGHTS thereafter.

	5.2	 	UTRF represents and warrants that:

	 	5.2.1	 	UTRF has the right to enter into this AGREEMENT, to accept and grant the
licenses herein.
	 
	 	5.2.2	 	To the best of its knowledge, by entering into and performing under this
AGREEMENT, it shall not be in violation of any applicable law, rule, regulation or
contractual obligation owed to any third party, and that it shall have obtained all
permits, licenses, or permissions required to comply with such laws, rules,
regulations, or obligations.

	5.3	 	EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY, ITS AFFILIATES, AND
THEIR TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AGENTS MAKE NO REPRESENTATIONS AND EXTEND
NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF IP RIGHTS, CLAIMS ISSUED OR
PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN
THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY
THAT THE PRACTICE BY ANY LICENSEE OR SUBLICENSEE OF THE LICENSE GRANTED SHALL NOT INFRINGE THE
IP RIGHTS OF ANY THIRD PARTY. NEITHER PARTY SHALL BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL
DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
REGARDLESS OF WHETHER THE OTHER PARTY IS ADVISED, HAS OTHER REASON TO KNOW, OR IN FACT DOES
KNOW OF THE POSSIBILITY.
	 
	6.	 	FINANCIAL TERMS
	 
	6.1	 	[ * ]
	 
	6.2	 	Each party is solely responsible for calculating and distributing to its respective inventors
any share of NET REVENUES due in accordance with its respective patent, inventorship, or
intellectual property policy.
	 
	7.	 	RECORDS AND REPORTS
	 
	7.1	 	[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	7.2	 	Within thirty (30) days following its receipt, UTRF shall provide to OSU a copy of any
written reports provided to UTRF by a LICENSEE pertaining to LICENSED INVENTIONS, if any.
	 
	7.3	 	Each of UTRF and OSU agrees to be responsible for its own reporting to federal agencies as
required. OSU and UTRF agree to cooperate as necessary for effecting such reporting.
	 
	8.	 	PATENT INFRINGEMENT
	 
	8.1	 	In the event that UTRF or OSU becomes aware of the infringement or claim of infringement of
any IP RIGHTS in the LICENSED INVENTIONS in whatever territory those IP RIGHTS exist, each
will inform the other in writing of all details available.
	 
	8.2	 	UTRF and its LICENSEE shall have the first right to enforce the rights of the parties. If
both UTRF and its LICENSEE elect not to enforce or to continue to enforce the right of the
parties, UTRF shall notify OSU in writing. Under such circumstances, OSU may elect to
prosecute the infringers [ * ] provided that (i) [ * ], and (ii) OSU shall not have any right
to surrender OSU’s, UTRF’s or any LICENSEE’S rights or to grant any infringer any rights in
the IP RIGHTS without the prior written approval of UTRF and any LICENSEE, such approval not
to be unreasonably withheld.
	 
	8.3	 	In any infringement suit instituted to enforce the IP RIGHTS pursuant to this AGREEMENT, both
parties will, at the request of the party initiating such suit, and to the extent permitted by
law, make a reasonable effort to cooperate in all respects and, to the extent possible, have
its employees testify when requested and make available relevant records, papers, information,
samples, and the like. [ * ]
	 
	8.4	 	Any sums recovered by UTRF or OSU, excluding such amounts as are otherwise payable to (or to
be retained by) any LICENSEE under a LICENSE AGREEMENT, with respect to any such action will
be [ * ].
	 
	9.	 	NOTICES
	 
	 	 	Any notice and/or correspondence required or permitted to be given to the parties hereto is
properly given if delivered in writing, in person, sent by first-class certified mail, or by
overnight carrier, or if transmitted by confirmed facsimile or email (with a copy provided
by another means specified in this Section) to the following addresses, or to such other
addresses as may be designated in writing by the parties from time to time during the
	 
	 	 	TERM of this AGREEMENT:

	 	 	 	 	 
	 

	 	to OSU:
	 	[ * ]
	 

	 	to UTRF :

with a copy to:
	 	[ * ]

[ * ]

	10.	 	TERMINATION
	 
	10.1	 	This AGREEMENT is in full force and effect from the EFFECTIVE DATE and remains

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	in effect for
the life of the last-to-expire patent in IP RIGHTS, unless otherwise terminated under Section
10.2 or by mutual written agreement of the parties (the “TERM”).
	 
	10.2	 	Upon any breach of this AGREEMENT by either party, the other party has the right to terminate
this AGREEMENT [ * ].
	 
	10.3	 	The parties acknowledge and agree that any provision that by its nature survives shall
survive cancellation or termination of this AGREEMENT.
	 
	10.4	 	Should UTRF breach Section [ * ], all of UTRF’ s right, title, and interest in and to OSU’s
interests in any LICENSED INVENTIONS and the associated IP RIGHTS shall revert to OSU. Any
LICENSE AGREEMENT or SUBLICENSE AGREEMENT executed prior to any expiration or termination of
this AGREEMENT between UTRF or a LICENSEE and a third party (a “PRIOR LICENSEE’) shall remain
in effect for the duration of such agreement as if this AGREEMENT was in full force and effect
with OSU standing in the shoes of UTRF as licensor to the extent only of OSU’s interest in the
LICENSED INVENTIONS, provided that any such LICENSE AGREEMENT or SUBLICENSE AGREEMENT was not
subject to a notice of termination by UTRF at the time of cancellation or termination of this
AGREEMENT. The parties further acknowledge and agree that UTRF’s right to exercise the OPTION
provided under Section 2.4 herein for any IMPROVEMENT INVENTION shall expire upon termination
of this AGREEMENT. Following such expiration, a PRIOR LICENSEE shall have the right, subject
to Section 2.8 herein, to exercise the OPTION to negotiate a license to an IMPROVEMENT
INVENTION under terms acceptable to OSU and the PRIOR LICENSEE.
	 
	10.5	 	Should OSU (i) breach its obligation under this Agreement [ * ], then its rights under the
LICENSED INVENTIONS shall revert to UTRF as follows. The grant to UTRF in Section 2.1 shall
become fully paid up, permanent, and irrevocable, and there shall be no further payment or
reporting obligations to OSU.
	 
	11.	 	CONFIDENTIALITY
	 
	11.1	 	To the extent permitted by law, UTRF and OSU, respectively, shall hold in confidence the
TECHNOLOGY, proprietary business information, patent prosecution information or other
information related to the LICENSED INVENTIONS or associated IP RIGHTS of the other party, or
any information of or pertaining to a LICENSEE or SUBLICENSEE that has been disclosed to UTRF
or OSU agents, personnel or employees (collectively, “PROPRIETARY INFORMATION”) using at least
the same degree of care as that party
uses to protect its own proprietary information of a like nature, but no less than
reasonable care, and shall not use or disclose the PROPRIETARY INFORMATION of the disclosing
party without the prior written consent of the disclosing party, except as otherwise
contemplated by this AGREEMENT. Notwithstanding the foregoing, UTRF and OSU agree that this
section does not apply to proprietary business information or other information related to
the LICENSED INVENTIONS disclosed by a LICENSEE or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	SUBLICENSEE to an OSU employee while that
employee is acting solely in the capacity as a private consultant or employee of the
LICENSEE or SUBLICENSEE. The disclosing party shall label or mark confidential, or as
otherwise appropriate, all such PROPRIETARY INFORMATION, provided that the parties agree
that all patent applications and related patent filings and correspondence shall be and
remain PROPRIETARY INFORMATION and covered by the confidentiality provision hereof without
any further written notification. If PROPRIETARY INFORMATION is orally disclosed, the
disclosing party shall reduce the PROPRIETARY INFORMATION to writing or to some other
physically tangible form and deliver it to the receiving party within thirty (30) days of
the oral disclosure, marked and labeled as set forth above. Nothing herein shall be
construed in such a manner as to preclude UTRF from disclosing PROPRIETARY INFORMATION of
OSU to a third party without the prior written consent of OSU for the purpose of marketing,
licensing, protecting, or defending LICENSED INVENTIONS or otherwise performing its
obligations or exercising its rights as contemplated by this AGREEMENT, provided that such
disclosure is made under the same degree of care as UTRF uses to protect its own
confidential and proprietary information of a like nature, but with no less than reasonable
care and conditions of confidentiality.
	 
	11.2	 	Except as otherwise set forth in Section 2, nothing in this AGREEMENT in any way restricts or
impairs the right of OSU and UTRF to use, disclose, or otherwise deal with any PROPRIETARY
INFORMATION that recipient can demonstrate by written records:

	 	(i)	 	was previously known to it, excluding, however, any PROPRIETARY INFORMATION
known to recipient on account of a confidentiality agreement to which it is subject;
	 
	 	(ii)	 	is now, or becomes in the future, public knowledge other than through acts or
omissions of recipient;
	 
	 	(iii)	 	is lawfully obtained without restrictions by recipient from sources
independent of the disclosing party;
	 
	 	(iv)	 	was made independently without the use of PROPRIETARY INFORMATION received
hereunder or under an existing confidentiality agreement; or
	 
	 	(v)	 	is required by applicable federal, state, or local law or court order to be
disclosed.

	11.3	 	In the event one of the parties to this AGREEMENT shall desire to publish or present a
manuscript, poster, abstract, presentation, thesis, dissertation, or
any other type of public disclosure (together, “Publications”) relating to the EXISTING INVENTIONS or any IMPROVEMENT
INVENTION, the publishing party shall provide the other party and any LICENSEE or
SUBLICENSEE about which the party has received prior notification with a copy of such
Publication 60 days prior to submission of such Publication for publication for purposes of
protecting PROPRIETARY INFORMATION or associated IP RIGHTS that might be contained in such
Publication. Should the receiving party or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	any LICENSEE or SUBLICENSEE identify potentially
patentable information in the proposed Publication, the receiving party or any LICENSEE or
SUBLICENSEE shall notify the publishing party, and the publishing party agrees to delay the
submission of the Publication for an additional sixty (60) days to allow for the preparation
and filing of a patent application if requested by a party having the right to file a patent
application hereunder. The parties agree to cooperate with each other to avoid publication
of trade secrets or other sensitive or potentially damaging information of any LICENSEE or
SUBLICENSEE.
	 
	11.4	 	The confidentiality obligations of the recipient under these terms will remain in effect as
to each item of PROPRIETARY INFORMATION for [ * ], and such obligations will survive
termination of this AGREEMENT should this AGREEMENT terminate prior to completion of the
period that the obligations are to remain in effect. Nothing herein shall be construed to
abrogate or reduce any existing confidentiality obligations relating to the subject matter
hereof.
	 
	12.	 	GENERAL
	 
	12.1	 	UTRF and OSU each represent and warrant that they have the full corporate power and authority
to enter into this AGREEMENT, and that this AGREEMENT constitutes the binding legal obligation
of the parties.
	 
	12.2	 	Other than for the licensing activities contemplated by this AGREEMENT, this AGREEMENT does
not confer any right to use any name, trade name, trademark, or other designation of either
party to this AGREEMENT (including contraction, abbreviation or simulation of any of the
foregoing) in advertising, publicity or other promotional activities.
	 
	12.3	 	This AGREEMENT may not be assigned by UTRF or OSU without the written consent of an
authorized representative of the other party, which consent may be granted or withheld in such
party’s sole and absolute discretion, except that either party may assign this AGREEMENT
without consent only (a) along with its ownership of the LICENSED INVENTIONS and associated IP
RIGHTS and (b) to a successor that is a university or an organization which has as one of its
primary functions the management of LICENSED INVENTIONS (a Bayh-Dole organization). This
Agreement shall apply to, inure to the benefit of, and be binding upon, the parties’ permitted
successors and assigns.
	 
	12.4	 	The scope and validity of any patent or patent application in IP RIGHTS in LICENSED
INVENTIONS are governed by applicable laws of the country of that patent or patent
application.
	 
	12.5	 	No waiver by either party hereto of any breach or default of any of the covenants or
agreements herein set forth may be deemed a waiver as to any subsequent and/or similar breach
or default.
	 
	12.6	 	This AGREEMENT does not confer by implication, estoppel, or otherwise any license or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	rights
under any patents of either party other than the specific LICENSED INVENTIONS and associated
IP RIGHTS licensed hereunder, regardless of whether such patents are dominant or subordinate
to such IP RIGHTS.
	 
	12.7	 	This AGREEMENT, including the Attachments and the NEW SARMS INVENTIONS INTER-INSTITUTIONAL
AGREEMENT being executed contemporaneously, constitutes the entire agreement, both written and
oral, between the parties, and it supersedes all prior and contemporaneous agreements between
the parties respecting the subject matter of this AGREEMENT, written or oral, expressed or
implied. This AGREEMENT shall not be amended or modified except by written instrument that has
been duly executed by the signature of an authorized representative of each of the parties.
This AGREEMENT may not be amended or modified by conduct manifesting assent and each party is
hereby put on notice that any individual purporting to amend or modify this AGREEMENT by
conduct manifesting assent is not authorized to do so. In the event this AGREEMENT is modified
except as provided in this Section, any party may deem such modification to be voidable at
will.
	 
	12.8	 	[ * ]
	 
	12.9	 	THE PARTIES INTEND THAT THIS AGREEMENT IS VALID AND SHALL BE ENFORCED AS WRITTEN. In the
event any provision of this AGREEMENT shall for any reason be held by a court of law or an
agency of the United States government with jurisdiction thereover to be invalid, illegal or
unenforceable in any respect (whether on the ground that it is excessively broad or
unreasonable as to scope or subject, or otherwise) (“AFFECTED PROVISION”), such AFFECTED
PROVISION shall be enforced, modified, or replaced by another equivalent provision, to the
extent necessary to render it valid, legal and enforceable under the circumstances and to the
extent consistent with applicable law, while reflecting as closely as possible the original
intent of the Parties with respect to the AFFECTED PROVISION, as expressed or implied therein.
If, however, such enforcement, modification or replacement is not permissible under applicable
law, then the AFFECTED PROVISION shall be severed from this AGREEMENT. The invalidity,
illegality or unenforceability of the AFFECTED PROVISION, or the enforcement, modification,
replacement or severance thereof (as the case may be), shall not affect the validity, legality
or enforceability of the other provisions of this AGREEMENT, which shall remain in full force
and effect
	 
	12.10	 	To facilitate execution, this AGREEMENT may be executed in as many counterparts as may be
required. It shall not be necessary that the signature of or on behalf of each party appears
on each counterpart, but it shall be sufficient that the signature of or on behalf of each
party appears on one or more of the counterparts. All counterparts shall collectively
constitute a single agreement. It shall not be necessary in any proof
of this AGREEMENT to produce or account for more than a number of counterparts containing the
respective signatures of or on behalf of all of the parties. Further, this AGREEMENT may be
executed through the use of facsimile transmission, and a counterpart of this AGREEMENT that
contains the facsimile signature of a party shall constitute an

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	 	executed counterpart of this
AGREEMENT.

{AUTHORIZED SIGNATURES APPEAR ON THE FOLLOWING PAGE}

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

IN WITNESS WHEREOF, the parties have caused this AGREEMENT to be executed by their respective duly
authorized officers or representatives.

	 	 	 	 	 
	UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
	By

	 	/s/ Fred D. Tompkins
	 	 
	 

	 	 	 	 
	Name

	 	Fred D. Tompkins, Ph.D.	 	 
	Title

	 	President	 	 
	Date

	 	12-22-04	 	 
	 
	 	 	 	 
	THE OHIO STATE UNIVERSITY
	By

	 	/s/ Ellen J. Purpus
	 	 
	 

	 	 	 	 
	Name

	 	Ellen J. Purpus, Ph.D.	 	 
	Title	 	Director, Office for Technology Licensing
	Date

	 	Dec. 22, 2004	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

ATTACHMENT A

PATENTS AND PATENT APPLICATIONS

COVERING BRIDGED SARMS

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Exhibit C

OSU IIA #2

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

NEW SARM INVENTIONS

INTER-INSTITUTIONAL AGREEMENT

BETWEEN

THE OHIO STATE UNIVERSITY

AND

THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

This NEW SARM INVENTIONS INTER-INSTITUTIONAL AGREEMENT (the “AGREEMENT”) is effective the
22nd day of December, 2004 (hereafter, the (“EFFECTIVE DATE”) by and between The Ohio
State University on behalf of itself and The Ohio State University Research Foundation and the Ohio
State University Office for Technology Licensing (collectively, hereinafter “OSU”) having an
address at 1960 Kenny Road, Columbus, Ohio 43210, and the University of Tennessee Research
Foundation (hereinafter “UTRF”) having an address at 1534 White Avenue, Knoxville, Tennessee 37996.

BACKGROUND

OSU and UTRF executed a formal inter-institutional agreement effective the same date hereof
(hereinafter referred to as the “BRIDGED SARM IIA”) with respect to the patenting,
enforcement, sharing of proceeds, and commercialization of certain BRIDGED SARM inventions
developed in whole or in part by OSU researcher Dr. James Dalton and/or other OSU research
staff and students.

OSU and UTRF now wish to establish an understanding between the parties with respect to the
patenting, enforcement, and commercialization of NEW INVENTIONS (as defined below) and how
any commercialization revenues derived therefrom will be divided between the parties.

In furtherance thereof, OSU wishes to grant UTRF an option to obtain an exclusive license to
OSU’s interest in the NEW INVENTIONS and UTRF wishes to obtain such an option pursuant to
the provisions of this AGREEMENT.

Therefore, in consideration of the mutual obligations set forth below, OSU and UTRF agree as
follows:

	1.	 	DEFINITIONS. The following capitalized terms used in this AGREEMENT have the following
meanings:
	 
	1.1	 	“BRIDGED SARMS” means SARM compounds [ * ], including those described in the patents and
patent applications listed in Attachment A to BRIDGED SARM IIA.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	1.2	 	“IP COSTS” means the documented, un-reimbursed, out-of-pocket, reasonable expenses incurred
by UTRF or OSU in the preparation, filing, prosecution, defense, enforcement and maintenance
of IP RIGHTS associated with the NEW INVENTIONS.
	 
	1.3	 	“IP RIGHTS” means any and all right, title and interest (whether now existing or arising in
the future) in, to and under NEW INVENTIONS, including, without limitation, patents, patent
applications, provisional patent applications and any divisions, reissues, renewals,
reexaminations, substitutions, continuations, continuations-in-part, and any corresponding
foreign counterparts thereof; and other proprietary rights arising or enforceable under any
United States federal or state law, rule or regulation, non United States law, rule or
regulation or international treaty.
	 
	1.4	 	“LICENSE AGREEMENT” means any agreement that is entered into by UTRF that grants to a third
party any right or license to the LICENSED INVENTIONS, including, without limitation, the two
existing Amended and Restated Exclusive License Agreements dated August 23, 2000 by and
between UTRF and GTx, Inc., as the same may be amended from time to time (the two referenced
pre-existing agreements between UTRF and GTx, Inc., being hereinafter referred to as the
“Exclusive License Agreements”), and any agreement entered into by UTRF granting an option for
such a right or license.
	 
	1.5	 	“LICENSEE” means any 3rd party licensee to a LICENSE AGREEMENT.
	 
	1.6	 	“LICENSED INVENTIONS” means NEW INVENTIONS and associated IP RIGHTS licensed to UTRF under
Section 2 herein.
	 
	1.7	 	“NET REVENUES” means all gross proceeds received by UTRF from the licensing of the LICENSED
INVENTIONS and/or associated IP RIGHTS less IP COSTS.
	 
	1.8	 	“NEW INVENTIONS” means any TECHNOLOGY pertaining to SARMS conceived, created, developed,
designed, invented, or reduced to practice, in whole or in part by OSU researcher Dr. James
Dalton and/or other OSU research staff and students that is not a LICENSED INVENTION under the
BRIDGED SARM IIA, and is patentably distinct therefrom and directly results from: (i) research
or clinical investigation utilizing any EXISTING INVENTION or IMPROVEMENT INVENTION as defined
in the BRIDGED SARM IIA; (ii) research or investigation conducted pursuant to specific
National Institutes of Health or other federally-funded projects, which involve collaboration
between UT and/or UTRF and OSU; or (iii) non-federally-funded research at OSU that is
sponsored by UT or UTRF or any of their respective licensees or sublicensees relating to
SARMS. Any other invention will be considered to be a NEW INVENTION subject to this Agreement
if OSU and UTRF agree thereto in writing. The parties acknowledge and agree that a NEW
INVENTION shall not include

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

TECHNOLOGY, EXISTING INVENTIONS, or IMPROVEMENT INVENTIONS as defined in the
BRIDGED SARM IIA.

	1.9	 	“SARM” means selective androgen receptor modulator.
	 
	1.10	 	“SUBLICENSE AGREEMENT” means any agreement that is entered into by LICENSEE that grants to
SUBLICENSEE thereunder any right or license to the LICENSED INVENTIONS, or any agreement
granting an option for such a right or license.
	 
	1.11	 	“SUBLICENSEE” means any sublicensee to a SUBLICENSE AGREEMENT.
	 
	1.12	 	“TECHNOLOGY” means any and all compounds; compositions; conclusions; designs; inventions;
methods procedures; processes; products; services; substances; techniques; and/or business,
engineering, manufacturing, scientific, medical, clinical, pharmacology, toxicology, or other
data or material, in any form, method or manner of expression or communication now known or
that hereinafter becomes known (whether or not tangible or intangible, or able to be protected
by patent or trademark), and any documentation or work product comprising the same.
	 
	1.13	 	“TERM” shall have the meaning set forth in Section 10.1 hereof.
	 
	1.14	 	“VALID CLAIM(s)” means any claim(s) in an unexpired patent or pending in a patent application
or provisional application which has not been held unenforceable, unpatentable, or invalid by
a decision of a court or other governmental agency of compete jurisdiction, unappealable or
unappealed within the time allowed for appeal, and o which has not been abandoned or admitted
to be invalid or unenforceable through issue or disclaimer. The parties acknowledge the
requirement under United States law that patent claims must satisfy the written description
requirement of 35 U.S. C. §112.
	 
	2.	 	GRANT OF OPTION FOR LICENSE
	 
	2.1	 	OSU hereby grants to UTRF an exclusive option to an exclusive, worldwide, sublicensable
(through multiple tiers) license to OSU’s interest in each NEW INVENTION and associated IP
RIGHTS and an option to a nonexclusive, sublicensable (through multiple tiers) license to
OSU’s interest in know-how related to an IMPROVEMENT INVENTION under the terms of this
AGREEMENT (collectively, the “OPTION”).
	 
	2.2	 	Within [ * ]. The OPTION shall commence for each NEW INVENTION upon the date of such notice
and shall expire [ * ].

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	2.3	 	UTRF may exercise the OPTION as to each NEW INVENTION by notifying OSU in writing during the
OPTION PERIOD for that NEW INVENTION.
	 
	2.4	 	Upon UTRF’s exercise of its OPTION as to a particular NEW INVENTION, OSU grants and agrees to
grant to UTRF an exclusive, worldwide, sublicensable (through multiple tiers) license to OSU’s
right, title, and interest in such NEW INVENTION and associated IP RIGHTS for the duration of
each such IP RIGHT and a non-exclusive sublicensable (through multiple tiers) license to OSU’s
interest in know-how related to the same NEW INVENTION, on the same terms and conditions as
the license to LICENSED INVENTIONS granted by OSU in the BRIDGED SARM IIA, [ * ].
	 
	2.5	 	Neither party shall be obligated to reimburse the other party for any IP COSTS incurred by
the other party with regard to a NEW INVENTION unless agreed to in writing by the parties in
advance on a case-by-case basis. Nothing in this AGREEMENT shall be construed in such as
manner as to preclude UTRF from entering into a LICENSE AGREEMENT that provides for
reimbursement by the LICENSEE of IP COSTS, in whole or in part. If OSU has incurred IP COSTS
for a particular NEW INVENTION prior to the date of execution of this Agreement, OSU shall
provide UTRF with a detailed accounting of these IP COSTS and UTRF shall seek reimbursement of
these IP COSTS by a LICENSEE and shall provide such reimbursement to OSU upon UTRF’s receipt
thereof.
	 
	2.6	 	If UTRF shall fail to exercise its OPTION to a NEW INVENTION and associated IP RIGHTS within
the OPTION PERIOD, then UTRF’s OPTION to license such NEW INVENTION and associated IP RIGHTS
under this Section shall automatically expire.
	 
	2.7	 	To the extent that any research pertaining to a LICENSED INVENTION has been or is in the
future funded in whole or in part by the United States government, the United States
government retains certain rights and requires certain obligations concerning such inventions
as set forth in 35 U.S.C. §§200-212 and all regulations promulgated thereunder, as amended,
and any successor statutes and regulations and applicable policies of such United States
government sponsors, including, without limitation, to the extent applicable, the utilization
and capability requirements found in the National Institutes of Health (NIH) Grants Policy
Statement: “Developing Sponsored Research Agreements: Considerations for Recipients of NIH
Research Grants and Contracts”, Federal Register, Vol. 59, No. 215, Tuesday, November 8, 1994,
pp. 55674-55679 (collectively, “Federal Policy”). UTRF and OSU acknowledge and shall
materially comply with all aspects of Federal Policy applicable to NEW INVENTIONS and shall
require that each LICENSE AGREEMENT include a provision requiring the LICENSEE to materially
comply with all applicable aspects of Federal Policy. In the event that either party receives
notice of any action or notification by the United States government with

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

respect to such rights and/or obligations, the party agrees to provide the other prompt
written notice of such action or notification.

	3.	 	WARRANTIES, INDEMNIFICATION, AND DISCLAIMERS
	 
	3.1	 	OSU represents and warrants that:

	 	3.1.1	 	OSU has the right to enter into this AGREEMENT, to grant the licenses herein
and to bind The Ohio State University Research Foundation to the terms of this
Agreement in the same manner that The Ohio State University is bound, and hereby binds
OSURF thereto;
	 
	 	3.1.2	 	To the best of its knowledge, by entering into and performing under this
AGREEMENT, it shall not be in violation of any applicable law, rule, regulation, or
contractual obligation owed to any third party, and that it shall have obtained all
permits, licenses, or permissions required to comply with such laws, rules,
regulations, or obligations;
	 
	 	3.1.3	 	Prior to and at any time during the TERM, it knowingly has not nor will it
make any agreements and/or transfer of rights or powers in the LICENSED INVENTIONS or
otherwise encumber the LICENSED INVENTIONS or the associated IP RIGHTS in a manner that
is inconsistent with or in derogation of the exclusive license or the OPTION granted to
UTRF herein, except as permitted und Sections 2 and 3 herein;
	 
	 	3.1.4	 	As of the EFFECTIVE DATE, OSU, to the best of its knowledge, is not aware of
any pending or threatened litigation involving the NEW INVENTIONS or associated IP
RIGHTS and agrees to notify UTRF in the event it becomes aware of pending or threatened
litigation involving any of the NEW INVENTIONS or associated IP RIGHTS thereafter.

	3.2	 	UTRF represents and warrants that:

	 	3.2.1	 	UTRF has the right to enter into this AGREEMENT, to accept and grant the
licenses herein.
	 
	 	3.2.2	 	To the best of its knowledge, by entering into and performing under this
AGREEMENT, it shall not be in violation of any applicable law, rule, regulation or
contractual obligation owed to any third party, and that it shall have obtained all
permits, licenses, or permissions required to comply with such laws, rules, regulation,
or obligations.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	3.3	 	EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY, ITS AFFILIATES, AND
THEIR TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AGENTS MAKE NO REPRESENTATIONS AND EXTEND
NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF IP RIGHTS, CLAIMS ISSUED OR
PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN
THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY
THAT THE PRACTICE BY ANY LICENSEE OR SUBLICENSEE OF THE LICENSE GRANTED SHALL NOT INFRINGE THE
IP RIGHTS OF ANY THIRD PARTY. NEITHER PARTY SHALL BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL
DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
REGARDLESS OF WHETHER THE OTHER PARTY IS ADVISED, HAS OTHER REASON TO KNOW, OR IN FACT DOES
KNOW OF THE POSSIBILITY.
	 
	4.	 	NOTICES

Any notice or other communication required or permitted hereunder (hereinafter “notice”)
shall be in writing and shall be hand-delivered, sent by overnight courier, mailed by
certified United States mail, return receipt requested, or sent by email or facsimile, to
the addresses given below or to such other addresses as the parties may hereafter specify in
writing. Notice shall be deemed given and received five (5) days after being deposited with
the U.S. Postal Service certified mail postage prepaid, or if notice is hand-delivered or
sent by overnight courier, upon the date of actual delivery, or if sent by facsimile or
email, upon the date the receiving party acknowledges receipt in writing by email or
otherwise. An email notice shall be given concurrently to all the email addresses provided
by the recipient party and the first acknowledgment of receipt from the recipient party
shall establish the date on which such notice is given. Any patent correspondence that is
required to be sent shall not be sent via email except where urgent response is required to
preserve patent rights of the NEW INVENTION.

UTRF:

If notice is given means other than email, to: 

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

If notice is given by email, to:

[ * ]

OSU:

If notice is given by means other than email, to: 

[ * ]

If notice is given by email, to: 

[ * ]

	5.	 	TERMINATION
	 
	5.1	 	This AGREEMENT is in full force and effect from the EFFECTIVE DATE and remains in effect for
the life of the last-to-expire patent in IP RIGHTS, unless otherwise terminated by mutual
written agreement of the parties (the “TERM”).
	 
	5.2	 	Upon any breach of this AGREEMENT by either party, the other party has the right to terminate
this AGREEMENT [ * ].
	 
	5.3	 	The parties acknowledge and agree that any provision that by its nature survives shall
survive cancellation or termination of this AGREEMENT.
	 
	6.	 	CONFIDENTIALITY
	 
	6.1	 	To the extent permitted by law, UTRF and OSU, respectively, shall hold in confidence the
TECHNOLOGY, proprietary business information, patent prosecution information or other
information related to the NEW INVENTIONS or associated IP RIGHTS of the other party, or any
information of or pertaining to a LICENSEE or SUBLICENSEE that has been disclosed to UTRF or
OSU agents, personnel or employees (collectively, “PROPRIETARY INFORMATION”) using at least
the same degree of care as that party uses to protect its own proprietary information of a
like nature, but no less than reasonable care, and shall not use or disclose the PROPRIETARY
INFORMATION of the disclosing party without the prior written consent of the disclosing party,
except as otherwise contemplated by this AGREEMENT. Notwithstanding the foregoing, UTRF and
OSU agree that this section does not apply to proprietary business information or other
information related to the LICENSED INVENTIONS disclosed by a LICENSEE or SUBLICENSEE to an
OSU employee while that employee is acting solely in the capacity as a private consultant or
employee of the LICENSEE or SUBLICENSEE. The disclosing party shall label or mark
confidential, or as otherwise appropriate, all such PROPRIETARY INFORMATION, provided that the
parties agree that all patent

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

applications and related patent filings and correspondence shall be and remain PROPRIETARY
INFORMATION and covered by the confidentiality provision hereof without any further written
notification. If PROPRIETARY INFORMATION is orally disclosed, the disclosing party shall
reduce the PROPRIETARY INFORMATION to writing or to some other physically tangible form and
deliver it to the receiving party within thirty (30) days of the oral disclosure, marked and
labeled as set forth above. Nothing herein shall be construed o such a manner as to
preclude UTRF from disclosing PROPRIETARY INFORMATION of OSU to a third party without the
prior written consent of OSU for the purpose of marketing, licensing, protecting, or
defending LICENSED INVENTIONS or otherwise performing its obligations or exercising its
rights as contemplated by this AGREEMENT, provided that such disclosure is made under the
same degree of care as UTRF uses to protect its own confidential and proprietary information
of a like nature, but with no less than reasonable care and conditions of confidentiality.

	6.2	 	Except as otherwise set forth Section 2, nothing in this AGREEMENT in any way restricts or
impairs the right of OSU and UTRF to use, disclose, otherwise deal with any PROPRIETARY
INFORMATION that recipient can demonstrate by written records:

	 	(i)	 	was previously known to it, excluding, however, any PROPRIETARY INFORMATION
known to recipient on account of a confidentiality agreement to which it is subject;
	 
	 	(ii)	 	is now, or becomes in the future, public knowledge other than through acts or
omissions of recipient;
	 
	 	(iii)	 	is lawfully obtained without restrictions by recipient from sources
independent of the disclosing party;
	 
	 	(iv)	 	was made independently without the use of PROPRIETARY INFORMATION received
hereunder or under an existing confidentiality agreement; or
	 
	 	(v)	 	is required by applicable federal, state, or local law or court order to be
disclosed.

	6.3	 	In the event one of the parties to this AGREEMENT shall desire to publish or present a
manuscript, poster, abstract, presentation, thesis, dissertation, or any other type of public
disclosure (together, “Publications”) relating to the NEW INVENTIONS, the publishing party
shall provide the other party and any LICENSEE or SUBLICENSEE about which the party has
received prior notification with a copy of such Publication 60 days prior to submission of
such Publication for publication for purposes of protecting PROPRIETARY INFORMATION or
associated IP RIGHTS that might be contained in such Publication. Should the receiving party
or any LICENSEE or SUBLICENSEE

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

identify potentially patentable information in the proposed Publication, the receiving party
or any LICENSEE or SUBLICENSEE shall notify the publishing party, and the publishing party
agree to delay the submission of the Publication for an additional sixty (60) days to allow
for the preparation and filing of a patent application if requested by a party having the
right to file a patent application hereunder. The parties agree to cooperate with each
other to avoid publication of trade secrets or other sensitive or potentially damaging
information of any LICENSEE or SUBLICENSEE.

	6.4	 	The confidentiality obligations of the recipient under these terms will remain in effect as
to each item of PROPRIETARY INFORMATION for [ * ], and such obligations will survive
termination of this AGREEMENT should this AGREEMENT terminate prior to completion of the
period that the obligations are to remain in effect. Nothing herein shall be construed to
abrogate or reduce any existing confidentiality obligations relating to the subject matter
hereof.
	 
	7.	 	GENERAL
	 
	7.1	 	UTRF and OSU each represent and warrant that they have the full corporate power and authority
to enter into this AGREEMENT, and that this AGREEMENT constitutes the binding legal obligation
of the parties.
	 
	7.2	 	Other than for the licensing activities contemplated by this AGREEMENT, this AGREEMENT does
not confer any right to use any name, trade name, trademark, or other designation of either
party to this AGREEMENT (including contraction, abbreviation or simulation of any of the
foregoing) in advertising, publicity or other promotional activities.
	 
	7.3	 	This AGREEMENT may not be assigned by UTRF or OSU without the written consent of an
authorized representative of the other party, which consent may be granted or withheld in such
party’s sole and absolute discretion, except that either party may assign this AGREEMENT
without consent only (a) along with its ownership of the LICENSED INVENTIONS and associated IP
RIGHTS and (b) to a successor that is a university or an organization which has as one of its
primary functions the management of LICENSED INVENTIONS (a Bayh-Dole organization). This
Agreement shall apply to, inure to the benefit of, and be binding upon, the parties’ permitted
successors and assigns.
	 
	7.4	 	The scope and validity of any patent or patent application in IP RIGHTS in LICENSED
INVENTIONS are governed by applicable laws of the country of that patent or patent
application.
	 
	7.5	 	No waiver by either party hereto of any breach or default of any of the covenants or
agreements herein set forth may be deemed a waiver as to any subsequent and/or similar

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

breach or default.

	7.6	 	This AGREEMENT does not confer by implication, estoppel, or otherwise any license or rights
under any patents of either party other than the specific LICENSED INVENTIONS and associated
IP RIGHTS licensed hereunder regardless of whether such patents are dominant or subordinate to
such IP RIGHTS.
	 
	7.7	 	This AGREEMENT, including the Attachments and the BRIDGED SARMS INVENTIONS
INTER-INSTITUTIONAL AGREEMENT being execute contemporaneously, constitutes the entire
agreement, both written and oral between the parties, and it supersedes all prior and
contemporaneous agreement between the parties respecting the subject matter of this AGREEMENT,
written or oral, expressed or implied. This AGREEMENT shall not be amended or modifies except
by written instrument that has been duly executed by the signature of an authorized
representative of each of the parties. This AGREEMENT may not be amended or modified by
conduct manifesting assent and each party is hereby put on notice that any individual
purporting to amend or modify this AGREEMENT by conduct manifesting assent is not authorized
to do so. In the event this AGREEMENT is modified except as provided in this Section, any
party may deem such modification to be voidable at will.
	 
	7.8	 	[ * ]
	 
	7.9	 	THE PARTIES INTEND THAT THIS AGREEMENT IS VALID AND SHALL BE ENFORCED AS WRITTEN. In the
event any provision of this AGREEMENT shall for any reason be held by a court of law or an
agency of the United States government with jurisdiction thereover to be invalid, illegal or
unenforceable in any respect (whether on the ground that it is excessively broad or
unreasonable as to scope or subject, or otherwise) (“AFFECTED PROVISION”), such AFFECTED
PROVISION shall be enforced, modified, or replaced by another equivalent provision, to the
extent necessary to render it valid, legal and enforceable under the circumstances and to the
extent consistent with applicable law, while reflecting as closely as possible the original
intent of the Parties with respect to the AFFECTED PROVISION, as expressed or implied therein.
If, however, such enforcement, modification or replacement is not permissible under
applicable law, then the AFFECTED PROVISION shall be severed from this AGREEMENT. The
invalidity, illegality or unenforceability of the AFFECTED PROVISION, or the enforcement,
modification, replacement or severance thereof (as the case may be), shall not affect the
validity, legality or enforceability of the other provisions of this AGREEMENT, which shall
remain in full force and effect.
	 
	7.10	 	To facilitate execution, this AGREEMENT may be executed in as many counterparts as may be
required. It shall not be necessary that the signature of or on behalf of each party appears
on each counterpart, but it shall be sufficient that the signature of or on behalf of

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

each party appears on one or more of the counterparts. All counterparts shall collectively
constitute a single agreement. It shall not be necessary in any proof of this AGREEMENT to
produce or account for more than a number of counterparts containing the respective
signatures of or on behalf of all of the parties. Further, this AGREEMENT may be executed
through the use of facsimile transmission, and a counterpart of this AGREEMENT that contains
the facsimile signature of a party shall constitute an executed counterpart of this
AGREEMENT.

IN WITNESS WHEREOF, the parties have caused this AGREEMENT to be executed by their respective duly
authorized officers or representatives.

	 	 	 
	UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
	By:

	 	/s/ Fred D. Tompkins
	 

	 	 
	Name: Fred D. Tompkins, Ph.D.
	Title: President
	Date: 12/23/05
	 

	 	 
	 
	 	 
	THE OHIO STATE UNIVERSITY
	By:

	 	/s/ Ellen J. Purpus
	 

	 	 
	Name: Ellen J. Purpus, Ph.D.
	Title: Director, Office for Technology Licensing
	Date: Jan. 12, 2006
	 

	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

APPENDIX A to the CONSOLIDATED, AMENDED & RESTATED LICENSE AGREEMENT

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.EX-10.41

 

Exhibit 10.41

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

and

GTx, INC.

AMENDED AND RESTATED LICENSE AGREEMENT

     THIS AMENDED AND RESTATED LICENSE AGREEMENT made and entered into this 24th day of
September, 2007, having an effective date of July 24, 1998 (the “Effective Date”) by and
between University of Tennessee Research Foundation (formerly known as The University of Tennessee
Research Corporation), a Tennessee corporation having an office at 1534 White Avenue, Knoxville,
Tennessee 37996. (hereinafter “UTRF”), and GTx, Inc. (formerly known as Genotherapeutics,
Inc.), a Delaware corporation, located at 3 N. Dunlap St., Memphis, Tennessee 38163 (hereinafter
“GTx”), hereinafter sometimes referred to individually as a “Party” and
collectively as the “Parties”.

RECITALS

     WHEREAS, UTRF owns, in whole or in part, certain Licensed Patents (as defined herein) and
Licensed Technology (as defined herein), the subject matter of which was initially developed by one
or more of the UT Contributors (as defined herein) in the course of their employment with The
University of Tennessee (“UT”);

     WHEREAS, the UT Contributors submitted to UT the invention disclosure form [ * ] designated by
UTRF as file number PD [ * ] (“Initial SERM Disclosure”);

     WHEREAS, UTRF and GTx have previously entered into a separate agreement, titled “Amended and
Restated Exclusive License Agreement” and made effective as of July 24, 1998, whereby GTx was
granted an exclusive license to Licensed Patents (as defined therein) and Licensed Technology (as
defined therein) which arose out of the technology described in the Initial SERM Disclosure (the
“Prior License Agreement”);

     WHEREAS, GTx entered into a Collaboration and License Agreement dated September 7, 2006 (the
“Ipsen Sublicense”) with Ipsen Limited (“Ipsen”) to grant Ipsen exclusive rights in
the European Territory (as defined in the Ipsen Sublicense) to GTx’s product candidate, Acapodene®,
and other products containing toremifene citrate, for methods of use that include those encompassed
within the Licensed Patents;

     WHEREAS, GTx provided UTRF with a copy of the Ipsen Sublicense in accordance with the
provisions of the Prior License Agreement;

     WHEREAS, the Parties now desire to enter into this “Amended and Restated License Agreement”
for the purpose of making certain changes regarding the rights and obligations of the Parties; and

     WHEREAS, the Parties intend that this Agreement shall supersede the Prior License Agreement
and render it null and void.

     NOW, THEREFORE, for and in consideration of the premises and other good and valuable
consideration, including a payment in the amount of Two Hundred Ninety Thousand Dollars ($290,000;
the “Consideration Fee”), which is paid by GTx in consideration of UTRF’s execution of this
Agreement, the Parties hereto expressly agree as follows:

 

 

SECTION 1

Definitions

     1.1 “Actions” shall have the meaning set forth in Section 17.1 hereof.

     1.2 “Active Ingredient” means the material(s) in a pharmaceutical product which
provide its pharmacological activity (excluding formulation components such as coatings,
stabilizers or controlled release technologies).

     1.3 “Affiliate” shall mean any corporation, partnership, or other entity that at any
time during the Term of this Agreement, directly or through one or more intermediaries, Controls or
is Controlled by or is under common Control with a Party to this Agreement or a Sublicensee, but
only for so long as the relationship exists. A corporation or other entity shall no longer be an
Affiliate when through loss, divestment, dilution or other reduction of ownership, the requisite
Control no longer exists.

     1.4 “Agreement” shall mean this Amended and Restated License Agreement.

     1.5 “Claims” shall have the meaning set forth in Section 8.1 hereof.

     1.6 “Combination Product” means either (i) any pharmaceutical product that consists of
at least one SERM and at least one other Active Ingredient that is not a SERM, or (ii) any
combination of a SERM and another pharmaceutical product that contains at least one other Active
Ingredient that is not a SERM where such products are not formulated together but are sold together
as a single product and invoiced as one product.

     1.7 “Confidential Information” shall have the meaning set forth in Section 18.2
hereof.

     1.8 “Control” or “Controls” or “Controlled” shall mean: (i) in the
case of a corporation, ownership or control, directly or indirectly, of at least fifty one percent
(51%) of the shares of stock entitled to vote for the election of directors; or (ii) in the case of
an entity other than a corporation, ownership or control, directly or indirectly, of at least fifty
one percent (51%) of the assets of such entity.

     1.9 “Effective Date” shall have the meaning set forth in the introductory paragraph
hereof.

     1.10 “Federal Policy” shall have the meaning set forth in Section 2.3 hereof.

     1.11 “Generic Product” shall mean a product that is derived from, made with, uses, or
incorporates, in whole or in part, Licensed Technology, but is not covered or claimed in whole or
in part by a Valid Claim of the Licensed Patents in the country of manufacture, use, or sale or
import.

     1.12 “GTx” shall mean GTx, Inc. and its Affiliate(s) (unless such Affiliates are
clearly excluded from the referencing provision(s) at issue), provided that in no instance shall
GTx, Inc. be relieved of any duty or obligation hereunder by the inclusion of its Affiliates in the
definition of “GTx”.

     1.13 “Independent SERM Invention” shall have the meaning set forth in Section 2.8 hereof.

     1.14 “Initial SERM Disclosure” shall have the meaning set forth in the Recitals.

     1.15 “Ipsen” shall have the meaning set forth in the Recitals.

     1.16 “Ipsen Sublicense” shall have the meaning set forth in the Recitals.

     1.17 “License Maintenance Fee” shall have the meaning set forth in Section 4.1A. hereof.

     1.18 “License Year” shall mean a 12-month period beginning on July 24th of
one year and ending on July 23rd of the following year.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

2

 

     1.19 “Licensed Patent” or “Licensed Patents” shall mean any or all of the (a)
the patents set forth on Appendix A, attached hereto and incorporated herein by reference, (b) the
patent applications set forth on Appendix A and any patents issuing therefrom, and (c) any other
patent applications that may in the future be filed pursuant to Section 6.1 of this Agreement by
GTx, whether in the United States of America or any other country, and any patents issuing
therefrom, including, as they pertain to patents and patent applications described in (a)-(c)
hereof, any and all substitutions for and divisional applications, continuation applications,
continuation-in-part applications, provisional applications, and non-provisional applications,
renewal applications, reissue applications, any foreign patent applications and divisional,
continuation and continuation-in-part applications therefrom or national phase applications which
claim priority from any of the pending patent applications set forth on Appendix A.

     1.20 “Licensed Product” or “Licensed Products” shall mean any Patented Product
or Generic Product, provided that in the case of a Combination Product (as defined under Section
1.6), Licensed Product shall mean only that portion of the Combination Product containing a SERM or
SERMS, and Net Sales for such Licensed Product contained within a Combination Product shall be
determined as set forth under Section 1.25.

     1.21 “Licensed Subject Matter” shall mean Licensed Patents and Licensed Technology.

     1.22 “Licensed Technology” shall mean, except to the extent published or otherwise
generally known to the public any technology, trade secrets, methods, processes, know-how,
show-how, data, information, or results (except technology, trade secrets, methods, processes,
know-how, show-how, data, information, or results solely related to Independent SERM Inventions to
the extent not published or otherwise generally known to the public) that are (i) developed by any
one or more of the UT Contributors in the course of employment by UT or developed by any other UT
employee directly from his or her research or clinical investigation of SERMs utilizing any
Proprietary SERM Know-How; and (ii) owned solely or in part by UTRF (but, if owned in part by UTRF,
only to the extent of the part owned by UTRF); and (iii) necessary or reasonably useful for the
practice of any of the Licensed Patent(s), including (for purposes of explaining, and without
expanding, the meaning of Sections 1.22 (i) through (iii)) the chemoprevention of prostate cancer
and any methods of which the primary purpose is to administer to a subject an effective dose of a
chemopreventive agent, toremifene, and analogs or metabolites thereof, to prevent recurrence of,
suppress or inhibit prostate carcinogenesis.

     1.23 “Major Markets” shall mean and include the United States, Great Britain, France,
Germany, and Japan.

     1.24 “Negotiation Period” shall have the meaning set forth in Section 2.8D. hereof.

     1.25 “Net Sales” shall mean the gross amount actually received by GTx or any
Sublicensee for the use, sale or distribution (hereinafter “Sale”) of a Licensed Product
(hereinafter “Gross Receipts”), less the following:

	 	A.	 	refunds, credits, and/or discounts actually given in connection with a
particular Sale in amounts customary in the trade for quantity purchases, cash
payments, and prompt payments, but only if such refunds, credits, and/or discounts
constitute a return of amounts already included in Gross Receipts;
	 
	 	B.	 	refunds, credits and/or discounts actually given for Licensed Products that are
rejected, recalled, returned, or destroyed by customers, but only if such refunds,
credits and/or discounts constitute a return of amounts already included in Gross
Receipts;
	 
	 	C.	 	sales, tariff duties and/or use taxes directly imposed and with reference to a
particular Sale, to the extent included in Gross Receipts;
	 
	 	D.	 	outbound transportation expenses (including insurance relating thereto)
directly related to a particular Sale, to the extent included in Gross Receipts;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

3

 

	 	E.	 	the cost of export licenses, import duties, value added tax, and prepaid
freight directly related to a particular Sale, to the extent included in Gross
Receipts;
	 
	 	F.	 	sales commissions paid by GTx to individuals who are not employees of GTx, a
Sublicensee, or their respective Affiliates, to the extent such commissions are
directly related to a particular Sale;
	 
	 	G.	 	out-of-pocket service fees consistent with normal industry practice paid to
distributors or wholesalers of drug product in payment for distribution of Licensed
Product, provided that (a) such distributors and wholesalers are not Affiliates of GTx;
(b) if any such distributor or wholesaler is an Affiliate of a Sublicensee, such fees
are no more than that which such distributor/wholesaler actually and contemporaneously
charges unaffiliated third party pharmaceutical companies for the same or similar
service; (c) such fees may not be deducted more than once; (d) if a Sublicense shall be
in effect, the fees paid by a Sublicensee may be deducted from Net Sales under this
Agreement only if such fees are deducted from the equivalent of Net Sales under the
relevant Sublicense agreement for purposes of calculating the royalty owed to GTx;
	 
	 	H.	 	retroactive price reductions, chargeback payments and rebates actually granted
in connection with a particular Sale to managed health care organizations or to
federal, state and local governments, their agencies, purchasers, and reimbursers, but
only if such reductions, chargeback payments, and rebates constitute a return of
amounts already included in or calculated as part of Gross Receipts; and
	 
	 	I.	 	[ * ] of any royalty (including a lump-sum payment) that is paid to a Third
Party by GTx pursuant to a patent license agreement between GTx and such Third Party,
provided that at the time of such payment (1) such Third Party owns or controls an
issued patent containing a Valid Claim that, in the absence of such patent license
agreement, would be infringed by the use, sale, or distribution of the composition of
matter of a SERM licensed to GTx hereunder; and (2) the purpose of such royalty is for
licensing of or acquiring such issued patent; and (3) the dollar amount of the [ * ]
deduction for any calendar quarter shall not exceed the dollar amount of Net Sales in
the same calendar quarter (computed without the application of this Section 1.25I.)
from the use, sale, or distribution of Licensed Products containing such SERM in the
country(ies) where such Third Party owns or controls such issued patent, it being
agreed, however, that GTx may carry forward to future quarter(s) the amount by which
the dollar amount of the [ * ] deduction exceeds the cumulative dollar amount of the
actual deductions taken; and (4) GTx has not entered into such patent license
agreement as of the date of execution of this Agreement.

For avoidance of doubt, no deductions shall be made for sales commissions paid to individuals who
are employees of GTx, a Sublicensee, or their respective Affiliates, or for cost of collections.
Notwithstanding the foregoing, Net Sales shall not include the amount received by GTx for the
transfer of Licensed Product to a GTx Affiliate or a Sublicensee or the amount received by a
Sublicensee for transfer or distribution of Licensed Product to GTx or a GTx Affiliate. Sales of
Licensed Product for use in conducting clinical trials of a Licensed Product candidate in a country
shall be excluded from Net Sales calculations for all purposes. Net Sales shall be determined in a
consistent manner for all products sold by or on behalf of GTx and its Sublicensees and in
accordance with applicable U.S. generally accepted accounting principles for GTx and any U.S. based
Sublicensee.

Combination Product. In the event one or more Licensed Products are sold as part of a
Combination Product in a particular country, the Net Sales of such Licensed Product(s), for the
purposes of determining payments based on Net Sales, shall be determined by multiplying the Net
Sales of the Combination Product in such country, during the applicable Net Sales reporting period,
by the fraction, A/(A+B), where:

A is the average sale price of the Licensed Product(s) by GTx or Sublicensees when sold separately
in finished form in such country and B is the average sale price by GTx or Sublicensees, or, if
they have no such right of sale, by a Third Party of the other product(s) included in the
Combination Product when sold separately in finished form in such country, in each case during the
applicable Net Sales reporting period.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

4

 

In the event one or more Licensed Products are sold as part of a Combination Product and are sold
separately in finished form in such country, but the other product(s) included in the Combination
Product are not sold separately in finished form in such country, the Net Sales of the Licensed
Product, for the purposes of determining payments based on Net Sales, shall be determined by
multiplying the Net Sales of the Combination Product in such country by the fraction C/D where:

C is the average sale price, in such country, of the Licensed Product(s) contained in such
Combination Product when sold separately and D is the average sale price, in such country, for the
Combination Product, in each case during the applicable Net Sales reporting period. Under no
circumstances can C/D exceed one hundred percent (100%).

In the event that one or more of the Licensed Product(s) are not sold separately in finished form
in the country, but all of the other product(s) included in the Combination Product in such country
are sold separately, the Net Sales of the Licensed Product, for the purposes of determining
payments based on Net Sales, shall be determined by multiplying the Net Sales of the Combination
Product in such country by the fraction (D-E)/D, where:

D is the average sale price, in such country, of the Combination Product, and E is the average sale
price of the other product(s) included in the Combination Product in finished form in such country,
in each case during the applicable Net Sales reporting period.

In the event that the Net Sales of the Licensed Product(s) when included in a Combination Product
cannot be determined using the methods above, Net Sales for the purposes of determining payments
based on Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by
the fraction of F/(F+G) where:

F is the fair market value of the Licensed Product(s) and G is the fair market value of all other
pharmaceutical product(s) included in the Combination Product, as reasonably determined in good
faith by the Parties.

     1.26 “Option” shall have the meaning set forth in Section 2.8 hereof.

     1.27 “Option Period” shall have the meaning set forth in Section 2.8A. hereof.

     1.28 “Patented Product” shall mean any product whose manufacture, use, sale or import
is covered in whole or in part by a Valid Claim of the Licensed Patents in the country of
manufacture, use, sale or import.

     1.29 “Party” and “Parties” shall have the meaning set forth in the
introductory paragraph hereof.

     1.30 “Prior License Agreement” shall have the meaning set forth in the Recitals.

     1.31 “Proprietary SERM Know-How” shall mean know-how pertaining to a SERM that is
obtained from GTx or a UT Contributor and is not published or otherwise generally known to the
public.

     1.32 “Regulatory Approval” shall mean any approvals granted by a governmental
authority in a particular regulatory jurisdiction (with the exception of conditional approvals)
that are necessary for the commercial manufacture, use, storage, importation, export, transport or
sale of Licensed Products in that regulatory jurisdiction.

     1.33 “Running Royalty” shall have the meaning set forth in Section 4.1B. hereof.

     1.34 “SERM” or “SERMS” shall mean toremifene, and analogs or metabolites
thereof.

     1.35 “Sublicense” shall mean a direct grant of right, license, or option to any
Licensed Subject Matter from GTx to a GTx Affiliate or a Third Party, including the Ipsen
Sublicense, and any further such grant at any tier.

     1.36 “Sublicense Revenue” shall mean all payments actually received by GTx pursuant to
each Sublicense, including, without limitation, up-front license fees, milestone payments, license
maintenance fees, election fees, and all other fees and payments paid to GTx under each Sublicense
agreement, excluding running royalties received by GTx that are calculated as a percentage of
Sublicensee’s Net Sales, and excluding the up-front fee GTx has already received from Ipsen in
October 2006 upon its entering into the Ipsen Sublicense. GTx may deduct from Sublicense Revenue
attributable to a particular Sublicense agreement payments received by GTx as

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

5

 

reimbursement for actual, otherwise unreimbursed, out-of-pocket expenses as set out in such
Sublicense agreement, provided that only reimbursements for expenses incurred in the development of
one or more Licensed Products covered by such Sublicense may be deducted from Sublicense Revenue
and then only to the extent of expenses incurred from and after the date of the Sublicense for
pre-clinical or clinical research and development, including development of the formulation and
manufacturing process, manufacturing of preclinical and clinical supplies and analytical and
stability testing as required by the Food and Drug Administration to support a New Drug Application
(NDA) filing for the Licensed Product. For the avoidance of doubt, Sublicense Revenue will not
include any payments made to Third Parties by or on behalf of a Sublicensee for conducting clinical
trials, filing new drug applications, commercially launching a product and/or marketing and selling
a product, since these are not payments received by GTx from a Sublicensee on account of the
Sublicense.

     1.37 “Sublicense Royalty” shall have the meaning set forth in Section 4.1C. hereof.

     1.38 “Sublicensee” shall mean and include any recipient of a Sublicense, including Ipsen.

     1.39 “Sublicensee Patent Rights” shall have the meaning set forth in Section 6.2 hereof.

     1.40 “Term” shall have the meaning set forth in Section 12.1 hereof.

     1.41 “Third Party” or “Third Parties” shall mean any person, party or entity
other than GTx, its Affiliates, UTRF, or UT.

     1.42 “UT” shall mean The University of Tennessee.

     1.43 “UT Contributor” and “UT Contributors” shall mean one or more of Mitchell
S. Steiner and Sharan Raghow, and any other UT employee who contributed, either before or after the
Effective Date, to the development of the Licensed Subject Matter.

     1.44 “Valid Claim” shall mean (a) a claim of an issued patent which has not expired
and which has not been held revoked, invalid or unenforceable by decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed with the time allowed for
appeal having expired, and which has not been admitted to be invalid through reissue or disclaimer
or otherwise; or (b) any claim of a pending patent application, which (i) was filed in good faith;
and (ii) has not been pending for more than eight (8) years.

SECTION 2

 Grant

     2.1 During the Term hereof, and subject to the terms and conditions of this Agreement, UTRF
hereby grants to GTx for the purpose of developing, making, having made, using, marketing, selling,
having sold, importing, distributing, and offering for sale the Licensed Product:

	 	A.	 	an exclusive, worldwide right and license, with the right to grant Sublicenses,
to practice under the Licensed Patents that are owned solely or in part by UTRF; and
	 
	 	B.	 	an exclusive, worldwide right and license, with the right to grant Sublicenses,
to utilize the Licensed Technology.

Subject to the other provisions of this Agreement, the Parties hereby agree that the term
“exclusive” means that to the extent of UTRF’s rights in the Licensed Subject Matter and subject to
Federal Policy, UTRF shall not grant any other license under Licensed Subject Matter to any Third
Party or take any action inconsistent with the rights granted to GTx under this Agreement. The
Parties further acknowledge and agree that to the extent UTRF owns any Licensed Subject Matter “in
part”, the license herein granted to GTx will not give GTx or its Sublicensees the right to exclude
UTRF’s co-owner(s) from exercising any rights attendant to such co-ownership, whether such rights
arise by law or contract, provided that UTRF agrees that it will not negotiate or enter into a
license agreement or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

6

 

sublicense agreement, or otherwise grant any option or licenses or other rights with respect to
such Licensed Subject Matter (whether in whole or in part), except as required by Federal Policy.
For avoidance of doubt, the exercise by GTx of its right to grant Sublicenses will not serve to
restrict GTx’s exercising of its right, as granted above, to practice under the Licensed Patents
and/or to utilize the Licensed Technology.

     2.2 GTx agrees that UT and those persons who, as of the date of signature hereto on behalf of
UTRF, are named UT Contributors shall have the royalty-free non-exclusive right to practice under
the Licensed Patents and to utilize the Licensed Technology for non-commercial educational,
research, and academic purposes only.

     2.3 To the extent that any research pertaining to inventions included in Licensed Technology
and/or claimed in Licensed Patents has been or is in the future funded in whole or in part by the
United States government, the United States government retains certain rights and requires certain
obligations concerning such inventions as set forth in 35 U.S.C. §§200-212 and all regulations
promulgated thereunder, as amended, and any successor statutes and regulations and applicable
policies of such United States government sponsors, including, without limitation, to the extent
applicable, the utilization and capability requirements found in the National Institutes of Health
(NIH) Grants Policy Statement; “Developing Sponsored Research Agreements: Considerations for
Recipients of NIH Research Grants and Contracts”, Federal Register, Vol. 59, No. 215, Tuesday,
November 8, 1994, pp. 55675-55679 (collectively, “Federal Policy”). GTx acknowledges that
all rights herein granted to GTx may be subject to any such rights held by the United States
government and further subject to any restrictions or obligations that may be imposed by the United
States government pursuant to such rights. GTx shall materially comply with all aspects of Federal
Policy applicable to a licensee pertaining to Licensed Technology and/or Licensed Patents and shall
include and require its Sublicensees to include a provision in each Sublicense agreement, at any
tier, that requires the Sublicensee to materially comply with all applicable aspects of Federal
Policy. In the event UTRF or GTx shall receive notice of any action or notification by the United
States government with respect to any rights and/or obligations under Federal Policy pertaining to
any rights licensed hereunder to GTx, the Party receiving such notice shall provide prompt written
notice thereof to the other Party.

     2.4 Intentionally omitted.

     2.5 GTx shall have the right to enter into Sublicenses and to permit further sublicensing by
Sublicensees through multiple tiers with respect to the Licensed Subject Matter, subject to
notifying UTRF of the identity and address of each Sublicensee within thirty (30) days after
execution of such agreement by the parties thereto. No GTx Affiliate or Third Party shall have the
right to practice under the Licensed Patents or utilize the Licensed Technology to make, have made,
use, market, sell, have sold, import, distribute, or offer for sale any Licensed Product in the
absence of a written Sublicense agreement. Any grant of rights by GTx or a Sublicensee to practice
under the Licensed Patents or to utilize the Licensed Technology to make, have made, use, market,
sell, have sold, import, distribute, or offer for sale any Licensed Product shall constitute a
Sublicense. All Sublicenses shall be subject to this Agreement in all respects and shall include
provisions that such Sublicensee is being granted a license under the Licensed Subject Matter as
defined herein and subject to the terms hereof. Notwithstanding anything to the contrary in this
Agreement (including, without limitation, this Section 2.5), UTRF hereby agrees that all provisions
of the Ipsen Sublicense, as executed on September 7, 2006, are in full compliance with the terms
and conditions of this Agreement. GTx agrees that it will not modify or otherwise amend the Ipsen
Sublicense in any manner that would deviate from any of the requirements of a Sublicense set forth
herein without obtaining UTRF’s prior written approval, which approval will not unreasonably be
withheld. The Parties agree that unless a modification or amendment shall affect any requirement of
a Sublicense as described in the immediately preceding sentence, GTx and Ipsen shall have the right
and discretion to negotiate and enter into such amendments and modifications to the Ipsen
Sublicense as they shall from time to time determine without first obtaining the approval of UTRF,
and GTx will furnish a copy of any such amendment or modification to UTRF within thirty (30) days
of the execution of such an instrument as required herein.

     2.6 GTx shall be responsible for its Affiliates and Sublicensees and, except as set forth
above as it pertains to Ipsen, shall not grant any rights that are inconsistent with the rights
granted to and obligations of GTx hereunder. Each Sublicense agreement shall include a requirement
that the Sublicensee use its commercially reasonable efforts to bring the subject matter of the
Sublicense into commercial use. In addition, each Sublicense agreement shall include an
acknowledgement that the ownership of the Licensed Patents are and shall remain in the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

7

 

name of UTRF, with the exception of Licensed Patents that are properly assigned to GTx, and,
except as set forth in Section 6.2 hereof, an obligation on the part of the Sublicensee to assign,
transfer and convey ownership of Licensed Patents to UTRF and/or, as UTRF may direct, to GTx. Upon
termination of this Agreement, each Sublicensee’s rights under any Sublicense agreement shall also
terminate, provided that if UTRF terminates this Agreement for default by GTx, a Sublicensee’s
rights under a Sublicense agreement shall terminate only if UTRF has given such Sublicensee notice
of default at least thirty (30) days prior to the effective date of termination and the Sublicensee
shall have failed to cure such default, as provided in Section 12.3. UTRF shall have discharged its
obligation to give notice of such default to a Sublicensee by sending (through any means
contemplated under Section 15) a copy of GTx’s notice of default to the Sublicensee’s most recent
street address of which UTRF has received written notice from GTx or the Sublicensee. No Sublicense
shall relieve GTx of any of its obligations under this Agreement, except that a Sublicensee shall
have the right to cure a default of GTx as set out in Section 12.3. GTx shall forward to UTRF a
complete copy of each Sublicense agreement (including, without limitation, all amendments and
addenda) granted hereunder within thirty (30) days after execution of such agreement by the parties
thereto, provided that each such Sublicense agreement (and any amendments and addenda related
thereto) shall be deemed GTx’s Confidential Information and UTRF shall receive such information and
documents in confidence and shall not publicly disclose, discuss or release such information or
document to Third Parties (other than such information as may be reasonably necessary to be
disclosed to UT Contributors and those persons within UT who have a need to know such information,
provided that only such information concerning the Sublicense that is necessary to explain any
payments to be made to a UT Contributor will be shared with the UT Contributors) without the prior
written approval of GTx except for the purposes of enforcement of UTRF’s rights, defense of any
claim against UTRF, UT, or UT Contributors, compliance with Federal Policy, or compliance with
applicable law, regulation, or court order. GTx shall be responsible for payment of royalties from
Sublicensees’ Net Sales provided, however, that GTx may arrange for such payments to be made to
UTRF by a Sublicensee, with the understanding that the amount paid to UTRF shall not be decreased
thereby and that UTRF’s acceptance of such payments from a Sublicensee does not relieve GTx of the
ultimate responsibility for any other or future payment required hereunder. Each such Sublicense
agreement shall include an audit right by UTRF of the same scope as provided in Section 5.1 herein
with respect to UTRF’s audit of GTx’s books of account.

     2.7 Any act or omission of an Affiliate or Sublicensee which would constitute a breach of this
Agreement if performed by GTx, shall be deemed to be a breach by GTx of this Agreement, subject
however to the same cure provisions in favor of GTx, an Affiliate, or Sublicensee as are otherwise
provided herein for breach by GTx.

     2.8 During the Term hereof, UTRF shall promptly notify GTx in writing upon becoming aware of
any SERM invention owned solely or in part by UTRF which is not (a) based on or developed from
Proprietary SERM Know-How or (b) developed at UT from grants or research payments made to UT by GTx
(each invention described above herein being an “Independent SERM Invention”). Subject to
the rights of Third Parties (in the event UTRF co-owns such Independent SERM Invention with a Third
Party), GTx will have an exclusive option to acquire, to the extent possible, a worldwide,
exclusive (as defined in Section 2.1), royalty-bearing license to such Independent SERM Invention
(“Option”), provided that the grant of such Option does not violate Federal Policy and
further subject to the following:

	 	A.	 	The Option shall commence upon UTRF’s written notice to GTx of the existence of
such Independent SERM Invention and shall terminate upon the earlier of (i) the
expiration of six (6) calendar months from the date of such notice; or (ii) the giving
of written notice to UTRF by GTx that it does not intend to exercise the Option; or
(iii) the termination of this Agreement (“Option Period”).
	 
	 	B.	 	GTx may exercise the Option during the Option Period by giving written notice
of same to UTRF, provided that GTx is not then in default or breach of any of its
obligations under this Agreement.
	 
	 	C.	 	Upon proper exercise of the Option by GTx, UTRF and GTx shall negotiate in good
faith in an effort to reach agreement on the economic terms of a license to GTx of the
Independent SERM Invention that is the subject of such Option, it being the intent that
upon agreement of the Parties as to such economic terms, they will be expeditiously
incorporated into a new license agreement

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

8

 

	 	 	 	with non-economic terms that are substantially similar to those contained herein, to
the extent applicable.
	 
	 	D.	 	In the event GTx does not exercise the Option for a particular Independent SERM
Invention within the Option Period or the Parties do not execute a license agreement
within six (6) months after exercise of the Option for a particular Independent SERM
Invention by GTx, which time period may be extended by written agreement of the Parties
(the “Negotiation Period”), UTRF shall have no further obligation to GTx under
this Agreement with regard to such Independent SERM Invention. In the absence of a
license agreement granting GTx rights to such Independent SERM Invention, GTx agrees
that it will not use such Independent SERM Invention for any commercial or
non-commercial purpose.
	 
	 	E.	 	During the Option Period and the Negotiation Period, if any, UTRF will confer
with GTx concerning proper protection of such Independent SERM Invention, but UTRF will
have sole authority regarding decisions concerning such protection, including patent
activities, provided that if GTx exercises the Option, UTRF shall coordinate all
decisions regarding patent protection with GTx and shall take no actions with regard to
intellectual property protection for such Independent SERM Invention that are contrary
to GTx’s advice unless UTRF reasonably believes rights may be lost unless it acts to
protect those rights. From and after the commencement of the Option Period, whether or
not GTx exercises the Option and whether or not the Parties subsequently execute a
license agreement for GTx to secure rights to the Independent SERM Invention prior to
the end of the Negotiation Period, GTx shall, within thirty (30) days after receipt of
each invoice, reimburse UTRF for all reasonable and documented out-of-pocket expenses
incurred by UTRF during the Option Period and the Negotiation Period, if any, for
filing, prosecution, and maintenance of United States and foreign patent applications,
issued patents, and other forms of intellectual property protection for such
Independent SERM Invention, which intellectual property rights shall be assigned solely
to UTRF or jointly to UTRF and its co-owner(s), if any, provided that UTRF shall have
consulted with GTx regarding such proposed patent protection and UTRF shall have
undertaken to make those filings that are reasonably necessary to protect and preserve
its rights in the Independent SERM Invention to reasonably minimize the expenses GTx
may be required to reimburse in accordance with this Section 2.8E until the Option
Period and Negotiation Period shall have expired. If GTx shall fail to enter into a
license agreement with UTRF for such Independent SERM Invention, it shall be entitled
to receive a dollar for dollar reduction against Running Royalties and/or Sublicense
Revenue (to be applied at GTx’s sole discretion) for the total amount of costs it shall
have reimbursed to UTRF for the expenses incurred by UTRF under this Section 2.8E.

SECTION 3

Diligence

     3.1 GTx shall use its commercially reasonable efforts to develop and commercialize Licensed
Products through a commercially reasonable program for exploitation of the Licensed Patents and the
Licensed Technology.

SECTION 4

Payments and Royalties

     4.1 For the rights, privileges and license granted hereunder, GTx shall pay to UTRF, in
addition to the Consideration Fee, the following fees and royalties in the manner hereinafter
provided until this Agreement expires or is terminated.

	 	A.	 	License Maintenance Fee. GTx shall pay UTRF a license maintenance fee
in the amount of [ * ] on [ * ] and on [ * ] thereafter during the Term of this
Agreement (“License Maintenance Fee”).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

9

 

	 	 	 	The License Maintenance Fee actually paid for a particular License Year shall
reduce, dollar for dollar, the Running Royalty (defined below) payable in the same
License Year. License Maintenance Fees paid in excess of the Running Royalty
payable in the same License Year shall not be creditable to the Running Royalty for
future years. The Parties acknowledge and agree that there are no License
Maintenance Fees due and owing to UTRF by GTx under the Prior License Agreement.
The Parties further acknowledge and agree that, prior to the date of execution of
this Amended and Restated License Agreement, GTx has paid [ * ] of the [ * ] license
maintenance fee that was due and owing on [ * ], and GTx agrees to pay the remaining
[ * ] of the [ * ] license maintenance fee upon submission of an invoice for same by
UTRF.

	 	B.	 	Running Royalty. For the purposes of this Section 4.1B., royalties on
Net Sales of all Patented Products and Generic Products incorporated in Combination
Products shall be subject to the calculation of Net Sales with respect to Combination
Products, as applicable, as set forth in Section 1.25.

	 	(1)	 	GTx shall pay UTRF [ * ] of Net Sales of all Patented Products; and
	 
	 	(2)	 	GTx shall pay UTRF a percentage of Net Sales attributable to
the use, sale or distribution of Generic Products, which percentage shall be
determined on a Generic Product-by-Generic Product, country-by-country, and
calendar quarter-by-calendar quarter basis. In each country the percentage
shall be calculated as the [ * ] during the applicable calendar quarter divided
by the [ * ] during the same calendar quarter [ * ] (provided that in no event
shall the resulting percentage [ * ]). Furthermore, until such time as this
Agreement shall expire in accordance with Section 12.1, should there be no
sales in the Major Markets by GTx or Sublicensees of the same Licensed Product
covered by a Valid Claim of Licensed Patents during the same calendar quarter,
the percentage shall be [ * ];

	 	 	 	(the royalty under 4.1B.(1) and 4.1B.(2) being the “Running Royalty”).
Notwithstanding the foregoing, in the event that, for a particular Licensed Product
in a given License Year under a specific Sublicense agreement, the running royalty
(as a percentage of Net Sales) owed to GTx (including the Running Royalty owed to
UTRF, if to be paid by the Sublicensee) is less than [ * ] of Sublicensee’s Net
Sales after deduction of running royalties (calculated as a percentage of Net Sales)
owed and actually paid by or on behalf of GTx to one or more Third Parties as
consideration for the grant by such Third Party(ies) of a license to technology
incorporated in such Licensed Product, including the royalty to be paid to Orion to
license toremifene, the Running Royalty owed to UTRF shall be [ * ] of the amount
owed to GTx (including the Running Royalty owed to UTRF, if to be paid by the
Sublicensee) for that License Year. By way of example only, in the event that
during a particular License Year GTx is entitled to receive a running royalty equal
to [ * ] of its Sublicensee’s Net Sales of a particular Licensed Product in the EU
and is in turn required to pay, and does actually pay, [ * ] of Sublicensee’s Net
Sales of that Licensed Product in the EU to a Third Party, then UTRF’s Running
Royalty would be [ * ] of Sublicensee’s Net Sales of that Licensed Product in the
EU.

     C. Sublicense Royalty. GTx shall pay UTRF [ * ] of Sublicense Revenue
(“Sublicense Royalty”)

     4.2 In the event that any taxes are required by law or regulation to be levied in any foreign
country by a foreign taxing authority on any Running Royalty or Sublicense Royalty payable in
UTRF’s name under this Agreement and GTx determines in good faith that it or its Sublicensee must
withhold such taxes:

	 	A.	 	GTx or its Sublicensee shall have the right to withhold and pay such taxes
withheld on the Running Royalty and/or Sublicense Royalty to the local tax authorities
in UTRF’s name;
	 
	 	B.	 	GTx or its Sublicensee shall pay the net amount of Running Royalty and/or
Sublicense Royalty due after reduction by the amount of such taxes that are actually
withheld and paid;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

10

 

	 	C.	 	GTx or its Sublicensee shall provide UTRF with appropriate documentation and
receipts supporting such withholding; and
	 
	 	D.	 	GTx or its Sublicensee shall inform UTRF in writing within thirty (30) days of
being notified that taxes will be or have been required by a taxing authority to be
withheld on the Running Royalty and/or Sublicense Royalty.

     4.3 In the event that a Running Royalty is payable to UTRF on the same Net Sales revenue or a
Sublicense Royalty is payable to UTRF on the same Sublicense Revenue under this Section 4 and under
one or more other UTRF/GTx license agreements, GTx shall only be required to pay UTRF such royalty
under one such license agreement, subject to the provisions of Section 5.2 and provided that if the
amount due varies from one such license agreement to another, GTx shall pay the highest amount.

     4.4 Within [ * ] following the close of each calendar quarter in which Net Sales revenue is
received by GTx or a Sublicensee, or Sublicense Revenue is received by GTx, payment of all amounts
due to UTRF, including but not limited to Running Royalty and Sublicense Royalty, shall be made to
UTRF or its designee in United States dollars in Knoxville, Tennessee, or at such other place as
UTRF may reasonably designate consistent with the laws and regulations controlling in any foreign
country, provided that the [ * ] period may be extended for up to [ * ] after the close of each
calendar quarter if a Sublicensee under a Sublicense requires more time than [ * ] to make its
sales and royalty calculation and its royalty payment available to GTx. In the event GTx arranges
for any payment under this Section 4.4 to be made to UTRF by a Sublicensee pursuant to Section 2.6,
if such payment is not received by UTRF within the [ * ] period set forth herein (or within up to
the [ * ] extension period as stated above, or [ * ]), GTx shall be deemed to be in breach of this
Agreement, subject to the same cure provisions in favor of GTx as set forth in Section 12. If any
currency conversion shall be required in connection with the payment of royalties hereunder, such
conversion shall be made by using the exchange rate procedure listed in a Sublicense, if
applicable, or in the absence of an applicable Sublicense provision addressing this issue, using
the exchange rate listed in the Wall Street Journal for major New York banks on the last business
day of the calendar quarter during which the royalty-bearing revenue was received by GTx or its
Sublicensees, as the case may be.

SECTION 5

Reports and Records

     5.1 No more often than once each License Year, UTRF or its accounting agents shall have the
right to inspect the books of account of GTx. GTx shall keep full, true and accurate books of
account containing all particulars that may be necessary for the purpose of showing the amounts
payable to UTRF hereunder. Said books of account shall be kept at GTx’s principal place of
business or the principal place of business of the appropriate division of GTx to which this
Agreement relates. Said books and the supporting data shall be open at all reasonable times for [
* ] following the end of the License Year to which they pertain, to the inspection of UTRF or its
accounting agents for the purpose of verifying GTx’s royalty statements. If any examination
reveals a shortage in amounts paid to UTRF, GTx shall promptly reimburse UTRF for the shortage,
together with interest thereon as provided in Section 5.4, and if the shortage is equal to or
greater than [ * ] of the total amount due in the period under audit, GTx shall reimburse UTRF for
the cost of the examination as well. If the examination reveals an overpayment to UTRF, GTx may
deduct the amount of such overpayment from future amounts owed to UTRF hereunder.

     5.2 GTx shall deliver to UTRF true and accurate reports to confirm a royalty accounting
hereunder within [ * ] after the close of each calendar quarter (provided that the [ * ] period may
be extended for up to [ * ] after the close of each calendar quarter if a Sublicensee under a
Sublicense requires more time than [ * ] to make such information and its royalty payment available
to GTx) and a summary of GTx’s activities during such quarter to develop and commercialize Licensed
Products. These reports shall be deemed GTx’s Confidential Information and shall include at least
the following, on a Licensed Product-by-Licensed Product, country-by-country, and
Sublicensee-by-Sublicensee basis:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

11

 

	 	A.	 	The number/amount of Licensed Product used, sold, or imported by and/or for GTx
and Sublicensees and other information that is reasonably necessary to allow UTRF to
properly calculate royalties due;
	 
	 	B.	 	The total amounts invoiced and received by GTx and Sublicensees for Licensed
Products used or sold by GTx and/or Sublicensees including (i) an accounting of Net
Sales for Running Royalty payments due to UTRF under Section 4.1B. above, with separate
calculations for Patented Products, Generic Products, and Combination Products
reflecting the type and amount of all deductions from Gross Receipts; and (ii) an
accounting of Sublicense Revenue for Sublicense Royalty payments due to UTRF under
Section 4.1C above reflecting the type and amount of all amounts deducted or excluded
from Sublicense Revenue;
	 
	 	C.	 	The Running Royalty and Sublicense Royalty due, showing the application of any
reduction pursuant to Section 2.8E., if applicable;
	 
	 	D.	 	For all royalties due to UTRF pursuant to Section 4.1, the report shall include
(i) the manner in which such royalties were calculated and the amount allocable to each
Licensed Product; and (ii) if any such royalties are payable to UTRF under this
Agreement and under one or more other UTRF/GTx license agreements, GTx shall set out in
its report the amount of such royalties covered by multiple license agreements and
identify all such license agreements to which such royalties apply, notwithstanding
that GTx is required to pay such royalties under only one such license agreement;
	 
	 	E.	 	The names and addresses of all Sublicensees for or on whose account royalty
payments are being made in accordance with the terms hereof; and
	 
	 	F. 	 	Upon request by UTRF, any other information that may be necessary for the
purpose of showing the amounts payable to UTRF hereunder or compliance by GTx with the
diligence provisions of Section 3.

     5.3 With each such report submitted, GTx shall pay to UTRF the royalties due and payable under
this Agreement. If no royalties shall be due, GTx shall so report.

     5.4 Any amount owed by GTx under this Agreement that is not received by UTRF on or before the
date due shall bear interest at a per annum rate [ * ] above the prime rate quoted in the Wall
Street Journal for major New York banks on the date due, or if not quoted on the date due, the rate
quoted on the first business day after the date due. GTx shall also pay all reasonable collection
costs at any time incurred by UTRF in obtaining payment of amounts past due, including reasonable
attorneys fees. If the transfer or the conversion into United States Dollar equivalents in any
such instance is not lawful or possible, the payment of such part of the royalties as is necessary
shall be made by the deposit thereof, in the currency of the country where the sales were made on
which the royalty was based, to the credit and account of UTRF or its nominee in any commercial
bank or trust company of its choice located in that country, prompt notice of which shall be given
by GTx to UTRF.

SECTION 6

Patent Prosecution

     6.1 During the Term and subject to the terms hereof, GTx shall have (a) complete control of
the prosecution of the Licensed Patents listed on Appendix A and will be responsible for
maintaining any patents issuing therefrom and (b) the exclusive right and responsibility to
prepare, file, prosecute and maintain all patent applications and patents claiming (i) inventions
solely owned by UTRF that are described in the Initial SERMS Disclosure; and (ii) Licensed
Technology defined in Section 1.22, and such patent applications and patents shall be added to
Appendix A. GTx shall use patent counsel of its own choice, at its own expense. GTx agrees to pay
all costs incident to the United States and foreign applications, patents and like protection
relating to the Licensed Subject Matter, including all costs incurred for filing, prosecution,
issuance and maintenance fees as well as any costs incurred in filing continuations,
continuations-in-part, divisionals or related applications and any re-examination, reissue,
opposition, or interference proceedings. Subject to the provisions of Section 6.4, GTx shall file
and maintain patent applications claiming Licensed Technology defined in Section 1.22 in such
countries as

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

12

 

GTx in its sole discretion shall select. Except for Licensed Patents listed on Appendix A
that are assigned to GTx or Sublicensee Patent Rights as described in Section 6.2, UTRF shall have
the sole and exclusive right, title and ownership in and to all Licensed Patents, including
Licensed Patents claiming Licensed Technology defined in Section 1.22 which now exist or may exist
in the future, including all United States and foreign patent applications filed and patents issued
pursuant to this Section 6, except Licensed Patents claiming invention(s) made in whole or in part
by one or more Third Parties as determined in accordance with applicable patent laws, ownership of
which shall be subject to the provisions of Section 6.2.

     6.2 GTx and its Sublicensees shall assign, transfer and convey to UTRF all right, title and
interest in and to all Licensed Patents, except (i) those claiming invention(s) made in whole or in
part by one or more Third Parties, which Licensed Patents are to be assigned, in whole or in part,
as the case may be, in accordance with the instructions of such Third Party(ies); and (ii) those
listed on Appendix A that, as of the Effective Date, have been assigned to GTx. GTx shall be
responsible for recording an assignment, as appropriate, to UTRF and/or to such individual(s) or
entity(ies) as such Third Party(ies) may direct, of patent applications filed pursuant to this
Section 6 with the United States Patent and Trademark Office and with each foreign Patent Office in
which such applications are filed. Notwithstanding the foregoing, GTx may permit its Sublicensees
to retain ownership of patent applications or patents claiming invention(s) made by employee(s) or
agent(s) of such Sublicensee which result from the Licensed Subject Matter (“Sublicensee Patent
Rights”), provided that the pertinent Sublicense agreement shall include provision(s) granting
to UTRF and UT a perpetual worldwide non-exclusive royalty-free right to practice, for
non-commercial educational, research and academic purposes only (such right to exclude the practice
of Licensed Patents for any fee-for-services arrangement or for sponsored research on behalf of any
commercial entity), under Sublicensee Patent Rights claiming inventions necessary or reasonably
useful in the practice of the Licensed Patents.

     6.3 GTx agrees to provide UTRF with reasonable (which the Parties agree generally means not
less than two weeks) advance notice prior to filing of new patent applications containing new
subject matter, including, without limitation, continuation-in-part applications, within Licensed
Patents. Copies of applications that are divisional or continuation applications of Licensed
Patents shall be furnished to UTRF within thirty (30) days of their being initially filed with an
appropriate patent office. GTx shall keep UTRF informed, at GTx’s expense, of filing, prosecution,
maintenance, and abandonment of applications and issued patents within Licensed Patents pursuant to
this Section 6, including submitting to UTRF copies of all patent applications in accordance with
the previous sentence, and submitting to UTRF copies of material, official actions and responses
thereto, and other material written communications it or its patent counsel receives from or files
with the U.S. Patent and Trademark Office and the equivalent foreign offices within forty-five (45)
days of filing or receipt, as the case may be. GTx shall consult with UTRF prior to the
abandonment of applications or issued patents with the Licensed Patents.

     6.4 UTRF agrees to reasonably cooperate with GTx, at GTx’s request and expense, to whatever
extent is reasonably necessary, to procure patent protection for Licensed Technology, including
execution of all appropriate documents to provide GTx the full benefit of the licenses granted
herein.

     6.5 In the event that GTx decides not to continue prosecution of any United States or foreign
patent application within Licensed Patents to issuance or not to maintain any United States or
foreign patent within Licensed Patents in a particular jurisdiction, GTx shall timely notify UTRF
in writing in order that UTRF may continue said prosecution or maintenance of such patent
applications or patents at its option and at its own expense in such jurisdiction. GTx’s right
under this Agreement to practice the invention(s) under such patents and patent applications shall
immediately terminate in such jurisdiction upon UTRF’s assuming said costs provided that the
application for which GTx decides not to continue prosecution, or the patent which GTx decides not
to maintain, is before the patent office of a country that is a Major Market. GTx shall not be
considered in default and this Agreement shall not terminate as to any particular jurisdiction
merely due to the fact that GTx decides not to continue prosecution of a patent application to
issuance, or not to maintain any patent in any country that is not a Major Market. If GTx fails to
notify UTRF in sufficient time for UTRF to reasonably continue prosecution, or the maintenance of,
a patent or patent application in a Major Market, GTx shall be considered in default of this
Agreement.

     6.6 Intentionally Omitted.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

13

 

     6.7 Intentionally Omitted.

     6.8 Intentionally Omitted.

     6.9 GTx and all its Sublicensees shall mark all products covered by Licensed Patents with
patent numbers in accordance with the statutory requirements in the country(ies) of manufacture,
use, and sale.

     6.10 UTRF and GTx agree that one or more senior administrators representing each of the
Parties will meet at least on a semi-annual basis at a mutually agreeable time and place so that
GTx may provide UTRF with an oral update on the current development, licensing, regulatory, and
commercialization status of Licensed Products and to discuss any issues raised by either UTRF or
GTx arising out of, under, or in connection with this Agreement.

SECTION 7

Infringement

     7.1 GTx shall inform UTRF and UTRF shall inform GTx promptly in writing of any alleged
assertion and/or claim of infringement of the Licensed Patents by a Third Party and of any
available evidence thereof.

     7.2 GTx shall have the first, sole and exclusive right, but shall not be obligated, to
prosecute or defend at its own expense all infringements or opposition, interference and ex parte
proceedings of the Licensed Patents, including prosecuting for any misappropriation of Licensed
Technology or Licensed Products. The Parties acknowledge that as to Licensed Patents that UTRF
owns “in part”, such right on the part of GTx shall not preclude UTRF’s co-owner(s) from taking any
action they may have available to them in law or by contract. In furtherance of such right granted
to GTx, UTRF hereby agrees that GTx may include UTRF as a party plaintiff in any such suit, without
expense to UTRF. The total cost of any such infringement action commenced or defended by GTx shall
be borne by GTx. No settlement, consent judgment, or other voluntary final disposition of such
suits may be entered into without the consent of UTRF, provided that such consent shall not be
unreasonably withheld and that UTRF shall not condition such consent on an increase in payments to
UTRF hereunder.

     7.3 If within six (6) months after having been notified of an alleged infringement by a Third
Party, GTx has not brought or is not diligently prosecuting an infringement action, or if GTx has
notified UTRF at any time prior thereto of its intention not to bring suit against any alleged
infringement of the Patents, then, and in those events only, UTRF shall have the right, but shall
not be obligated, to prosecute at its own expense any infringement of the Licensed Patents, and
UTRF may, for such purposes, use the name of GTx as party plaintiff. No settlement, consent
judgment, or other voluntary final disposition of the suit may be entered into without the consent
of GTx, which consent shall not unreasonably be withheld. After deduction of outstanding expenses
of UTRF, including attorney fees, and any expenses of GTx, including attorney fees incurred prior
to UTRF’s pursuit of such infringement, the balance remaining from any such recovery shall be
divided equally between GTx and UTRF.

     7.4 Intentionally Omitted.

     7.5 In the event that GTx undertakes the enforcement and/or defense of the Licensed Patents by
litigation, opposition, interference or ex parte proceedings or an inter partes proceeding
(including the defense of a declaratory judgment action pursuant to Section 7.6) in the United
States or a foreign country against a Third Party, GTx may withhold up to [ * ] of the payments
otherwise thereafter due UTRF under Section 4 that are attributable to sales of Licensed Products
in the country where such litigation or inter partes proceeding takes place and apply the same
toward reimbursement of up to [ * ] of GTx’s expenses, including reasonable attorneys’ fees, in
connection therewith. GTx may not withhold any portion of the payments due UTRF under Section 4 in
the event that GTx undertakes the enforcement and/or defense of the Licensed Patents by litigation
or an inter partes proceeding in the United States or a foreign country against an Affiliate or
Sublicensee. Any recovery of damages by GTx resulting from each such suit or inter partes
proceeding shall be applied first in satisfaction of any unreimbursed expenses and legal fees of
GTx relating to such suit, and next toward reimbursement of any unreimbursed expenses and legal
fees of UTRF relating to such suit, and next toward reimbursement of UTRF for any payments under
Section 4 withheld and applied pursuant to this Section 7.5, and the remaining balance, if any,
shall be divided equally between GTx and UTRF unless the damage award is identified by judgment of
the court or in a settlement in such suit as compensating GTX for loss of sales revenue for
Licensed Product on account of such Third Party’s unlicensed or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

14

 

illegal actions, in which event (instead of dividing the remaining balance equally between the
Parties), GTX shall pay to UTRF an amount equal to the lesser of: (i) [ * ] the remaining balance;
or (ii) [ * ] of the equivalent of the lost Net Sales upon which such judgment or settlement award
is based, and GTX shall retain the rest. For sake of clarity, any recovery attributable to loss or
diminution of the value of Licensed Patents shall be divided equally between UTRF and GTX. As to a
settlement of such claim or suit, the rebuttable presumption shall be that any payment to be made
to GTX under the settlement agreement is not attributable to lost sales revenue and GTx shall have
the burden of proof to reasonably establish that the recovery of damages resulting from such
settlement represents compensation for loss of sales revenue (i.e., the equivalent of lost Net
Sales hereunder).

     7.6 In the event that a declaratory judgment action alleging invalidity or noninfringement of
any of the Licensed Patents shall be brought against UTRF, GTx at its option shall have the right,
within thirty (30) days after commencement of such action, to intervene and take over the sole
defense of the action against UTRF at its own expense, provided that GTx may not enter into a
settlement, consent judgment, or other voluntary final disposition of the matter without the prior
written approval of UTRF, which approval shall not be unreasonably withheld.

SECTION 8

Liability and Indemnification

     8.1 GTx shall at all times during the Term of this Agreement, indemnify, defend and hold UTRF,
UT, and their respective trustees, directors, officers, employees and Affiliates, harmless against
all claims, proceedings, demands and liabilities of any kind whatsoever, including legal expenses
and reasonable attorneys fees (collectively, “Claims”), arising out of the death of or
injury to any person or persons or out of any damage to property, to the extent resulting from the
production, manufacture, sale, use, lease, or consumption of the Licensed Products, Licensed
Technology, or associated intellectual property rights, including Licensed Patents, or arising from
any obligation or act of GTx hereunder, except, as to UTRF and UT, for Claims arising (i) out of
the use or practice of Licensed Subject Matter by UT as described in Section 2.2 or (ii) from the
willful misconduct or misrepresentation by UTRF, UT, or their respective trustees, directors,
officers, employees or Affiliates; or (iii) breach of this Agreement by UTRF. Infringement of a
Third Party patent by GTx, a GTx Affiliate, or a Sublicensee shall not be deemed for purposes of
this Agreement an improper action, omission, or negligent act on the part of UTRF, UT, or their
respective trustees, directors, officers, employees or Affiliates.

     8.2 GTx shall obtain and carry in full force and effect from the first manufacture, use or
sale of the Licensed Products or Licensed Technology to [ * ] after such manufacturing, use or
sales cease, commercial, general liability insurance which shall protect GTx, UTRF, UT, and their
respective trustees, directors, officers, employees and Affiliates with respect to events covered
by Section 8.1 above. Such insurance shall be written by a reputable insurance company, reasonably
acceptable to UTRF, shall list UTRF as an additional named insured, shall be endorsed to include
product liability coverage and shall require thirty (30) days written notice to be given to UTRF
prior to any cancellation or material change thereof. The limits of such insurance shall not be
less than [ * ] per occurrence with an aggregate of [ * ] for personal injury or death. Upon the
request of UTRF, GTx shall provide UTRF with Certificates of Insurance evidencing the same.

     8.3 GTx, UTRF, UT, AND THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND
AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR
IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, IN ANY LICENSED
PRODUCT, LICENSED TECHNOLOGY OR LICENSED PATENT. SUBJECT TO THE PROVISIONS OF SECTION 8.1 AND
EXCEPT FOR A BREACH OF SECTION 18, IN NO EVENT SHALL GTx, UTRF, UT, OR THEIR RESPECTIVE TRUSTEES,
DIRECTORS, OFFICERS, EMPLOYEES OR AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF
ANY KIND, INCLUDING, WITHOUT LIMITATION, ECONOMIC DAMAGE, INJURY TO PROPERTY OR LOST PROFITS,
REGARDLESS OF WHETHER GTx, UTRF, OR UT SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN
FACT SHALL KNOW OF THE POSSIBILITY OF ANY OF THE FOREGOING. NOTHING IN THIS AGREEMENT SHALL BE
CONSTRUED AS:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

15

 

	 	A.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF THAT THE PRACTICE BY GTX OF ANY
LICENSE OR SUBLICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENTS OF ANY THIRD
PARTY;
	 
	 	B.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF THAT ANY PATENT APPLICATION
INCLUDED IN THE PATENTS WILL ULTIMATELY ISSUE AS A PATENT;
	 
	 	C.	 	A REPRESENTATION MADE OR WARRANTY GIVEN THAT GTX SHALL HAVE THE RIGHT TO USE
ANY PORTION OF THE LICENSED PATENTS THAT IS CLAIMED IN A PATENT OF ANY THIRD PARTY;
	 
	 	D.	 	A REQUIREMENT THAT UTRF SHALL BE RESPONSIBLE FOR THE EXPENSES OF FILING OR
PROSECUTING ANY PATENT APPLICATION OR MAINTAINING ANY LICENSED PATENTS IN FORCE;
	 
	 	E.	 	AN OBLIGATION ON THE PART OF UTRF TO BRING OR PROSECUTE ACTIONS OR SUITS
AGAINST THIRD PARTIES FOR INFRINGEMENT OF THE LICENSED PATENTS OR FOR UNAUTHORIZED USE
OF THE PATENTS OR MISAPPROPRIATION OF THE LICENSED TECHNOLOGY;
	 
	 	F.	 	AN OBLIGATION ON THE PART OF UTRF TO DEFEND ANY ACTION OR SUIT BROUGHT BY ANY
THIRD PARTY;
	 
	 	G.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF AS TO THE SAFETY, RELIABILITY
OR EFFICACY OF: 1) THE LICENSED TECHNOLOGY OR THE INVENTIONS COVERED BY THE LICENSED
PATENTS; OR 2) ANY LICENSED PRODUCT; OR
	 
	 	H.	 	A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRF THAT ANY OF THE UT CONTRIBUTORS
WILL AGREE TO PROVIDE TECHNICAL ASSISTANCE OR CONSULTATION TO GTX, OR THAT SUCH
TECHNICAL ASSISTANCE OR CONSULTATION, IF PROVIDED, WOULD BE SUFFICIENT TO ENABLE GTX TO
SUCCESSFULLY EXPLOIT THE LICENSED TECHNOLOGY OR THE LICENSED PATENTS.

     8.4 UTRF represents and warrants that to the best of its actual knowledge as of the Effective
Date: (i) it has the full corporate power and authority to enter into this Agreement, to carry out
the provisions of this Agreement, and to grant the rights granted to GTx herein; (ii) it has not
previously granted and shall not grant to any Third Party any rights which are inconsistent with
the rights granted to GTx herein; (iii) it is the owner of the entire right, title, and interest in
and to the Licensed Patents and Licensed Technology except for such rights held by GTx, UT, the
United States government, Sublicensees, and/or their respective designees and/or assignees, if any;
and (iv) it has fully complied with all requirements of 35 U.S.C. § 200 et seq. and all
implementing regulations necessary to perfect title to the rights and license granted to GTx
herein.

     8.5 UTRF acknowledges and understands that Dr. Mitchell S. Steiner is an employee of UT and
that as of the Effective Date, he is the Chief Executive Officer of GTx.

     8.6 GTx represents that: (i) it has full corporate power and authority to enter into this
Agreement and carry out all the provisions of this Agreement; (ii) it is authorized to execute this
Agreement on its behalf; (iii) the person executing this Agreement is duly authorized to do so; and
(iv) no consent, approval or authorization of any Third Party is required. GTx further represents
and warrants that it shall not deny, contest (through declaratory judgment action or otherwise), or
take any action inconsistent with UTRF’s ownership in or the validity or enforceability of any of
the Licensed Patents associated with or arising from the Licensed Subject Matter except those
Licensed Patents listed on Appendix A that are assigned to GTx.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

16

 

SECTION 9

Export Controls

     9.1 GTx acknowledges that the export of goods and/or technical data from the United States may
require some form of export control license from the United States Government. GTx agrees that
neither it nor its Sublicensees will disclose, export or re-export any materials or technical data
received under this Agreement to any countries for which the U.S. Government requires an export
license, unless GTx or its Sublicensees have obtained prior written authorization from the U.S.
Department of State, Directorate of Defense Trade Controls, Department of Commerce, U.S. Bureau of
Industry and Security or other authority responsible for such matters. GTx agrees that it or its
Sublicensees are responsible for any fees or expenses associated with obtaining an export license,
if required, and acknowledges that failure to obtain such export control license may result in
criminal liability. UTRF neither represents that a license shall not be required nor that, if
required, it shall be issued.

SECTION 10

Non-Use of Names

     10.1 GTx shall not use the names or trademarks of UTRF or UT, or any adaptation thereof, in
any advertising, promotional or sales literature without prior written consent obtained from UTRF
or UT, as the case may be, except that GTx may state that it has licensed the Licensed Patents and
Licensed Technology from UTRF.

     10.2 Neither UTRF nor UT shall use the names or trademarks of GTx, or any adaptation thereof,
in any advertising, promotional or sales literature without prior written consent obtained from
GTx, except that UTRF may state that it has licensed the Licensed Patents and Licensed Technology
to GTx.

SECTION 11

Dispute Resolution

     11.1 Except for the right of either party to apply to a court of competent jurisdiction for a
temporary restraining order, a preliminary injunction, or other equitable relief to preserve the
status quo or to prevent irreparable harm, any and all claims, disputes or controversies arising
under, out of, or in connection with this Agreement, shall be resolved upon thirty (30) days
written notice of either party to the other by final and binding arbitration in Knoxville,
Tennessee under the Commercial Arbitration Rules of the American Arbitration Association, or the
Patent Arbitration Rules if applicable, then in effect. The arbitrator(s) shall have no power to
add to, subtract from or modify any of the terms or conditions of this Agreement, nor to award
punitive damages. The prevailing party in any such arbitration shall, in addition to recovering
reasonable out-of-pocket costs of the arbitration, be entitled to an award of reasonable attorneys
fees incurred in connection with the arbitration, with any action necessary to perfect the
arbitration award as a judgment, and for any collection action required to secure payment of any
arbitration award. Any award rendered in such arbitration may be entered and enforced by either
party in either the courts of the State of Tennessee or in the United States District Court for the
Eastern District of Tennessee, to whose jurisdiction for such purposes UTRF and GTx each hereby
irrevocably consents and submits, or in any other United States court having jurisdiction.

     11.2 Notwithstanding the foregoing, nothing in this Section shall be construed to waive any
rights or timely performance of any obligations existing under this Agreement.

SECTION 12

Term of Agreement and Termination

     12.1 This Amended and Restated License Agreement shall take effect for all purposes upon the
date of execution by the Parties, and unless earlier terminated in accordance with the provisions
of this Section 12, shall continue in full force and effect on a country-by-country basis for the
longer of (i) a period of twenty (20) years from the Effective Date, or (ii) in each country in
which a Valid Claim for any Licensed Patent shall continue to

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

17

 

exist, until the last Valid Claim for any Licensed Patent shall expire in the country, at which
time this Agreement shall expire as to such country (“Term”).

     12.2 After expiration of the Term in a country, GTx shall have a perpetual, fully paid,
royalty-free license to the Licensed Patents and Licensed Technology in such country, such license
being of no greater scope than that granted hereunder. GTx shall continue to be obligated to pay
(i) Running Royalties on account of Licensed Product used, marketed, sold, manufactured or
distributed in or imported from any country for which the Term shall not have expired; and (ii)
Sublicense Royalties on Sublicense Revenue generated under any Sublicense that includes a grant of
rights in any Major Country for which the Term shall not have expired; and (iii) the License
Maintenance Fee as long as there is at least one Major Country for which the Term shall not have
expired. GTx shall continue to enjoy the rights and license to the Licensed Subject Matter granted
hereunder in each country for which the Term shall not have expired.

     12.3 In the event of default or failure by GTx to perform any of the terms, covenants or
provisions of this Agreement (hereinafter, “default”), GTx shall have thirty (30) days to cure such
default after the giving of written notice of such default by UTRF. In accordance with Section
2.6, no Sublicensee’s rights under a Sublicense shall terminate on account of a default by GTx
unless UTRF shall have given written notice of such default to the Sublicensee and the Sublicensee
shall have failed to cure or have cured such default within thirty (30) days of such notice. If
such default is not cured by GTx, its Affiliates, and/or its Sublicensees within the said thirty
(30) day period, UTRF shall have the right, at its option, to terminate this Agreement. The failure
of UTRF to exercise such right of termination for non-payment of royalties or otherwise shall not
be deemed to be a waiver of any right UTRF might have, nor shall such failure preclude UTRF from
exercising or enforcing said right upon any subsequent failure by GTx.

     12.4 UTRF shall have the right, at its option, to terminate this Agreement in the event that
GTx is finally declared bankrupt, or is placed in receivership pursuant to proceedings affecting
the operation of its business In the event of termination of this Agreement pursuant to Sections
12.3 or 12.4 hereof, all rights to the Licensed Patents and Licensed Technology granted to GTx
herein shall revert to UTRF, except as otherwise provided in Section 2.6.

     12.5 Upon termination of this Agreement for any reason, nothing herein shall be construed to
release either party from any obligation that matured prior to the effective date of such
termination; and Sections 1, 4.4, 5, 8, 9-12, 14, 18, 20, and 21 shall survive any such
termination.

     12.6 No termination of this Agreement shall constitute a termination or a waiver of any rights
of either Party against the other Party accruing at or prior to the time of such termination.

     12.7 GTx shall have the right to terminate this Agreement at any time on three (3) months
notice to UTRF and upon payment of all amounts due UTRF through the effective date of the
termination.

SECTION 13

Assignability

     13.1 This Agreement shall be binding upon and shall inure to the benefit of UTRF and its
assigns and successors, and shall be binding upon and shall inure to the benefit of GTx and its
assigns provided that prior written approval by UTRF is first obtained, which approval shall not be
unreasonably withheld. Notwithstanding the foregoing, no prior written approval from UTRF shall be
required for any assignment by GTx to (i) an Affiliate of GTx (or any entity into which GTx shall
have been merged or consolidated, provided that at least 51% of such merged or consolidated entity
is owed by shareholders holding at least 51% of GTx immediately prior to such merger or
consolidation) or (ii) a Third Party which acquires all or substantially all of GTx’s assets or a
Controlling interest in the business to which this Agreement relates if, but only if, the Third
Party can reasonably demonstrate a financial net worth or market cap equal to or better than the
financial net worth of GTx existing prior to the acquisition, but not less than a net worth of One
Hundred Million Dollars ($100,000,000) or a market cap of Five Hundred Million Dollars
($500,000,000). No assignment shall be deemed effective unless such assignee has agreed in
writing to be bound by the terms and provisions of this Agreement. Any attempt to assign or
assignment made in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

18

 

violation of this Section 13.1 shall be void ab initio. GTx shall give notice to UTRF of any
assignment of this Agreement within thirty (30) days thereafter, such notice to include a copy of
assignee’s written agreement to be bound by the terms and provisions of this Agreement.

SECTION 14

Governmental Compliance

     14.1 GTx shall at all times during the Term of this Agreement and for so long as it shall
develop, make, have made, use, market, sell, have sold, import, distribute, or offer to sell
Licensed Products or Licensed Technology comply and cause its Sublicensees to comply with all laws
that may control the import, export, manufacture, use, sale, marketing, distribution and other
commercial exploitation of Licensed Products, Licensed Technology, or Licensed Patents or any other
activity undertaken pursuant to this Agreement.

SECTION 15

Notices

     15.1 Any notice or other communication required or permitted hereunder (hereinafter “notice”)
shall be in writing and shall be hand-delivered, sent by overnight courier, mailed by certified
United States mail, return receipt requested, or sent by email, to the addresses given below or to
such other addresses as the parties may hereafter specify in writing. Notice shall be deemed given
and received five (5) days after being deposited with the U.S. Postal Service with sufficient
postage, or if notice is hand-delivered or sent by overnight courier, upon the date of actual
delivery, or if sent by email, upon the date the receiving party acknowledges receipt. An email
notice shall be given concurrently to all the email address(es) provided by the recipient party and
the first acknowledgment of receipt from the recipient party shall establish the date on which such
notice is given.

UTRF:

If notice is given by means other than email, to:

University of Tennessee Research Foundation

1534 White Avenue, Suite 403

Knoxville, Tennessee, U.S.A. 37996-1527

Attn: President

          With
a copy to:

University of Tennessee Research Foundation

920 Madison, Suite 515

Memphis, TN 38163

If notice is given by email, to:

rmagid1@utmem.edu

jlsnider@utk.edu

vhunley@tennessee.edu

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

19

 

GTx:

If notice is given by means other than email, to:

GTx, Inc.

3 N. Dunlap Street, 3rd Floor

Memphis, Tennessee 38163

Attn: Dr. Mitchell Steiner, CEO

          With a copy to:

GTx, Inc.

3 N. Dunlap Street, 3rd Floor

Memphis, TN 38163

Attn: Henry P. Doggrell, Vice President, General Counsel

If notice is given by email, to:

msteiner@gtxinc.com

hdoggrell@gtxinc.com

SECTION 16

Severability of Provisions

     16.1 If any provision of this Agreement shall be declared by a court of competent jurisdiction
to be invalid, illegal or incapable of being enforced in whole or in part, the remaining conditions
and provisions or portions thereof shall nevertheless remain in full force and effect and
enforceable to the extent they are valid, legal and enforceable, and no provision shall be deemed
dependent upon any other covenant or provision unless so expressed herein.

SECTION 17

Governing Law

     17.1 This Agreement shall be deemed to be subject to, and have been made under, and shall be
construed and interpreted in accordance with the laws of the State of Tennessee. This Agreement is
expressly acknowledged to be subject to all applicable federal laws. No conflict-of-laws rule or
law that might refer such construction and interpretation to the laws of another state, republic,
or country shall be considered. The Parties irrevocably and unconditionally agree that the
exclusive place of jurisdiction for any action, suit or proceeding for a temporary restraining
order, a preliminary injunction, or other equitable relief to preserve the status quo or to prevent
irreparable harm, arising under, out of, or in connection with this Agreement (“Actions”),
shall be in the courts of the United States of America sitting in the city, state and country of
State of Tennessee, or, if such courts shall not have jurisdiction over the subject matter thereof,
in the courts of the State of Tennessee sitting therein, and each such party hereby irrevocably and
unconditionally agrees to submit to the jurisdiction of such courts for the purposes of any such
Actions. If any such State court also does not have jurisdiction over the subject matter thereof,
then such an Action may be brought in the federal or state courts located in the states of the
principal place of business of any Party hereto.

SECTION 18

Confidentiality

     18.1 Nothing herein shall preclude a Party from disclosing the existence of this Agreement and
the general scope of the license granted hereunder. However, neither Party shall disclose the
economic terms of this Agreement except that UTRF may disclose such economic terms to the UT
Contributors and UT, or as required by Federal Policy.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

20

 

     18.2 Subject to the exceptions set forth herein, all information or material disclosed
pursuant to this Agreement and/or related to the Licensed Patents, Licensed Products, Licensed
Technology, and Independent SERM Inventions shall be confidential (“Confidential
Information”). Recipient (the “Receiving Party”) of another Party’s Confidential Information
(the “Providing Party”) agrees to hold in confidence, and not to distribute or disseminate to any
person or entity, for any reason for a period of seven (7) years after receipt, any Confidential
Information received, under or relating to this Agreement, except for Confidential Information of
the Providing Party which:

	 	A.	 	was known or used by the Receiving Party prior to the date of disclosure to the
Receiving Party as evidenced by written records; or
	 
	 	B.	 	either before or after the date of disclosure is lawfully disclosed to the
Receiving Party by sources other than the Providing Party which are rightfully in
possession of the Confidential Information and not subject to any obligation of
confidentiality, as evidenced by written records; or
	 
	 	C.	 	either before or after the date of disclosure to the Receiving Party becomes
published, through no fault or omission on the part of the Receiving Party; or
	 
	 	D.	 	is independently developed by or for the Receiving Party without reference to,
knowledge of, or reliance upon the Confidential Information as evidenced by written
records; or
	 
	 	E.	 	is required to be disclosed by the Receiving Party to comply with applicable
laws or court order, to defend or prosecute litigation or arbitration or to comply with
governmental regulations or Federal Policy, provided that the Receiving Party provides
prior written notice of such disclosure to the Providing Party and takes reasonable and
lawful actions to avoid and/or minimize the degree of such disclosure, and further
provided that specific information shall not be deemed to be within any of these
exclusions merely because it is embraced by more general information falling with these
exclusions; or
	 
	 	F.	 	is disclosed by UTRF to UT, the UT Contributors, or the State of Tennessee,
such disclosure being subject to the provisions of Section 2.6, if and as applicable.

All information concerning (i) Licensed Patents and/or Licensed Technology owned solely or partly
by UTRF and (ii) Independent SERM Inventions shall be deemed Confidential Information of UTRF.
Disclosures of Confidential Information to GTx concerning (i) and (ii), including, without
limitation, disclosures that are made to GTx by UT Contributors, shall be deemed, for purposes of
this Section, to be disclosures made by UTRF. Nothing herein shall be construed in such a manner as
to permit UTRF, UT, or any UT Contributor to take any action with regard to Licensed Patents,
Licensed Technology, or Independent SERM Inventions that is contrary to the rights herein granted
to GTx or to permit UTRF, UT, or any UT Contributor to include any Confidential Information of GTx
in any patent application or regulatory filing or application without obtaining GTx’s prior written
approval except to the extent such activity falls within the exceptions to confidentiality set
forth in Sections 18.2A through F.

     18.3 GTx recognizes that under UTRF and UT policy, research results must be publishable and
agrees that researchers engaged in such research shall have the right, with regard to the Licensed
Subject Matter, to present at symposia, professional meetings and to publish in journals, theses or
dissertations, or otherwise of their own choosing (“Publications”) provided that UTRF shall
provide to GTx a copy of a draft of such Publication, if received by UTRF in draft form, or a copy
of the final Publication, if first received by UTRF in that form, in either case promptly upon
receipt and in the manner and form in which received in order that GTx may review the Publication
to identify and protect any Confidential Information of GTx that may be contained therein and to
allow for the preparation and filing of a patent application by GTx or Sublicensees. UTRF shall
not be deemed in breach or default of this Agreement merely due to a Publication that UTRF does not
receive prior to publication.

     18.4 Intentionally Omitted.

     18.5 The Parties agree that counsel of the Parties, who have a duty of confidentiality to the
respective Parties, may receive Confidential Information.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

21

 

SECTION 19

Reformation

     19.1 All Parties hereby agree that neither Party intends to violate any public policy,
statutory or common law, rule, regulation, treaty or decision of any government agency or executive
body thereof of any country or community or association of countries; that if any word, sentence,
paragraph or clause or combination thereof of this Agreement is found, by a court or executive body
with judicial powers having jurisdiction over this Agreement or any of its Parties hereto, in a
final unappealed order to be in violation of any such provision in any country or community or
association of countries, such words, sentences, paragraphs or clauses or combination shall be
inoperative in such country or community or association of countries, and the remainder of this
Agreement shall remain binding upon the Parties hereto.

SECTION 20

Non-Waiver 

     20.1 The Parties covenant and agree that if a Party fails or neglects for any reason to take
advantage of any of the terms provided for the termination of this Agreement or if a Party, having
the right to declare this Agreement terminated, shall fail to do so, any such failure or neglect by
such Party shall not be a waiver or be deemed or be construed to be a waiver of any cause for the
termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants
or conditions of this Agreement or of the performance thereof. None of the terms, covenants and
conditions of this Agreement may be waived by a Party except by its written consent.

SECTION 21

Entire Agreement 

     21.1 This Agreement, as amended and restated herein, contains the entire agreement and
understanding of the parties as of the Effective Date with respect to the subject matter hereof,
supersedes any prior agreements and understandings with respect thereto, including, without
limitation, the Prior License Agreements, and cannot be modified, amended or waived, in whole or in
part, except in writing signed by the Party to be charged. Any such purported non-written
modification, amendment, or waiver shall be null and void. A discharge of the terms of this
Agreement shall not be deemed valid unless by full performance of the Parties hereto or by writing
signed by the Parties hereto. A waiver by UTRF of any breach by GTx of any provision or condition
of this Agreement to be performed by GTx shall not be deemed a waiver of similar or dissimilar
provisions or conditions at the same or any prior or subsequent time.

SECTION 22

Effect of Agreement

     22.1 This Amended and Restated License Agreement shall supersede and render null and void the
Prior License Agreements.

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple
originals by their duly authorized officers and representatives on the respective dates shown
below. The undersigned representative of UTRF is authorized to execute this Agreement on its behalf
and bind UTRF to the terms and conditions set forth herein, and the undersigned representative of
GTx is authorized to execute this Agreement on its behalf and bind GTx to the terms and conditions
set forth herein.

	 	 	 	 	 	 	 	 	 	 	 
	UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (UTRF)	 	 	 	GTx, INC. (GTx)	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Fred D. Tompkins
	 	 	 	By:
	 	/s/ Henry P. Doggrell	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name: Fred D. Tompkins	 	 	 	Name: Henry P. Doggrell	 	 
	Title: President	 	 	 	Title: Vice President, General Counsel & Secretary	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	9/26/07
	 	 	 	Date:
	 	Sept. 26, 2007	 	 
	 

	 	 
	 	 	 	 	 	 	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

22

 

APPENDIX A AMENDED & RESTATED LICENSE AGREEMENT

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]